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ABSTRACT 
The Wiskott-Aldrich syndrome protein (WASP) is confined to hematopoietic cells 
and regulates Arp2/3-mediated actin polymerization. Absence or impaired expression 
of WASP leads to the Wiskott-Aldrich syndrome (WAS), characterized by the triad of 
eczema, microthrombocytopenia and severe immune deficiency. Cellular defects have 
been described in a variety of cells, but how these defects contribute to the clinical 
phenotype, remains poorly understood. Patients with residual WASP expression, as in 
X-linked thrombocytopenia (XLT), have generally less severe clinical symptoms and 
do not develop hematologic malignancies. To date, bone marrow transplantation is the 
only curative therapy for WAS. However, new hope is nurtured by the 
implementation of gene therapy strategies, based on the administration of gene-
corrected hematopoietic stem cells, when no compatible donor is available.  
Since WAS patients are highly susceptible to infections, autoimmune diseases and 
tumors, we reasoned that defects in their CD8+ cytolytic T cells (CTL) might 
contribute to a state of reduced immune-surveillance. Therefore we investigated the 
role of WASP in this T cell subset. We identified defects in cytokine production (IL-
2, IFN-γ and TNF-α) and proliferation of CD8+ T cells in response to stimulation with 
superantigens presented on allogeneic EBV-transformed B cells. This defect however 
was milder than the defects described in response to anti-CD3/anti-CD28 stimulation. 
In addition, the cytolytic capacity of CD8+ CTL against SAg-loaded EBV-
transformed B cells was reduced, especially when those B cells were of tumoral 
origin. Although WAS CTL expressed normal levels of the lytic molecules, granzyme 
B and perforin, they appeared not to properly polarize these molecules toward the 
target cells. Reconstitution of WASP expression in CD8+ T cells by lentiviral 
transduction led to restoration of the lytic defect against tumoral B cells, confirming a 
direct role for WASP in CTL-mediated cytotoxicity. WASP-deficient EBV-
transformed B cells appeared to exacerbate defective CTL-mediated killing, despite 
their normal stimulatory capacity.  
Our data reveal a role for WASP in regulating the threshold for CD8+ T cell activation 
and lytic function in response to APC stimulation, likely contributing to the severe 
immune deficiency observed in WAS patients. 
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RESUME 
La protéine du syndrome de Wiskott-Aldrich (WASP) est exprimée uniquement dans 
les cellules hémapoïetiques dans lesquelles elle régule la polymérisation de l’actine 
médiée par Arp2/3. L’absence d’expression de WASP ou une expression réduite est la 
cause du syndrome de Wiskott-Aldrich (WAS), caractérisé par de l’eczéma, une 
microthrombocytopénie et une déficience immunitaire sévère. Des défauts cellulaires 
ont été décrits dans une multitude de cellules. Cependant, la contribution relative de 
ces défauts au phénotype clinique reste en grande partie inconnue. Les patients avec 
une expression résiduelle de WASP, comme dans la thrombocytopénie liée à l’X 
(XLT), ont généralement des symptômes cliniques moins graves et ne développent pas 
de tumeurs malignes hématologiques. Jusqu’à présent, la transplantation de moelle 
osseuse est la seule thérapie curative pour WAS. Cependant, un nouvel espoir justifie 
la mise en œuvre de stratégies de traitement par thérapie génique, basée sur 
l’administration de cellules souches hématopoïétiques avec le gène corrigé, quand un 
donneur compatible n’est pas disponible. 
En raison de la susceptibilité accrue aux infections, maladies auto-immunes et 
tumeurs, nous avons émis l’hypothèse que les lymphocytes T CD8+ cytolytiques 
pourraient jouer un rôle dans le déficit immunitaire observé chez les patients WAS. 
Par conséquent, nous avons étudié le rôle de WASP dans cette population 
lymphocytaire T. Nous avons identifié des défauts dans la production cytokinique (IL-
2, IFN-γ and TNF-α) et la prolifération des cellules CD8+ T en réponse à une 
stimulation par des superantigènes présentés par des cellules B transformées par 
l’EBV. Ce défaut a toutefois été plus modéré que ceux décrits dans la littérature en 
réponse à la stimulation avec des anticorps dirigé contre le CD3 et le CD28. En 
outre, la capacité cytolytique des cellules T CD8+ contre les cellules B transformées 
par EBV était réduite, en particulier lorsque ces cellules B sont d’origine tumorale. 
Bien que les cellules T CD8+ de patients WAS expriment des niveaux normaux de 
molécules lytiques, la polarisation des granules lytiques vers les cellules cibles s’est 
avérée incomplète. La reconstitution de l’expression de WASP dans les cellules CD8+ 
T conduit à la correction du défaut lytique contre les cellules tumorales B, confirmant 
un rôle direct pour WASP dans la cytotoxicité médiée par les CTL. Une déficience de 
WASP du côté des lymphocytes B transformés par l’EBV semble agraver la 
 9 
cytotoxicité défectueuse exercée par les CTL, en dépit d’une capacité activatrice 
normale.  
Nos données révèlent donc un rôle de WASP dans la régulation du seuil d’activation 
des lymphocytes T CD8+ et de la fonction lytique en réponse à une stimulation avec 
des APC. Le défaut d’activation et de fonction des lymphocytes T CD8+ pourrait 
contribuer à la déficience immunitaire sévère observée chez les patients WAS. 
 10 
ABBREVIATIONS 
ADA  Adeosine-deaminase 
Ag  Antigen 
APC  Antigen presenting cell 
Arp2/3  Actin-related protein 2/3 
BCR  B cell receptor 
CD  Clusters of differentiation 
CIP4  Cdc42-interacting protein-4 
CFSE  Carboxyfluorescein diacetate succinimidyl ester 
CMFDA Chloromethylfluorescein diacetate (cellTracker Green) 
CMTMR Chloromethyl benzoyl amino tetramethylrhodamine (cellTracker Red) 
CMV  Cytomegalo virus 
CRIB  Cdc42-and-Rac interactive binding site 
CSF-1  Colony-stimulating factor 1 
cSMAC Central supra-molecular activatory cluster 
CTL  Cytotoxic T lymphocyte 
DC   Dendritic cell  
dSMAC Distal supra-molecular activatory cluster 
EAE  Experimental autoimmune encephalitis 
EBV  Epstein-Barr virus 
EVH1  Ena/ VASP homology domain 1 
FACS  Fluorescence activated cell sorter 
FasL  Fas-Ligand 
FHL  Familial hemophagocytic lymphohistiocytosis 
Foxp3  Fork-head winged helix transcription factor 3 
GrB  Granzyme B 
GTP  Guanosine triphosphate 
GVHD  Graft-versus-host disease 
HD  Healthy donor 
HLA  Human leucocyte antigen 
HLA:p  HLA:peptide complex 
HSC  Hematopoietic stem cell 
HSCT  Hematopoietic stem cell transplantation 
 11 
HSV  Herpes simplex virus 
HTLV-1 Human T cell leukemia virus type 1 
ICAM-1 Intra-cellular adhesion molecule-1 (CD54) 
Ig  Immunoglobulin 
IL  Interleukin 
IFN-γ  Interferon gamma 
iNKT  Invariant natural killer T cell 
IS  Immunological synapse 
IU  International units 
KD  Knock-down 
KO  Knock-out 
Lamp  Lysosomal-associated membrane protein 
LFA  Leukocyte functional antigen 
MHC  Major histocompatibility complex 
MHC:p Major histocompatibility peptide complex 
MMLV Murine Moloney leukaemia virus 
MMRD Mismatched related donor 
MOI  Multiplicity of infection 
MTOC  Microtubule-organizing center 
MUD  Matched unrelated donor 
MZ  Marginal zone 
NFAT  Nuclear factor of activated T cells 
NK  Natural killer 
OMIM  Online Mendelian Inheritance in Man 
PBMC  Peripheral blood mononuclear cells 
PHA  Phytohemagglutinin 
PI  Propidium iodide 
PID  Primary immune deficiency 
PIP2  Phosphatidylinositol(4,5)biphosphate 
PKC  Protein kinase C 
PRF  Perforin 
pSMAC Peripheral supra-molecular activatory cluster 
rHu  Recombinant human 
 12 
RID  Related HLA-identical donor 
SAg  Superantigen 
SCID  Severe combined immune deficiency 
SEB  Staphylococcus enterotoxin B 
SEE  Staphylococcus enterotoxin E 
TCR  T cell receptor 
Tfh  Follicular T helper 
TGFβ  Transforming growth factor beta 
Th  T helper 
TNF-α  Tumor necrosis factor alfa 
Treg  Regulatory T cell 
TSST-1 Toxic shock syndrome toxin-1 
VCA  Verprolin homology central acidic region 
WAS  Wiskott-Aldrich syndrome 
WASP  Wiskott-Aldrich syndrome protein 
WIP  WASP interactive protein 
X-CGD X-linked chronic granulomatous disease 
XLN  X-linked neutropenia 
XLT  X-linked thrombocytopenia 
 
Introduction 
 13 
I. Introduction 
The primary aim of the PhD research project presented in this manuscript has been to 
characterize the T cell subpopulation of CD8+ cytotoxic T lymphocytes (CTL) from 
patients with Wiskott-Aldrich syndrome (WAS). This rare disease, caused by 
inherited gene mutations in the WAS gene, leading to WAS protein (WASP) 
deficiency, can turn out life-threatening when left untreated due to severe 
hemorraghes and immune deficiency. Since CTL are crucial in immune responses to 
fight infection and cancer and, in addition, can contribute to the onset of 
autoimmunity, three important features in WAS, we believe that these cells from 
WAS patients need to be studied at the level of their physiological behavior in terms 
of activation, differentiation and effector function. In the next pages, I will give an 
overview on the immune system, and in particular the mounting of an adaptive T cell-
mediated immune response with a specific emphasis on the activation and role of 
CTL. I will then present WAS and explain the rationale for studying CTL in WAS.  
1. General introduction on the immune system 
Leukocytes, or white blood cells, form a heterogeneous group of immune cells that 
have one common goal: protecting the host from disease. They all stem from a 
common pluripotent hematopoietic precursor cell that differentiates into more 
specialized progenitor cells in the bone marrow. Neutrophils, monocytes, 
macrophages and immature dendritic cells (DC) originate from common myeloid 
precursor cells, whereas B- and T lymphocytes and natural killer (NK) cells arise 
from common lymphoid progenitors. These differentiated leukocytes circulate in the 
bloodstream or reside in peripheral tissues to scan the environment for danger or 
respond to it through different effector mechanisms1. 
Maturation of most immune cells, including B cells, occurs within the bone marrow. 
In contrast, T cell precursors migrate to the thymus, a central lymphoid organ, where 
they develop and undergo maturation. The thymus plays an important role in the 
development of tolerance. Indeed, T cells capable of recognizing self-MHC are 
positively selected while T cells with self-reactive T cell receptors (TCR), reacting 
strongly to self-antigens are purged from the repertoire by clonal deletion1,2 or by the 
induction of anergy1,3 to prevent autoimmune reactions. 
Introduction 
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The immune system comprises two components that work closely together and 
protect the host from disease, despite the constant presence of potentially pathogenic 
organisms: the innate and the adaptive immune systems. The innate immune system 
largely involves phagocytic cells, such as macrophages and neutrophils. It provides 
immediate defense mechanisms against infection in a non-specific manner and does 
not confer long-lasting or protective immunity to the host. In contrast, the adaptive 
immune system comprises the action of B- and T lymphocytes, providing the immune 
system with the ability to recognize and remember specific pathogens and to mount 
stronger attacks each time the pathogen is encountered. It is adaptive in the sense that 
the body's immune system prepares itself for future challenges1. 
When a microorganism succeeds in crossing the epithelial barriers of the host and 
starts to replicate, the innate immune system is activated. Very often intruded 
pathogens are immediately recognized by macrophages that guard peripheral tissues. 
Binding of molecular patterns associated with pathogens to receptors on the surface of 
macrophages triggers them to engulf and destroy them. Pathogen destruction occurs 
either through the fusion of the phagosome with lysosomes that contain antimicrobial 
compounds or through the generation of a “respiratory burst”. In addition, activated 
macrophages secrete cytokines and chemokines, causing inflammation and the 
recruitment of other immune cells. Briefly, inflammatory responses increase the local 
blood flow, reduce blood flow velocity and induce the up-regulation of adhesion 
molecules on activated endothelial cells. Together these actions promote the adhesion 
and consequent extravasation of circulating leukocytes into the infected tissues. 
Neutrophils are the first to arrive at the site of infection, followed by monocytes that 
differentiate into more tissue-macrophages. In case of viral infection or infection with 
some intracellular pathogens, NK cells will as well be activated. These cells attack 
harmful cells by the directed release of lytic molecules leading to target cell 
destruction. Inflammatory responses also increase the flow of antigens from infected 
tissue to draining lymph nodes, a mechanism that will help the mounting of an 
adaptive immune response later on1. 
In addition to the actions of innate immune cells, microbial products will activate the 
complement system. This humoral compound of innate immunity is composed of a 
series of plasma proteins that react with one another to opsonize pathogens. Due to 
increased vascular permeability during inflammation, these plasma proteins will 
facilitate pathogen removal by phagocytes in infected tissues. Macrophage-induced 
Introduction 
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cytokines will also induce activation of the clotting system, inhibiting the spread of 
infection to the bloodstream. Either the innate immune response clears infection, 
either it controls infection by preventing dissemination, while the adaptive immune 
response develops1. 
 
The adaptive immune system is activated by the innate immune system. Since 
immature DC are recruited already during innate responses, they serve as a “link” 
between innate and adaptive immunity. Upon capture of antigens (Ag), substances 
that stimulate the production of antibodies, in infected tissues, immature DC migrate 
to secondary lymphoid organs. During this migration, and promoted by 
proinflammatory cytokines, DC undergo maturation characterized by the up-
regulation of costimulatory molecules. In addition, on their route to lymphoid tissues 
DC degrade Ag-derived peptides to load them on MHC class I or II molecules 
expressed on their membrane. Intracellular pathogens, such as viruses and some 
intracellular bacteria, are degraded into peptides in the proteasome and loaded on 
MHC class I molecules (MHC-peptide complex = MHC:p). Intravesicular and 
extracellular pathogens are degraded in lysosomal vesicles and loaded on MHC class 
II molecules1,4. Once arrived in secondary lymphoid organs mature DC, now highly 
professional antigen presenting cells (APC), present Ag to recirculating T cells. 
Pathogen-derived Ag also arrives in the secondary lymphoid tissues through the 
lymph as result of inflammation enabling other APC, such as macrophages and B 
cells, to capture and present Ag to naïve T cells. Lymphocytes that completed their 
maturation leave the thymus via the bloodstream until reaching a peripheral lymphoid 
organ. In the absence of cognate Ag, they migrate through it, regaining the 
bloodstream. However, upon recognition of MHC:p via their specific TCR and 
simultaneous costimulation, naïve T lymphocytes get activated. Activation signals 
induce their clonal expansion and differentiation into effector cells. CD8+ T 
lymphocytes and CD4+ T helper (Th) 1 cells, being the soldiers mediating cellular 
immunity and CD4+ Th2 cells mediating humoral immunity. The activation of naïve 
T cells upon Ag-recognition, or “T cell priming” is known as the primary immune 
response. After having exerted their effector function, most T lymphocytes go into 
apoptosis and a small part survives as memory T cells. This pool of cells will rapidly 
re-differentiate into effector T cells when the host encounters the same pathogen on a 
Introduction 
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later time point, providing the adaptive immune system with immunological 
memory1,5.  
B cells also recirculate through lymphoid organs, and unlike T cells, B cells can 
recognize soluble pathogens with their B cell receptor (BCR) without prior 
degradation1,4. Upon internalization and degradation peptides can be loaded on MHC 
class II molecules in order to activate naïve CD4+ T cells. However, B cells are very 
poor in initiating adaptive immune responses. In contrast, upon activation B cells can 
differentiate into very powerful antibody-producing plasma cells and contribute to the 
humoral immune response. The most direct way in which antibodies protect the host 
against pathogens is by the neutralization of viruses and bacterial toxins. A second 
mechanism comprises the action of antibodies to opsonize bacteria that are invisible 
to the immune system because of an outer coat, lacking molecular patterns recognized 
by phagocytes. Opsonized bacteria however will be ingested and destroyed by 
phagocytes. A third action of antibodies is complement activation that will strengthen 
the action of antibodies in promoting the coating of pathogens to subsequently be 
removed and destroyed by phagocytes1. 
Thanks to the high variety of lymphocytes with unique TCR recognizing specific 
pathogen-derived peptides, and the powerful action of antibody-producing B cells, the 
adaptive immune response conquers almost every infection and we become ill only 
very rarely. However, tumor cells and certain pathogens have developed defense 
mechanisms protecting themselves from being recognized by the host’s immune 
system making their clearance more difficult, and facilitating their survival and 
replication in the host. Additionally, in some cases the immune system, whether it is 
the innate or adaptive system or a combination of both, does not work properly. 
Together, these events can eventually contribute to latent infections with periodical 
outbreaks and the development of chronic diseases, autoimmunity and malignancies. 
2. T cell stimulation by APC at the immunological synapse 
APC, and in particular DC, that migrate from inflamed tissues to peripheral lymphoid 
tissues will secrete chemokines to attract naïve T cells. Chemokine signaling activates 
a cascade of signal transduction leading to cytoskeletal rearrangements and 
polarization of T cells, displaying a leading edge, the lamellipodium highly sensitive 
to MHC:p complexes, and a trailing edge or uropod. Independently of the presence of 
antigen, APC will scan a large number of migrating naïve T cells in order to find one 
Introduction 
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or more T cells recognizing the Ag presented by the APC. Only when the TCR is 
engaged, Ag-specific T cells can stop migrating and can be fully activated6. At 
saturating Ag doses, the stop signal results in a tight interaction with APC and low T 
cell motility7, whereas at lower, more physiological Ag doses the stop signal is more 
transient and permits the T cell to crawl over the APC to sustain T cell signaling8,9. 
APC, and in particular DC, can engage several T cells simultaneously10,11, and these 
APC:T cell interactions can last for several hours6,10, or can be dynamic, short-lived 
and sequential as has been demonstrated between stromal cells and thymocytes12 and 
between DC and T cells13. 
Upon Ag recognition, a multi-step process leading to the formation of the 
immunological synapse (IS), a specialized junction between a T lymphocyte and an 
APC14, occurs. An intact actin cytoskeleton is required to initiate TCR clustering and 
signaling8,15. Indeed, the actin cytoskeleton plays a very important role in Ag-
recognition. First, it allows the movement of molecules on the surface of T cells, 
permitting T cells to scan APC and vice versa. Second, actin filaments serve as 
scaffolds for signaling complexes and might also be involved in the recruitment and 
stabilization of membrane molecules involved in T cell activation16. 
2.1 Model for immunological synapse formation 
The first step of synapse formation begins with the adhesion between two cells. Initial 
interactions are mediated through large adhesion molecules, such as the integrin 
leukocyte functional antigen-1 (LFA-1), expressed at high levels on T lymphocytes, 
and its ligand intracellular adhesion molecule-1 (ICAM-1) on APC17. LFA-1 requires 
activatory signals to modify its conformation so that ligation with ICAM-1 can be 
initiated. This activation is provided, at least in part, by the chemokine-signaling 
cascade. After establishment of a close cell-cell contact, smaller molecules, such as 
CD2 and its ligand CD58 on APC, can interact. Only when the T cell recognizes a 
specific antigen presented on the MHC molecules of the APC, a stable IS is formed. 
TCR bind with high affinity to the MHC:p complexes, resulting in the formation of a 
central supra-molecular activatory cluster (cSMAC), while integrins are forced to 
move to the periphery, resulting in the formation of a peripheral SMAC (pSMAC) 14. 
Finally, the outer ring of the IS contains very large molecules, such as CD45, and is 
called the distal SMAC (dSMAC) 18. This structure with a segregation of the cSMAC, 
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pSMAC and dSMAC, is called the “mature” IS and is maintained for several hours6. 
However, the formation of this prototypical IS is only observed in specific 
experimental conditions, such as the use of very high, non-physiological Ag 
concentrations, the use of B cell lines18, or the use of surrogate lipid-bilayers instead 
of APC14. Indeed, other types of synapses with a multi-focal character (multiple 
distinct TCR clusters) have been described in more physiological systems for example 
between naïve T cells and DC19, between CD4+ T cells and B cell lymphomas at low 
Ag dose20, and between thymocytes and thymic epithelial cells21. It is now well 
established that the type of IS depends on the activation state of T cells, the nature of 
the APC and the strength and quality of antigenic stimulation9. A lot of controversy 
exists to explain how the IS between a T cell and an APC can trigger and sustain the 
T cell activation process. Indeed, to some the IS is a stable adhesive junction between 
a polarized T cell and an Ag-bearing APC6,16,22, whereas to others the IS is a dynamic 
event, characterized by serial TCR triggering8,23-25.  
2.2 Functions of the IS 
Since the cSMAC contains TCR, CD28 and a variety of signaling molecules, it was 
suggested that the mature IS functions as a microenvironment facilitating 
TCR:MHC:p and costimulatory interactions, indispensable for T cell activation. The 
IS is believed to allow a continuous scanning of the T cells to find a maximum of 
MHC:p complexes to ensure optimal T cell activation16,22,26. However, the mature IS 
does not seem to be required for T cell activation, since TCR signaling occurs before 
this molecular structure is formed between macrophages and T cells27 or between B 
cells and T cells28. Moreover, TCR signaling appears also maximal before the mature 
IS is formed and is weak at its center. Therefore, it has been proposed that the 
cSMAC arises from the convergence of TCR microclusters that are formed upon 
initial contact formation, and are actively transported to the center29. Additionally, it 
appeared that these microclusters sustained TCR signaling during T cell activation15. 
Recently, it has been suggested that signaling components would be degraded in the 
cSMAC and thus the cSMAC would be the place of extinction of TCR signaling, 
whereas intensive TCR triggering would take place in the periphery15,30. The current 
view on the role of the cSMAC in T cell signaling postulates that at high antigenic 
stimulation, signal transduction occurs in the cSMAC, although, it is accompanied by 
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a high rate of degradation of TCR and signaling compounds. In contrast, for weak 
antigenic stimuli, the rate of TCR degradation in the cSMAC is slower and thus 
promotes sustained signaling as result of TCR accumulation and its interaction with 
cognate MHC:p complexes9. 
Early observations that the microtubule-organizing center (MTOC) polarizes at the 
interface between cytolytic cells and susceptible targets31,32, and that lytic granules are 
exocytosed within this synaptic cleft (region of contact between a T cell and another 
immune cell)32 suggested a role for the mature IS in polarized secretion. This 
structure could retain the secreted granules to protect bystander cells from killing33. In 
contrast to naïve CD8+ T cells, it appears that a cSMAC is formed at the interface of 
effector CD8+ T cells and opposing target cells34. Later it has been demonstrated that 
a stable pSMAC is required for effective CD8+ CTL-mediated lysis of target cells35. 
In the mature synapse, accumulated F-actin and adhesion receptors are thought to 
form a ring in the pSMAC through which perforin and other lytic granule contents are 
secreted36. However, it has been described that at low antigen dose, the “lytic 
synapse” does not display segregated SMACs as observed for the “activatory 
synapse” at high antigen dose, required for full T cell activation37. In addition, it has 
been demonstrated that CTL-mediated cytotoxicity does not require a stable mature 
IS38.  
In the same line, exocytosis of cytokines, such as IL-2, IFN-γ and IL-10 is thought to 
occur in the synaptic cleft39.  
3. T cell activation and effector functions: old friends and new 
acquaintances 
T lymphocytes are executive soldiers in the adaptive immune response. Indeed, as 
result of gene rearrangements during their development, each individual T 
lymphocyte expresses a unique TCR, responding to a specific Ag-derived peptide. 
This mechanism ensures that most pathogens can be recognized and removed from 
the body. T lymphocytes are characterized by the simultaneous expression of the 
lineage marker CD3 in combination with CD4 or CD8, molecules that are intimately 
tied to target recognition. In this group we find the CD8+ cytotoxic T lymphocytes, 
CD4+ Th1 and CD4+ Th2 cells, Th17 cells, follicular Th cells and a heterogeneous 
group of regulatory T cells (Figure 1). There exist however, additional T lymphocyte 
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subpopulations that have a more limited diversity of receptors and unlike the adaptive 
T lymphocytes, do not require clonal expansion before responding to Ag-recognition. 
They are somehow “intermediates” between innate and adaptive immunity. In that 
group we find amongst other the γ:δ T cells, and invariant NKT cells. The current 
picture of T cell biology is that of a very diversified family of cell subsets that display 
some level of differentiation plasticity and that carry either effector or regulatory 
functions at a specific time and location during an immune response. 
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Figure 1: Schematic representation of T cell activation and differentiation in response to 
APC stimulation. TCR stimulation by recognition of HLA:p complexes in combination with 
costimulatory signals and cytokines provided by APC, triggers the activation and 
differentiation of naïve CD4+ and CD8+ T cells. CD4+ T cells can differentiate into 
conventional (Th1, Th2, Th17 and Tfh) or regulatory T cells, depending on the cytokine 
milieu in which activation occurs. After activation and differentiation, effector T cells 
undergo clonal expansion to assure host defense.  
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3.1 CD8+ Cytotoxic T lymphocytes  
Naïve CD8+ T cells have no cytotoxic potential but must undergo prior activation, a 
process requiring 1-3 days for maximal activity. They recognize peptides derived 
from dangerous cells presented in the context of HLA class I molecules on APC. 
Upon activation, Ag-specific CD8+ T cells will expand several orders of magnitude to 
form an army of effector cells42. They then up-regulate the lytic molecules, granzymes 
and perforin, and Fas-Ligand (FasL) expression levels transforming into armed and 
highly specific cytotoxic T lymphocytes14,32,43,44. CTL are the snipers of the cellular 
arm of the adaptive immune response and eliminate their target cells in several 
ways42,45. It is thought that the granzyme/perforin pathway dominates the class I 
elimination pathway46,47, whereas the Fas-FasL pathway would dominate class II 
elimination by CD4+ Th1 cells48,49. In addition, upon activation CTL secrete high 
levels of TNF-α and IFN-γ, 2 cytokines with antimicrobial activity50. CTL also play 
an important role in the surveillance of viral-infected cells and tumor cells42,45. 
However, CTL have a dark side: when they direct their lytic machinery against cells 
from self, or foreign tissue after transplantation, they can cause severe autoimmune 
disorders and graft rejection. In addition, after transplantation, donor-derived CTL can 
cause graft-versus-host disease (GVHD), by directing their lytic machinery toward 
host cells. 
3.2 CD4+ T lymphocytes 
Upon recognition of Ag-derived peptides presented in HLA class II molecules of 
APC and simultaneous costimulation, CD4+ T cells undergo expansion and 
differentiation. In general, depending on the inflammatory milieu in which Ag-
presentation takes place, they will differentiate into conventional (Th1, Th2, Th17, 
Tfh) or regulatory T cells1,51. Conventional Th cells mediate the adaptive immune 
response by activating CD8+ T cells, B cells and macrophages, whereas Treg suppress 
potential destructive actions of effector T cells (Figure 1). 
a) Conventional T helper cells 
Th1 and Th2 cells are specialized cytokine producers and skew the immune response 
in cellular or humoral direction. Th1 cells develop when activation signals are 
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delivered in a milieu rich in IL-12, provided by APC1,5,52. Thanks to their exquisite 
capacity to produce high amounts of IFNγ, Th1 cells are central players in the cellular 
immune response. They activate the bactericidal activities of macrophages and induce 
B cells to make opsonizing antibodies. In addition, they activate CD8+ CTL either by 
direct interactions or indirectly via cytokines and through CD40L-CD40 mediated 
interaction with DC1,5. Th1 cells can also differentiate into cytotoxic cells. Indeed, 
they appear to kill dangerous cells mainly by the Fas-FasL-mediated pathway48,49, but 
also through granzyme B/perforin-mediated mechanisms. They seem to play a role in 
lymphocyte homeostasis by killing anergized B cells53 and by the elimination of 
chronically activated cells recognizing self-antigens54. 
Th2 cells develop under the influence of APC-derived IL-4 during CD4+ T cell 
activation1,5,52. They mediate the humoral arm of the immune response through the 
production of cytokines. Indeed, they activate naïve Ag-specific B cells to produce 
antibodies via the production of IL-4 and IL-13. Th2 cells also activate mast cells and 
eosinophils via IL-5, and inhibit the development of a Th1 response via IL-10 and IL-
131,5. 
Th17 cells represent a more recently discovered Th subset. Their differentiation from 
naïve CD4+ T cells appears to involve signals from TGF-β, IL-6, IL-21, IL-1β and IL-
2355-57. Their differentiation occurs early after infection, since DC are rapidly 
triggered to produce IL-6 and TGF-β upon activation by pathogens. They are 
characterized by the production of IL-17A and IL-17F. They can also produce IL-21, 
IL-22, TNF-α, IL-6 and GM-CSF, but usually not IFN-γ and IL-4. IL-21 signaling 
induces the expression of RORγt, a key transcription factor for Th17 cell 
differentiation. Th17 cells are thought to enhance inflammation by the recruitment of 
leukocytes to sites of infection for pathogen clearance58, and seem to be important in 
immune responses against extracellular bacteria and fungi56, which are not efficiently 
cleared by Th1 or Th2 cells56,57. Th17 cells are highly cytopathic and are involved in 
several autoimmune diseases55-57. 
Finally, follicular Th cells (Tfh) represent a group of Th cells that specifically help B 
cells to produce high affinity, class-switched antibodies important for the clearance of 
pathogens after infection and for the establishment of humoral memory immunity. In 
contrast to Th1 and Th2 cells, expressing only transiently the chemokine receptor 
CXCR5, Tfh express CXCR5 constitutively, promoting their unique localization in 
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the CXCL13-rich germinal centres of B cell follicles in peripheral lymphoid tissues. B 
cell help is provided by direct interactions involving the costimulatory molecules 
CD40L and ICOS and by the secretion of IL-2159,60. 
b) CD4+ regulatory T cells 
Similar to Th17 cells, it is thought that regulatory T cells (Treg) also require TGF-
β during activation, but provided in the absence of IL-6. The characterization of CD4+ 
Treg seems to be difficult, since the phenotypic markers for Treg, CD25, CTLA-4, 
GITR, CD127, LAG-3 and Foxp3, are not strictly Treg-specific, since their 
expression is also up-regulated by conventional T cells upon activation51. As their 
name suggests, Treg “regulate” the potentially deleterious activities of effector T cells 
(reviewed in 61). There is evidence that decreased numbers and/or function of Treg 
can lead to autoimmunity, allergy and graft rejection, whereas over-abundance of 
Treg would inhibit antitumor and antipathogen immunity62. The way these cells 
restrain effector cells to destroy Ag-bearing tissue is mediated through multiple 
mechanisms, including the direct interactions with effector and dendritic cells, the 
release of immunosuppressive cytokines, such as TGF-β and IL-10, and the 
generation of adenosine  (commented in 55). 
Nowadays, different subsets of Treg have been characterized. Besides a thymic-
derived subpopulation with potent regulatory properties, the “natural” Treg, naïve 
CD4+ T cells can differentiate into Treg upon activation by Ag-bearing tolerogenic 
APC (reviewed in 62). To this group belong the IL-10-producing Tr1 cells, 
differentiation of which is driven by IL-1063. 
 
It has to be noted that the classification of the different CD4+ T cell subsets into 
conventional versus regulatory T cells does not exclude regulatory functions for 
conventional T cells and immunostimulatory functions for Treg. Indeed, conventional 
T cells exert besides their effector functions suppressive activity. For example: the 
production of IFNγ by Th1 cells inhibits the development of Th2 cells, and 
conversely, Th2-derived IL-4 suppresses the development of Th1 cells51. In the same 
line, both IFNγ and IL-4 inhibit the development of Th17 cells whereas Th17 cell-
derived IL-17 inhibits Th1 differentiation51,56. 
Introduction 
 25 
Some regulatory T cells secrete high amounts of TGF-β, a cytokine with strong 
immunosuppressive properties. However, TGF-β has been shown to exert 
immunostimulatory actions as well. Indeed, it seems to specifically promote IgA and 
Ig2b isotype class switch in mouse B cells. In addition, some Foxp3 Treg have been 
shown to release IL17, a proinflammatory cytokine, important for immunity against 
extracellular bacteria, and normally produced by Th17 cells51. 
3.3 γ :δ  T cells 
Unlike the majority of mature T cells expressing an αβ TCR, γδ T cells express a 
TCR composed of a γ and δ chain. This population represents 1-10% of circulating T 
cells and is abundantly present in the skin and gut mucosa within a population of 
lymphocytes, known as intraepithelial lymphocytes. γδ T cells display several 
characteristics that place them at the border between the innate and the adaptive 
immune system64. For example: γδ T cells can respond very rapidly to infection, and 
unlike adaptive αβ T cells do not require priming to do so (innate). On the other hand, 
they display TCR rearrangement as do conventional αβ T cells, and they confer 
immunological memory as in the adaptive immune response65. γδ T cells recognize 
non-conventional antigens, such as phosphorylated microbial metabolites and lipid 
antigens presented in MHC class I-like molecules and require costimulation provided 
by professional APC. Their effector mechanisms are not fundamentally different from 
αβ T cells, in the sense that they can kill infected cells by death receptor/death ligand 
(eg Fas-FasL) signaling or in a granzyme B/perforin-mediated manner and they are 
potent cytokine producers64. Besides their role in fighting infection, γδ T cells have 
also been shown to be involved in the onset and propagation of autoimmune disease.  
3.4 Invariant NKT cells 
Invariant NKT (iNKT) cells represent a peculiar thymic-derived T cell subset that 
express both NK cell markers in combination with a semi-invariant α:β TCR (strictly 
conserved α-chain paired with a limited diversity of β-chains). They act as immune 
sentinels, recognizing lipid antigens presented in the MHC class I-like molecule, 
CD1d. iNKT cells become very rapidly activated upon infection and are potent 
immunoregulatory cells by the production of cytokines profoundly affecting both the 
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innate and adaptive arms of the immune system. iNKT cells play an important role in 
the control of infection and cancer immune surveillance. In addition, they are 
implicated in the protection against some autoimmune diseases1,66,67. 
4. A closer look at CD8+ T cell activation and effector functions 
Although the focus of this work lays on the sniper function of effector CTL, it is 
worth to note that CD8+ T cells also exert other functions. Indeed, effector CD8+ T 
cells have a suppressor function, in the sense that they kill Ag-bearing DC in order to 
terminate an immune response45,68, whereas memory CD8+ T cells can provide “help” 
to effector cells of cellular immunity indirectly via stimulation of DC maturation and 
prolongation of Ag-presentation68. 
As mentioned above, CD8+ T cells recognize with their specific TCR pathogen-
derived antigens presented in the groove of HLA class I molecules, expressed on the 
surface of APC, and leading to their activation (Figure 2). Those antigens are 
generally derived from pathogens that invade host cells and multiply in the cytoplasm. 
Proteins derived from these pathogens are broken down in the proteasome and 
peptides are loaded on the HLA class I molecules. However, CTL can also be 
implicated in fighting infections caused by extracellular bacteria or bacteria in 
intracellular vesicles, since DC have the ability to present Ag normally destined for 
HLA class II presentation in the groove of HLA class I, a process called “cross-
presentation” 1,4. This makes CD8+ T cells extremely potent killers of cells infected 
with pathogens from different origin. Indispensable during T cell activation is 
simultaneous costimulation, provided by APC. Indeed, mature DC express high levels 
of costimulatory molecules such as the B7 molecules (CD80 and CD86) and 4-1BB 
that will bind their receptors (CD28 and 4-1BBL) expressed on T cells. CD8+ T cells 
also receive help from Th1 cells via cytokines, in particular IL-2 and IFN-γ69 that 
activate the cellular arm of the adaptive immune response or via direct or indirect 
CD40-CD40L interactions70-72. 
Once properly activated, CD8+ T cells undergo clonal expansion. This expansion is 
driven by an enormous IL-2 production by the activated T cells themselves. The 
produced IL-2 works in an autocrine or paracrine fashion by binding the IL-2-
receptor, that is up-regulated upon T cell activation. The army of Ag-specific CD8+ T 
cells then differentiates into effector soldiers armed with lytic molecules (granzymes, 
perforin, FasL) and leaves the lymphoid tissues to migrate to the site of infection. 
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CTL can kill compromised cells (I) by firing their lytic granules in a very polarized 
manner towards target cells14,31,32, (II) by ligation of death receptors expressed on 
target cells, and (III) by the secretion of cytotoxic cytokines with antiviral and 
antitumoral actions.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Naïve CD8+ T cells recognize peptides presented in HLA class I molecules with 
their specific TCR. Simultaneous costimulation will trigger their activation. CD8+ T cells also 
receive help from Th1 cells by means of direct interactions and cytokines (left panel). Upon 
activation, CD8+ T cells differentiate into highly cytotoxic T cells, up-regulating granzymes, 
perforin and FasL. CTL kill target cells in a contact-dependent manner by the polarized 
secretion of granzymes and perforin or by triggering receptors bearing death-domains 
expressed on target cells. In addition, CTL can exert cytolytic function without contacting 
target cells by the secretion of cytotoxic cytokines, such as IFN-γ and TNF-α (contact-
independent- killing) (right panel). 
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4.1 Contact-dependent destruction of target cells 
The main weapons used by CTL to kill target cells is the granzyme/perforin-mediated 
pathway and in lesser extent the Fas-FasL-mediated pathway. These mechanisms are 
highly specific and require an intimate cell-cell contact.  
a) Granzyme and perforin-mediated cytotoxicity 
LYTIC GRANULE CONTENT 
Lytic granules are specialized endo-lysozomes, containing multiple proteins: 
Membrane-perturbing proteins: the pore-forming molecule “perforin” and granulysin.  
Granule serine proteases: in humans a family of 5 “granzymes” has been identified: 
granzyme A, B, H, M and K.  
Proteoglycan matrix: serglycin 
Perforin-inhibitor: calreticulin 
Lysosomal enzymes or cathepsins with roles in granzyme processing (Cathepsin C) 
and protecting CTLs against perforin (Cathepsin B) 
Stored T effector molecules: Fas Ligand 
Upon T cell activation, the transcription of the genes encoding perforin and 
granzymes starts. De novo synthesized proteins are non-functional and need to 
undergo post-translational modifications in order to take their biological active form. 
Once modified, they are assembled in lytic granules. Lytic granules have a low pH, 
keeping granzymes in an inactive state and contain lysosomal-associated mebrane 
glycoproteins (LAMPs) 1,2 and 345. These molecules are up-regulated upon CD8+ T 
cell activation and are associated with exocytosis of lytic granules73. 
DELIVERY OF THE KISS OF DEATH 
Recognition of dangerous cells has been shown to induce rapid reorientation of the 
MTOC, the golgi-apparatus and lytic molecules to the contact site with the target 
cell31,74,75. These observations led to the formulation of the “granule exocytosis 
pathway” in 198576. Upon target cell identification and conjugation, granules move 
towards the contact site, fuse with the plasma membrane and their content is released 
into the synaptic cleft at the target cell interface. In the presence of calcium, perforin 
polymerizes and enters the target cell. Originally, perforin was thought to directly 
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induce target cell apoptosis, by “perforating” the target cell membrane. However, 
perforin by itself does not induce DNA fragmentation in target cells77. Then, it was 
hypothesized that the pores induced by perforin polymerization, formed a portal for 
the entrance of other granule proteins to induce apoptosis. However, those pores are 
probably not large enough to allow entry of granzymes78. Additionally, granzyme A, 
B and H have been shown to enter target cells in the absence of perforin. Indeed, 
mannose-6-phosphate receptor-mediated endocytosis has been demonstrated for 
granzyme B. Moreover, it has been demonstrated that absence of this receptor 
prevented the rejection of mismatched tumor allografts, a finding that provides a 
mechanism for tumor immune evasion79. These findings have led to a more recent 
hypothesis for lytic granule delivery: after secretion of lytic granules by exocytosis, 
serglycin-bound-granzyme B binds to the mannose-6-phosphate receptor on target 
cells and is internalized80. Perforin would be involved in the release of serglycin-
bound-granzyme B from the granules, since in the absence of perforin, granzyme B 
remains innocuously confined within the endo-lysosomal vesicles81,82. However, the 
exact role of perforin is still not fully understood. The group of Griffiths discovered 
that calcium-dependent directional exocytosis of lytic granules, present in the 
cytoplasm of killer cells occurs in a specialized secretory domain32 that lies next to 
the cSMAC18,83. The MTOC transiently contacts the plasma membrane to directly 
deliver lytic granules into the IS. Granule delivery seems to occur independently of 
actin, but requires minus-end directed movement along microtubules84. The group of 
de Saint Basile demonstrated that the effectors of the exocytic apparatus, Rab27a and 
hMunc13-4 and effectors of cytotoxic function, perforin and granzymes, are localized 
in distinct structures, endosomal and lysosomal vesicles, respectively. Both vesicles 
move to the contact site with the target cell where during a late maturation step both 
vesicles are likely to fuse, a mechanism indispensable for lytic granule exocytosis85. 
Mice lacking Rab27 expression display compromised granzyme/perforin-mediated 
killing due to defective granule exocytosis in effector T lymphocytes86. 
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HOW LYTIC MOLECULES INDUCE APOPTOSIS 
Individual granzymes seem to have considerable functional redundancy, since mice 
that are deficient in one or several granzymes display less dramatic immune deficits, 
than do perforin-deficient mice87. Granzymes induce DNA fragmentation in the 
nucleus of target cells. Granzyme B is the best characterized and is believed to be a 
key player in the rapid induction of target cell death81,82. Indeed, granzyme B can 
cleave various caspases resulting in the activation of the cellular apoptotic cascade. 
However, granzyme B can also activate caspase-independent apoptosis pathways. 
One of them is granzyme B-induced mitochondrial collapse, resulting in the release of 
the pro-apoptotic protein, cytochrome c. Granzyme B has also been shown to directly 
activate nuclear DNAses by cleavage, contributing to target cell DNA apoptosis88.  
Granzyme A has a different substrate specificitiy and does not induce apoptosis by 
activation of caspases, as does granzyme B. Granzyme A induces slow cell death89 by 
destroying the nuclear envelope by targeting lamins and opening up DNA for 
degradation by targeting histones90, inducing single-stranded DNA breaks, rather than 
oligo-nucleosomal DNA degradation91.  
The role of the other “orphan” granzymes (H, K and M) is largely unknown.  
Once the “apoptotic switch” has been triggered the dying cell undergoes typical 
morphological transformation, characterized by:  
• cell shrinkage and rounding because of the breakdown of the cytoskeleton by 
caspases 
• dense cytoplasm with tightly packed organelles 
• chromatin condensation (pyknosis) and fragmentation (karyorrhexis) 
• the nucleus breaks into several nucleosomal units due to DNA degradation 
• the cell membrane displays “ blebbing” 
• and finally the cell breaks apart into apoptotic bodies, which are then cleared by 
phagocytes 
RELEVANCE OF GRANZYME AND PERFORIN-MEDIATED KILLING 
- Immune surveillance and defense against pathogens and tumors  
The role of perforin-expressing cells, including CTL, NK cells, NKT cells, γδ T cells 
in immune surveillance92 has been strengthened by the observation that perforin-
deficient mice develop spontaneous malignancies with age, in particular B cell 
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lymphomas93. Also in humans, it was suggested that perforin deficiency disturbed 
normal T cell homeostasis, favoring the uncontrolled proliferation of pre-malignant 
lymphoid cells, which in turn can acquire malignant phenotype94. Both CTL and NK 
cells share common cytolytic pathways that are implicated in the defense against 
virus-infected cells and transformed cells. As discussed above, the main pathway used 
by CTL is mediated through the directed release of cytolytic granules inducing 
apoptosis in the infected or malignant target cells. Studies in perforin-deficient mice 
have underlined the importance of this pathway in the response against viral 
infections and in tumorigenesis87. 
- Termination of immune responses, T cell homeostasis and T cell memory:  
T lymphocytes with a certain Ag-specificity are present in low numbers in non-
pathological conditions. However, upon antigen exposure these cells proliferate and 
differentiate to form reactive clones of effector T cells that efficiently kill infected 
target cells. Once the pathogen has been cleared, reactive T cells must undergo 
controlled deletion to reset cell numbers around initial levels (T cell homeostasis), 
leaving behind a pool of memory cells. Perforin seems to be implicated in the 
elimination of CD8+ T cells after acute exposure to foreign antigen. Moreover, 
perforin-deficient mice display increased clonal expansion and persistence of 
superantigen and virus-specific T cells95. The disappearance of effector T cells is 
essential as its persistence causes a fatal hemophagocytic syndrome resulting from 
uncontrolled activation and proliferation of T lymphocytes, leading to excessive 
macrophage activation and multiple deleterious effects96-98. Different mechanisms 
have been proposed to regulate T cell homeostasis. One explanation could be that 
CTL become infected themselves, making them targets for CTL-mediated fratricide. 
Indeed, some lymphotropic viruses (eg CMV, HTLV-1) naturally infect CD8+ T 
cells99. Another mechanism consists of a trans-activation of cytotoxic granules 
exerted against neighboring T cells if a high density of HLA:p is transferred from the 
stimulating APC to the surface of the target T cells, leading to fratricidal lysis100,101. 
Finally, trans-cytolytic action could also be exerted on APC. Perforin-dependent 
elimination of DC would act as a regulatory feedback mechanism to prevent the 
access of Ag-loaded DC to the lymph node and the further activation of Ag-specific T 
cells102.  
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- Autoimmunity 
CD8+ T cells also seem to be implicated in the onset of some autoimmune disorders. 
This has been clearly illustrated in mouse models for induced or spontaneous diabetes 
and autoimmune encephalomyelitis (EAE). Indeed, perforin-deficiency eliminated or 
dramatically reduced the severity of autoimmune responses against β-cells without 
affecting lymphocyte infiltration of the pancreatic islets, and EAE symptoms103,104.  
- Graft-versus-host disease 
Finally, CD8+ T cells derived from transplanted tissues can direct their lytic 
machinery towards host cells, resulting in life threatening GVHD after bone marrow 
transplantation105. Besides Fas-FasL-mediated cytotoxicity, granzymes have been 
shown to be required for the lethal effects of GVHD induced by transferred allo-
reactive CD8+ T cells87,89,106. 
b) Receptor-mediated cytotoxicity 
A second contact-dependent mechanism of CTL to kill dangerous cells involves 
ligation of death receptors expressed on the target cells. A well-characterized 
mechanism is the Fas-FasL-mediated pathway, inducing caspase-dependent apoptosis 
in target cells. This mechanism requires neither calcium nor lytic granules. Maximal 
expression of FasL requires prior activation of the effector cell107. Only little ligand is 
stored in CTL and for maximal killing the induction of new ligand synthesis is needed 
and requires TCR stimulation108. Lymphocyte homeostasis is thought to be regulated 
in part through the up-regulation of Fas and FasL upon T cell activation and 
subsequent triggering of activation-induced cell death95,109. Defective Fas-mediated 
apoptosis could allow prolonged survival of lymphocytes, which could then become 
targets of transforming events, suggesting a role for Fas-FasL in tumor 
development110. Fas-FasL interactions are also implicated in GVHD and autoimmune 
diseases. Indeed, Fas-FasL-mediated killing would play a role in the elimination of 
cells chronically exposed to self-antigens, either by fratricide or by specialized suicide 
processes111,112. In addition, mutations in Fas or FasL are associated with onset of 
autoimmune phenomena113,114.  
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4.2 Contact-independent destruction of target cells 
Upon activation, CTL secrete cytokines such as IFN-γ and TNF-α that exhibit 
cytotoxic action when secreted in the vicinity of target cells. 
a) IFN-γ 
IFN-γ is produced predominantly by NK cells, NKT cells, CD4+ Th1 cells and CD8+ 
CTL. Its critical role in immunity is illustrated by the occurrence of tumors, and 
inflammatory- and autoimmune phenomena when its production and/or secretion is 
defective. IFN-γ can directly inhibit viral replication and has antitumoral, 
immunostimulatory and immunomodulatory properties. IFN-γ promotes Ag-
presentation and lysosomal activity by macrophages, APC activation, up-regulation of 
MHC class I molecules, adhesion and binding required for leukocyte migration, NK 
cell activity and Th1 differentiation (by up-regulating the transcription factor T-
bet)(reviewed in 115,116). 
b) TNF-α 
TNF-α is an important regulator of the immune response. TNF-α is also able to 
induce apoptotic cell death and inflammation, and to inhibit tumorigenesis and viral 
replication. TNF-α is produced mainly by macrophages, but also by other immune 
competent cells, in particular, T lymphocytes. A local increase in concentration of 
TNF will cause the typical signs of inflammation: heat, swelling, redness and pain. 
Abnormal regulation of TNF-α production has been implicated in a variety of human 
diseases, as well as cancer117. Binding of TNF-α with the TNF-Receptor1 (expressed 
in most tissues) can lead to activation of death domains, inducing apoptosis in the 
target cell. Moreover, this pathway seems to be involved in activation-induced cell 
death of CD8+ T cells, regulating the termination of immune responses95,118. However, 
TNF-induced cell death plays only a minor role compared to its overwhelming 
functions in the inflammatory process.  
5. Failure of the immune system 
The pivotal role of a functional immune system is highlighted by the existence of 
immune deficiencies, pathologies in which the immune system does not work 
properly or is partially missing. Immune deficiencies are classified as primary or 
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secondary. Primary immune deficiencies (PID) are the consequence of mutations in 
genes that are involved in the control of immune responses, and are inherited. 
Secondary immune deficiencies are acquired as a consequence of other diseases (eg 
infection with HIV), or can be secondary to environmental factors (eg malnutrition), 
or adverse effects of medical intervention (eg chemotherapy). By examining which 
infections accompany specific immune disorders, it is possible to understand which 
components of the immune system contribute to the selective clearance of pathogens. 
In addition, PID reveal how interactions between different cell types contribute to the 
immune response and to the development of T and B lymphocytes. They lead to the 
identification of the defective gene, providing information for diagnosis, treatment 
and eventually gene therapy strategies1. More than hundred immune deficiencies have 
been described so far and are the result of defects in innate and/or adaptive 
responses1. 
A large proportion of PID are caused by recessive mutations in the X-chromosome. 
Since male subjects have only 1 X-chromosome, all males who inherit an X-
chromosome carrying a defective gene will manifest disease. In contrast, female 
carriers with one defective X-chromosome are usually healthy because the mutated X 
chromosome is inactivated.  
This work is focusing on a specific X-linked primary immune deficiency, the 
Wiskott-Aldrich syndrome. 
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6. The Wiskott-Aldrich syndrome 
In 1937, an early paper written by the German paediatrician, Alfred Wiskott, 
described for the first time a ‘familial and innate thrombopathia’, affecting 3 brothers. 
The boys suffered from thrombocytopenia, bloody diarrhea, eczema and recurrent ear 
infections. All three of them died as result of intestinal hemorrhages and sepsis119. 
Seventeen years later, in 1954, the group of Aldrich investigated this syndrome in a 
family where 16 out of 40 males were affected, and they concluded that the disease 
was X-linked120.  
Nowadays, the Wiskott-Aldrich syndrome (WAS; OMIM: 301000) is described as an 
X-linked primary immunodeficiency characterized by thrombocytopenia with small 
platelet size, eczema, recurrent infections and increased incidence of autoimmunity 
and hematologic malignancies, especially B cell lymphomas121-125. 
Linkage studies were employed to map the WAS gene to the small arm of the X-
chromosome (Xp11.22-p11.23)126. In 1994, the gene was isolated by positional 
cloning and found to encode an intracytoplasmatic protein that counts 1823 basepairs 
and is organized in 12 exons127. The Wiskott-Aldrich syndrome protein (WASP) 
participates in the dynamic regulation of actin polymerization, primarily through 
activation of the actin-related protein (Arp) 2/3 complex and is involved in cellular 
processes, such as a) cell signaling and subsequent cytoskeleton reorganization128 b) 
formation of podosomes, actin-rich structures identified in motile primary cells like 
macrophages129,130 and DC131,132, c) migration and cell trafficking of lymphocytes, 
DC, and granulocytes133.  
The incidence of classical WAS has been estimated between 1 and 10 individuals in 1 
million newborns, but might be much higher due to difficult early diagnosis in mild 
and evolutive cases. Clinical symptoms, such as petechiae, bruises, bloody diarrhea 
and infections manifest already early after birth. Due to microthrombocytopenia and 
severe disturbance in both the humoral and cellular immune system, affected patients 
develop life-threatening hemorraghes, infections, autoimmune diseases and/or tumors. 
The life expectancy of boys affected by WAS is estimated around 15 years in the 
absence of treatment123-125,134. 
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7. Genetic defects 
Mutations in the WAS gene give rise to a broad spectrum of clinical symptoms and is 
associated with distinct syndromes. Approximately 300 unique mutations in the WAS 
gene have been reported (see databases for WAS gene mutations135,136), spanning all 
12 exons, but clustered in the first 4123,137. 
Nonsense or frame-shift mutations and splicing defects leading to the absence of 
WASP expression or expression of a truncated, non-functional protein generally result 
in the very severe WAS phenotype123,124,138. 
Missense mutations or in-frame deletions or insertions are mostly associated with a 
milder phenotype as referred to as X-linked thrombocytopenia (XLT). These patients 
express reduced levels of full-length WASP and generally suffer from 
microthrombocytopenia, with minor or absent immunodeficiency, no malignancies 
and longer survival123,124,138. Intermittent thrombocytopenia, an even milder 
phenotype, has been described in males originating from 2 families who also display 
missense mutations in the WAS gene139. 
Finally, gain-of-function mutations in a specific domain of WASP, the Cdc42- and 
Rac-interactive binding (CRIB) domain, resulting in constitutive activation of WASP, 
leads to X-linked neutropenia (XLN; XLN, OMIM 300299). It was originally 
described in a three-generation family with five affected members. This syndrome is 
characterized by severe neutropenia and monocytopenia, low numbers of NK cells, a 
skewed lymphocyte CD4/CD8 ratio, recurrent bacterial infections and increased risk 
to develop myelodysplasia140-142. 
In general, the type of mutation in the WAS gene dictates the expression level and 
functionality of WASP, which in turn is associated with the severity of clinical 
disease. Patients lacking WASP are generally more susceptible to bacterial, viral and 
opportunistic infections, severe hemorraghes and malignancies and have a lower life 
expectancy as compared to patients with residual WASP expression123.  
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8. Clinical manifestations 
As mentioned above, full-blown WAS is characterized by bleeding disorders, eczema, 
recurrent infections and increased incidence of autoimmune manifestations, and 
hematologic malignancies. The causes of the different clinical manifestations 
characteristic of WAS have not been fully elucidated. However, recent progress in the 
understanding of the molecular role of WASP and in the identification of single 
defects in WASP-deficient immune cells allows to propose direct links between 
molecular/cellular defects and disease. 
8.1 Bleeding disorders due to microthrombocytopenia 
Over 80% of WAS and XLT patients suffer from bleeding disorders and 20% of them 
eventually succumb to it143. Bleeding is due to reduced number and size of platelets, 
which is a general finding in WAS and XLT patients 144. 
The most common and non-life-threatening bleeding disorders are epistaxis, 
petechiae, purpura and oral bleedings. Life-threatening intracranial and intestinal 
hemorraghes however appear to affect more WAS than XLT patients121. The severity 
of the bleeding episodes appears to correlate with the number of circulating platelets. 
The persistence of microthrombocytopenia, even in mildest patient phenotypes, is 
explained by absence of WASP in platelets, probably due to increased protein 
instability, even when residual WASP is expressed in other cell lineages144. 
Despite intensive research, the mechanism underlying WASP-related 
microthrombocytopenia and hemorraghes is still not fully understood. Abnormal 
platelet destruction, platelet formation and platelet function have been hypothesized. 
The half-life of platelets in WAS patients is decreased145-147 and might be explained 
by intrinsic platelet abnormalities144, the presence of auto-antibodies123,148,149 or 
increased expression levels of phosphatidylserine144 leading to their sequestration in 
the spleen150. Subsequent peripheral destruction is thought to contribute to 
thrombocytopenia, as evidenced by the partial correction of the size and number of 
platelets after splenectomy 146-148,151-153. Even if splenectomy corrects 
thrombocytopenia in WAS and XLT patients, it increases the risk to develop life-
threatening sepsis, and is thus not recommended. 
Alternatively, decreased platelet production could be at the origin of 
thrombocytopenia. This hypothesis was suggested since platelet survival seemed only 
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moderately reduced, whereas platelet turnover was significantly decreased in WAS 
and XLT patients as compared to normal donors145, despite normal or even increased 
megakaryocytopoiesis and megakaryocyte numbers145,153. A recent study in WAS-/- 
mice demonstrated that despite normal platelet production, proplatelet formation 
might occur ectopically within the bone marrow hampering platelet release in the 
bloodstream154. 
Finally, it has been proposed that intrinsic platelet dysfunction could also contribute 
to the frequent bleeding episodes. Indeed, it has been demonstrated that thrombin-
mediated platelet activation and integrin-mediated platelet adhesion to fibrinogen 
would be defective149,155. 
8.2 Eczema 
Eczema is a very common characteristic of WAS and develops in 80% of WAS 
patients. It is very heterogeneous in severity and persistence. Indeed, in its most 
severe form, eczema resists to therapy and persists into adulthood. Areas of affected 
skin, create excellent heards for infections with viruses (eg Herpes simplex, 
Molluscum contagiosum), fungal or bacterial pathogens124,125. The incidence and 
severity of eczema are significantly lower in patients with residual WASP 
expression123. Defective homing of Langerhans cells and DC to peripheral lymphoid 
tissues after activation may play a role in the local generation of Ag-specific T cell 
responses, causing development of eczema125. In addition, it has been described that 
upon T cell triggering, Th1 cytokine production is defective, skewing the immune 
response into Th2 response, promoting the development of allergy and eczema in 
WAS patients156. High levels of IgE could also play a role, however, IgE 
concentrations do not correlate with the severity of eczema123. 
8.3 Recurrent infections 
The increased susceptibility of WAS patients to infection most probably results from 
a combination of defects in cells involved both in innate and adaptive immunity. 
Patients with full-blown WAS are significantly more affected by infections than 
patients with XLT123. Infections account for nearly 50% of the death cases143, and are 
caused by a variety of pathogens, including bacteria, viruses and fungi. 
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Bacterial infections are very frequently caused by encapsulated bacteria, probably due 
to decreased responses to polysaccharide antigens in WAS patients145. Commonly 
reported bacterial infections affect the ear, the skin, the gut, and the respiratory and 
urinary tract. Systemic infections, such as meningitis and sepsis are also reported123. 
WAS patients are also very vulnerable to viral infections. Infection with Herpes 
simplex virus or Cytomegalovirus causes encephalitis or hepatitis, respectively. Other 
reported viral infections are caused by Molluscum contagiosum and Pappiloma 
viruses123. 
Fungal infections caused by Candida or Aspergillus as well as opportunistic 
pulmonary infection due to Pneumocystis carinii are also frequently reported in WAS 
patients123. 
8.4 Autoimmunity 
The incidence of autoimmunity in WAS patients in Europe and USA is estimated 
around 40-72%, while it appeared to be less frequent in a Japanese survey (22%)121-
123. Most common autoimmune diseases are haemolytic anemia, cutaneous vasculitis, 
arthritis and nephropathy. Less common are inflammatory bowel disease, idiopathic 
thrombocytopenic purpura and neutropenia. In general, patients who develop 
autoimmunity suffer from several autoimmune pathologies at the same time122. The 
presence of autoimmune disease is associated with development of tumors and 
increased risk of mortality121,122. Several hypotheses have been proposed to explain 
the mechanisms of WAS-related autoimmune disease. Recurrent bacterial, viral and 
fungal infections result from defects in both cellular and humoral immunity. The 
inability of the immune system to eradicate pathogens efficiently from the system can 
lead to compensatory, chronic immune responses which do not only destroy infected 
cells, but also the surrounding healthy tissues143. Compromised clearance of apoptotic 
cells by macrophages as result of defective phagocytosis is thought to contribute to 
onset of autoimmune phenomena157. Invariant NKT cells might as well be implicated, 
since circulating iNKT cells seem to protect the host from developing autoimmunity. 
However, these cells seem to be absent in patients with WAS, but not in patients with 
XLT66. Alternatively, Park et al demonstrated that B cells from patients with WAS, 
express lower levels of CD21 and CD35, 2 complement factors involved in the 
capture and presentation of antigens by B cells. Downregulation of CD21 and CD35 
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on B cells has been reported in several autoimmune diseases in humans, as well as in 
murine models for autoimmunity158. In addition, the high levels of serum-IgM 
produced by activated plasmacells in WAS patients, have also been associated with 
autoimmune disorders122. Another possibility would be the loss of central or 
peripheral tolerance to self-antigens. Given the role of WASP in TCR signaling, 
WASP deficiency might affect TCR-induced apoptosis during the process of negative 
selection of thymocytes, leading to the escape of self-reactive T cells from the thymus 
to the bloodstream159. Finally, defective localization and suppressor function of CD4+ 
CD25+ Foxp3+ regulatory T cells has been demonstrated in WAS patients and might 
as well contribute to the onset of autoimmune disorders160-163. 
8.5 Hematologic malignancies 
Tumors develop more frequently in adolescents and young adults with an incidence of 
13-22%121,123. However, tumors can also develop at young age, especially 
myelodysplasia. Most of WAS-related tumors are lymphoreticular malignancies, 
including leukemia, myelodysplasia and lymphoma and cover 90% of the cases. Life 
expectancy of WAS patients, who developed malignancies, is very low and is 
responsible for 25% of death cases143. Indeed, less than 5% of WAS patients survive 2 
years after diagnosis121. Since the majority of tumors are associated with Epstein-Barr 
virus (EBV) infection, immune deficiency is likely to contribute to the development 
of tumors164. Defective NK cell165 and CTL cytotoxicity (De Meester et al., JLB, 
2010) as well as other alterations in immune surveillance or defects in regulatory T 
cells may play a role in the susceptibility to development of WAS-related 
malignancies. WASP might also play a role in maintenance of genomic stability and 
cytokinesis140,142. 
8.6 Scoring system 
Zhu and colleagues developed a scoring system to evaluate the severity of the clinical 
symptoms of patients with WAS and XLT. In the group of XLT patients, a score of 
0,5 or 1 is assigned to patients with intermittent or chronic thrombocytopenia and 
small platelets, and score 2 is assigned to patients with additional symptoms, such as 
mild, transient eczema or minor infections. Patients who display treatment-resistant 
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eczema and recurrent infections, despite optimal treatment receive score 3 (mild 
WAS) or 4 (severe WAS). Patients who present autoimmune disorders or 
malignancies automatically receive score 5, regardless their original score (Table 1). 
 
  XLT    WAS  
Clinical scores 0.5 1 2  3 4 5 
Thrombocytopenia +/- + +  + + + 
Eczema - - +/-  + ++ ++/- 
Immunodeficiency - - +/-  + ++ ++/- 
Autoimmunity and/or tumors - - -  - - + 
Table 1: WAS scoring system according to Zhu and colleagues166, with subsequent 
refinements123,139. 
9. Therapy 
Considerable progress has been made in the last 2 decades in the diagnosis and 
treatment of WAS. However, management of patients with WAS still represents 
major challenges, particularly in patients with attenuated phenotypes where the 
natural history of disease progression is less predictable. Early diagnosis is of great 
importance for effective prophylaxis and treatment125. Today, treatment consists of 
prevention, symptomatic treatment and bone marrow transplantation. The latter, 
representing the only curative therapy available at present. However, due to many 
difficulties associated with bone marrow transplantation, the quest for alternative 
approaches continues. Clinical trials based on genetic correction of WASP expression 
in hematopoietic cells by gene therapy are ongoing or will soon be initiated and will 
hopefully provide a safe and life-long solution for patients with WAS who are today 
without any hope to cure. 
a) Symptomatic therapy 
Platelet transfusions are restricted to treat serious bleeding (intracranial and intestinal 
hemorraghes) and in some cases splenectomy can be considered for patients with 
XLT. Splenectomy efficiently stops the bleeding disorder by repairing the number of 
circulating platelets. However, it increases the risk of septicemia, and requires lifelong 
antibiotic prophylaxis. Severe eczema can be treated using local steroids or if 
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indicated short-term systemic use of Prednisone. In case of infection and after careful 
evaluation of the nature of the pathogen, appropriate antimicrobial therapy is crucial. 
Cutaneous infections can be treated with local or systemic antibiotics. Prophylactic 
intravenous immunoglobulin infusions are recommended if antibody responses are 
inefficient towards protein or polysaccharide antigens. Also vaccination with killed 
vaccines might be considered, but life vaccines are not recommended. To silence 
autoimmune diseases, aggressive immunosuppressive therapy might be required125. 
Chemotherapy protocols, including anti-CD20 monoclonal antibodies are used to 
conquer WAS-related malignancies and results in higher cure rates167,168. 
b) Curative therapy 
Hematopoietic stem cell transplantation  
Hematopoietic stem cell transplantation (HSCT) remains the treatment of choice for 
WAS patients who have an HLA-matched donor. Indeed, HSCT with a related HLA-
identical donor (RID) leads to 80% survival rate and therefore is the most 
recommended therapeutic option. An alternative option is to use bone marrow from a 
matched unrelated donor (MUD), leading to 71-81% survival rate167,169,170. However, 
when no RID or MUD is available, bone marrow from a related mismatched donor 
(MMRD) can be used for transplantation, but results in decreased survival rates169-172. 
In addition, it is associated with elevated risks to develop life-threatening EBV+ 
lymphoproliferative syndrome, infections, autoimmunity and GVHD169. It has been 
suggested to perform transplantation early in life, since better outcome has been 
reported for HSCT from MUD or MMRD when performed before 5 and 2 years of 
age, respectively. When successful, immune and hemostatic functions are restored. In 
patients with stable mixed chimerism in both myeloid and lymphoid compartments, 
clinical conditions usually improve167,173. However, results from a recent long-term, 
retrospective, multi-center study showed that mixed chimerism led to autoimmune 
disease in 72% of the WAS patients after HSCT as compared to only 8% when full 
chimerism was established172. 
Gene therapy 
Despite the improvement of HSCT, patients for whom no HLA-identical sibling is 
found, who reject their graft, or develop GVHD, need alternative approaches. For this 
reason, many efforts are focused on the development of gene therapy strategies. The 
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wide range of cellular defects characterizing WAS points to hematopoietic stem cells 
(HSC) as target cells for therapeutic options. Gene correction of precursor CD34+ 
HSC would eventually lead to restoration of WASP expression in all cell lineages 
from myeloid and lymphoid origin. Transplantation of these autologous and 
genetically repaired HSC would avoid graft rejection and GVHD, and would not 
require intensive conditioning regimen as performed for allogeneic HSCT. In 
addition, gene therapy could be performed early in life (no need for the time-costing 
search of a compatible donor), before development of autoimmune diseases and 
malignancies. 
The rationale for gene therapy for WAS is based on reported cases of spontaneous 
reverse mutations. Indeed, initial studies demonstrated spontaneous back-to-normal 
reversions in the WAS gene from WAS patients by deletion of an inserted repeat 
sequence174, site-specific single nucleotide reversion175, or frame restoration by 
insertion of a single nucleotide176. Originally, it was thought that reversion occurred 
only in the T lymphocyte compartment. However, a WAS patient with NK cell 
mosaïcism has been described177. Independently from the cell type that displayed the 
reversion, re-expression of the normal WAS protein seemed to provide a growth 
advantage. For T lymphocytes, revertant cells have been shown to regain functions. 
Indeed, the majority of revertant T cells displayed normal morphology and microvilli 
numbers175. In a revertant case recently described by our group, revertant CD4+ T 
cells displayed normal subcellular localization of WASP, proliferation and cytokine 
production upon stimulation with anti-CD3/anti-CD28-coated beads178. Importantly, 
revertant T cells appeared to localize normally within secondary hematopoietic organs 
(spleen and lymph nodes). In another recent WAS revertant case, a high diversity of 
genotypic revertants was shown in a same patient. Indeed, over 30 different second-
site mutations, leading to restoration of WASP expression, have been detected in 
primary T cell clones from a WAS patient that carries a nonsense mutation in exon 10 
of the WAS gene179. It has been estimated that at least 11% of WAS patients display 
somatic mosaïcism due to spontaneous in vivo reversion of the original mutation or 
second-site compensatory mutations, leading to restoration of the production of the 
WAS gene product. This high prevalence could be explained by selective growth 
advantage of revertant cells, abnormally high mutation rates and/or increased 
susceptibility of specific WAS gene sequences to DNA polymerase errors180. 
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First reports on gene therapy trials for patients with ADA-SCID have been described 
in the early 90s, but appeared to lack clinical benefits probably because of 
concomitant treatment with ADA enzyme replacement therapy181. However, 
perseverance of several groups eventually led to the first described successful trials 
for patients with SCID (SCID-X1 and ADA-SCID) and X-CGD. Gene therapy with 
retroviral vectors based on murine Moloney leukemia virus (MMLV) induced long-
lasting immune reconstitution with proviral integration and was accompanied with 
resolution of immune deficiency and clear clinical benefits. Unfortunately, some 
years after gene therapy, some patients with SCID-X1 presented with leukemia as 
result of insertional mutagenesis of the retrovirus in the proximity of proto-oncogenes 
(eg LMO2) and 2 out of 3 patients with X-CGD developed monosomy 7, probably 
due to insertional activation of cancer-associated genes (MDS1-EVI1, PRDM16 and 
SETPB1), suggesting potential genotoxicity of retroviral-based gene therapy182. 
Even if the use of MMLV-based retroviral vectors for WAS raises several concerns in 
view of the adverse events that occurred in SCID-X1 and X-CGD183-186, a clinical trial 
was started in Germany where MLV-derived retroviral vectors, encoding full length 
cDNA for WASP, were used for gene therapy of WAS patients. Preliminary data on 
the first 2 treated patients demonstrate correction of thrombocytopenia and resolution 
of eczema and autoimmunity approximately 2.5 years after gene therapy187.  
In vitro studies based on retroviral gene therapy vectors in human WASP-deficient B 
and T lymphocytes demonstrated restoration of proliferative reponses to anti-CD3 
stimulation and cytoskeletal dynamics188-190. 
Ex vivo transduction of murine HSC with WASP-encoding retroviruses resulted in 
normal B and T cell numbers, restoration of TCR-driven T cell proliferation and 
cytokine production and normalization of secondary responses against infection with 
Influenza virus in mice191,192.  
Nowadays, it is well established that onco-retroviral vectors integrate preferentially at 
the proximity of transcriptional start sites of genes, and insert frequently nearby proto-
oncogenes. Therefore, new gene therapy approaches are based on the use of third 
generation self-inactivating lentiviral vectors, which have been demonstrated to be 
less genotoxic than retroviral vectors. Indeed, they have been shown to integrate 
within genes without preference for regions nearby transcription start sites, possibly 
avoiding trans-activation of oncogenes. Lentiviral transduction experiments using 
vectors expressing full-length human WASP under the control of the internal spleen 
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focus-forming virus led to restoration of podosome formation and chemotaxis to SDF 
in WAS patient macrophages and DC129. Transduction of HSC derived from WASP-
deficient mice with a human WASP encoding vector under the control of the human 
phosphoglycerate kinase (PGK) promoter restored T cell proliferative responses and 
podosome formation in DC193. 
Further improvement of HIV-based clinical vectors was reached with the 
development of lentiviral vectors encoding the human WAS protein under control of 
the endogenous WASP promoter. These vectors have been shown to efficiently 
transduce T lymphocytes from WAS patients, restore TCR-driven T cell proliferation 
and provide a selective growth advantage in vitro194,195. In addition, in vivo studies 
performed in 2 different WAS-/- strains showed evidence of long-term multi-lineage 
WASP expression in hematopoietic cells and correction of B and T cell functions 
after lentiviral transduction of CD34+ HSC. Importantly, long-term observations of a 
large cohort of gene therapy treated mice did not display any severe adverse event 
related to vector toxicity. All these findings represent a critical step in moving 
towards the implementation of a lentiviral vector-mediated gene therapy clinical 
trial194-198. Parallel clinical trials based on the use of third generation lentiviral vectors 
to restore WASP expression are starting by the end of 2010 in different European 
centers, including London, Milan and Paris. 
Together these observations provide new hope to cure WAS patients in the future. 
Lentiviral vectors under control of the endogenous WASP promoter have the 
advantage to drive WASP expression exclusively in cells of hematopoietic origin. In 
addition, the developed vectors contain self-inactivating sequences, greatly improving 
the biosafety of virus-based gene therapy approaches. Whether transplantation of 
genetically corrected HSC also confers selective growth advantage and corrects 
defects in immune cells, other than lymphocytes, needs to be further explored. 
 
10. The Wiskott-Aldrich syndrome Protein 
10.1 Characteristics 
The product of the WAS gene is a 502 amino-acid intracellular protein, the WAS 
protein (WASP). WASP is selectively expressed in the cytoplasm of hematopoietic 
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cells and has been shown to be involved in the regulation of migration and IS 
formation between different immune cells. Besides its role in cytoskeletal remodeling, 
WASP is required for signal transduction downstream from T and NK cell activation 
and subsequent effector functions. WASP is a member of a family of proteins 
involved in the integration and transduction of extracellular signals into actin 
cytoskeletal remodeling. Other members of this family are the more widely expressed 
neural-WASP (N-WASP) and the WAVE (or Scar) proteins 1, 2 and 3. All these 
proteins are organized into evolutionary conserved modular domains responsible for 
their subcellular localization and activation123,125,138,199 (Figure 3). 
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Figure 3: Schematic representation of WASP-family proteins in mammals (Provided by 
Ronan Calvez). 
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a) Verprolin homology, central, acidic domain (VCA domain) 
Cytoplasmatic WASP is mainly present in an auto-inhibited conformation caused by 
interactions of the C-terminal-VCA domain with a hydrophobic pocket in the Cdc42 
and Rac-interactive binding (CRIB) domain200, forming a hairpin in the WAS protein. 
The activated, unfolded WASP however, allows direct interactions of the VCA 
domain with G-actin monomers, a pre-existing actin filament and the Arp2/3 
complex, resulting in the nucleation of G-actin in a network of branched actin 
filaments124,125 (Figure 4). 
b) Poly-proline rich region 
This domain is required for optimal WASP-mediated actin polymerization and 
recruitment to the immunological synapse formed between APC and T cells. The 
poly-proline region contains a binding site for vasodilator-stimulated phosphoprotein 
(VASP) and Scr homology 3-domains of proteins such as Nck, several tyrosine 
kinases and endocytotic proteins. Interaction with these proteins is believed to be 
important for migration, localization and activation of WASP within the cell and 
membrane remodeling124,125. 
c) Cdc42 and Rac-interactive binding domain 
In the absence of active guanosine triphosphate (GTP)-bound Cdc42, the CRIB 
domain interacts with the VCA domain, preventing Arp2/3-mediated actin 
polymerization. However, active GTP-Cdc42 binds with high affinity to the CRIB 
domain, resulting in the unfolding of WASP, facilitating interaction of the VCA 
domain with the Arp2/3 complex and resulting in the nucleation of actin200.  
d) Basic domain 
This highly basic region is probably responsible for the binding of 
phosphatidylinositol (4,5) biphosphate (PIP2) to WASP. PIP2 synergizes with Cdc42 
in the activation of WASP and since this protein is anchored in the membrane, 
provides a route through which WASP could respond to membrane composition124,125. 
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Figure 4: Schematic representation of the regulation of WASP activity. Cytosolic WASP 
exists in an auto-inhibited conformation in which the VCA domain is bound to the CRIB 
domain (A). Activation of WASP by GTP-bound Cdc42/Toca-1 complex or by 
phosphorylation of Tyrosine 291 disrupts the auto-inhibited conformation, enabling Arp2/3 
binding and actin polymerization (B) 201.  
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e) Ena/ VASP homology 1 domain (EVH1 domain) 
This domain is located on the N-terminus of WASP and binds the WASP-interacting 
protein (WIP). Constitutive interaction between the EVH1 domain and WIP stabilizes 
WASP through inhibition of calpain and proteasome degradation202,203.  Binding of 
WIP to the EVH1 domain would also inhibit spontaneous activation of WASP. 
Indeed, it has been hypothesized that dissociation of the WIP-WASP complex is 
crucial for WASP activation in T cells upon TCR triggering204. Recently, a subject 
with reduced WASP expression as result of mutations in the WIP gene, resulting from 
a premature stop codon and abolished WIP expression has been described, 
demonstrating the importance of WIP-WASP interactions for WASP stability205. 
 
Not only interaction with other proteins leads to activation of WASP. Collagen 
stimulation of platelets, IgE-receptor stimulation of mast cells and TCR stimulation of 
T cells induces phosphorylation of the tyrosine residue, Y291, by Src kinases, such as 
Btk and protein tyrosine phosphatase (PTP)-PEST. This phosphorylation is 
indispensable for the opening of the WAS protein from its auto-inhibited 
conformation and for its role in actin polymerization and IS formation (Figure 4 and 
5). 
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Figure 5: TCR-mediated WASP activation and consequent Arp2/3-mediated actin 
polymerization in T lymphocytes. WASP is recruited to the IS by Zap70 upon TCR triggering 
in 2 ways: by interaction with WIP, leading to the formation of a Zap70-CrkL-WIP-WASP 
complex, or through direct interaction of its proline-rich region with the SH3 domain of Nck. 
Zap70 then phosporylates the adaptor SLP76 and binds both Nck and Vav-1, localizing both 
WASP and GTP-bound Cdc42 to the IS (provided by Ronan Calvez). 
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10.2 Cellular defects mediated through WASP 
As exposed above in our introduction to the immune system, the orchestration of an 
effective immune response for host defense and maintenance of tolerance requires a 
narrow cooperation between immune cells both from the innate and adaptive immune 
systems. Thereby, dynamic actin reorganization involved in cell polarization, 
migration, Ag-uptake, cell interactions etc …, is of crucial importance. As an 
important actin cytoskeletal regulator, WASP regulates the function of different cell 
types contributing to host defense. It has become clear that absence of this protein 
results in compromised immune functions in both innate and adaptive immune cells 
(Figure 6). 
a) Hematopoietic stem cells 
WASP is expressed in CD34+ hematopoietic precursors, suggesting that it plays a role 
in hematopoiesis and differentiation206. Studies of carrier female subjects of classic 
WAS show selective inactivation of the mutated X-chromosome in HSC, suggesting a 
role for WASP in the lyonization process207. However, a direct role for WASP in X-
chromosome methylation has never been demonstrated208. Competitive repopulation 
studies have demonstrated a selective advantage for normal HSC in the migration 
from foetal liver to the bone marrow and for their engraftment. Furthermore, 
hematopoiesis established by means of engraftment of chimeric foetal liver 
populations results in non-random dominance of normal HSC over WASP-deficient 
cells209, suggesting a preferential establishment of hematopoiesis by normal, rather 
than mutant HSC, probably caused by an intrinsic homing advantage125. However, 
studies in a murine model have challenged these results. Indeed, 2 groups failed to 
confirm the selective advantage of WASP+ HSC in WAS +/- mice210,211. 
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Figure 6: Cellular functions affected by WASP deficiency. Abbreviations used: HSC: 
hematopoietic stem cell; B: B lymphocyte; T: T lymphocyte; Th: T helper cell; Tr: regulatory 
T cell; CTL: cytotoxic T lymphocyte; NK: natural killer cell; mDC: mature dendritic cell; 
iDC: immature dendritic cell212. 
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b) Natural killer cells 
NK cells are involved in first line defense against certain viruses, microbial products 
and parasites. Defective NK cell cytotoxicity due to defective accumulation of F-actin 
and perforin at the IS has been demonstrated in 2 WAS patients. These functional 
defects may be in part compensated by increased NK cell numbers in WAS 
patients165. Gismondi et al demonstrated that in addition to defective F-actin 
enrichment, defective conjugate formation with susceptible cells contributes to the 
cytolytic defect in NK cells. Addition of high amounts of exogenous IL-2 restored the 
functional defects in WAS and XLT patients, suggesting that IL-2 could trigger a 
WASP-independent signaling pathway that can compensate for its loss of function or 
complete absence. Patients with the milder XLT phenotype displayed similar 
defective F-actin accumulation and conjugate formation, but the cytolytic defect was 
less pronounced213. 
c) Macrophages 
WASP is essential in the maintenance of cell shape during migration. In contrast to 
normal counterparts, human and murine WASP-deficient macrophages display hyper-
elongated morphology and lack the typical broad lamellipodium at the leading edge 
and a narrow contractile tail at their trailing edge215. Phagocytotic cup formation and 
IgG-mediated and apoptotic cell phagocytosis are impaired in the absence of 
WASP215,216. Chemotactic responses in response to a variety of stim0uli are defective 
in WASP-deficient macrophages in vitro129,217-219. In addition, abnormalities in the 
regulation of the cytoskeleton have been reported, including abnormal actin 
distribution, protrusive activity, cell polarization and the formation of 
podosomes129,215,218,220,221. Reconstitution of WASP in WASP-deficient cells restores 
the assembly of podosomes and chemotaxis129. Very recently, Dovas et al 
demonstrated that WASP activity was restricted only to podosome structures. 
Furthermore, pharmacological and RNA-interference approaches suggested that 
continuous WASP activity is required for the steady state of these structures. In 
addition, they demonstrated that Cdc42 is indispensable for podosome formation, 
whereas phosphorylation of the WASP-tyrosine residue Y291 seems to be important 
for efficient nucleation of nascent podosomes, podosome stability, restriction of 
WASP activity to podosomes and matrix degradation. Finally they suggested that 
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complex regulation of phosphorylation and de-phosphorylation regulates chemotaxis 
in response to CSF-1130. 
d) Dendritic cells 
As for macrophages, DC also display several morphological, cytoskeletal and 
functional abnormalities. Indeed, formation of podosomes upon maturation is 
abrogated in WASP-deficient human DC214,222. In addition, WASP-deficient DC fail 
to cluster β2 integrins at podosome sites, resulting in impaired adhesion to ICAM-
1222. WASP-deficient DC show defective polarization and aberrant lamellipodia 
formation, resulting in compromised translocation on fibronectin223. All these 
observations suggest a role for WASP in the movement of activated immature DC 
from peripheral tissues into secondary lymphoid organs224. Indeed, defective homing 
from the skin into peripheral lymphoid tissues and defective localization into T cell 
areas has been demonstrated in WASP-deficient murine DC132,133. Therefore, it is 
very likely that trafficking abnormalities and defective localization of DC contribute 
to the physiopathology observed in WAS. Down-modulation of WASP in healthy 
donor DC by means of lentiviral vector-mediated sh-RNA interference, induced 
similar morphological and migratory defects131. Restoration of WASP expression by 
gene transfer, restored podosome assembly and migratory defects both in vivo and in 
vitro193,214,225. In addition, it has been described that WASP is required for efficient 
processing of particulate, but not soluble, antigen by murine DC226. Recently, 2 
studies showing defective in vivo CD4+ and CD8+ T cell priming by WASP-/- DC in 
mice due to defective DC homing to draining lymph nodes, defective localization into 
T cell areas and impaired ability to form stable conjugates were reported227,228. In 
addition, priming of both CD4+ and CD8+ T cells by WASP-deficient DC required 
higher Ag doses, as compared to T cell priming with normal DC, suggesting a role for 
WASP in threshold-dependent T cell activation even if successful colocalization 
occurred227,228. Finally, WASP-deficient DC fail to activate NK cells properly as 
result of defective polarization of IL-12229. 
e) T lymphocytes 
T cell dysfunction is a major clinical component of WAS-associated 
immunodeficiency124. Early in life, T cell counts are normal to moderately reduced in 
WAS patients. With age, circulating T cell counts drop, probably as a result of 
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accelerated cell death. Indeed, it has been demonstrated that B and T lymphocytes 
from WAS patients undergo higher levels of spontaneous apoptosis as result of 
attenuated expression of Bcl-2230. Furthermore, accelerated cell death in T 
lymphocytes from WAS patients, but not XLT patients, has been shown to result from 
increased caspase-3 activity and increased expression of FasL231. More recent studies 
however, demonstrate decreased numbers of lymphocytes already very early after 
birth, probably due to defective maturation of T lymphocytes in the thymus and bone 
marrow. In addition, it has been demonstrated that within the T cell compartment, the 
naïve CD4+ and CD8+ T subsets are reduced but not the memory T lymphocyte 
subsets232. Morphologically, lymphocytes isolated from WAS patients contain 
decreased frequencies of cells densely covered with microvillus projections. 
Additionally, microvilli seemed shorter and blunted as compared to normal 
lymphocytes and cells with irregular surface projections were detected in T cell lines 
generated from WAS patients233-235. Ag-receptor capping (clustering of TCR upon 
Ab-mediated cross-linking) was attenuated in WASP-/- mice and associated with 
decreased TCR internalization and defective proliferative responses upon stimulation 
with anti-CD3 antibodies159,236. In contrast, proliferation appeared unaffected upon 
stimulation with PMA and Ionomycin159. In humans T cells derived from WAS 
patients were unable to polymerize actin and consequently displayed severe defects in 
actin reorganization and spreading in response to CD3-stimulation235. Additionally, 
normal proliferative responses towards allogeneic antigens and mitogens have been 
described in T cell lines generated from WAS patients. However, a restricted defect in 
CD3-mediated proliferation was identified234,235. Restoration of WASP expression by 
retroviral- or lentiviral-mediated gene transfer, restores T cell proliferative responses 
in response to TCR ligation190,192-194,197. Given the prominent role of WASP in 
cytoskeletal reorganization and the fact that WASP is recruited to the contact site 
between T cells and APC, WASP might play a role in the formation or stabilization of 
the IS. However, results are controversial: defective formation of the IS has been 
described in WAS patients, as result of impaired up-regulation and defective 
clustering of the glycosphingolipid raft marker GM-1 during T cell activation in WAS 
T cells. In addition, defective actin polymerization has been demonstrated at the T-
APC contact site upon TCR/CD28 or CD2 stimulation189,237. In contrast, upon 
stimulation in the presence of high Ag dose, IS formation was shown to occur 
normally in WASP-deficient mice, along with normal actin polymerization and 
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normal recruitment of talin and PKCθ. Lowering Ag dose revealed a role for WASP 
in facilitating IS formation and recruitment of talin and PKCθ238. Recently, new 
findings indeed strengthened this hypothesis. The group of Dustin proposed that both 
PKCθ and WASP are dispensable for the formation of an IS by naïve T cells in 
contact with a lipid bilayer presenting peptide-MHC molecules. PKCθ would be 
localized in the pSMAC and would regulate periodically breaking of the pSMAC, to 
reform at another site. This symmetry breaking and reformation of the IS would allow 
naïve T cells to “scan” APC continuously to find a maximum of activatory stimuli. 
They also proposed that WASP would act as a negative regulator of symmetry 
breaking processes, regulated by PKCθ. In T cells lacking WASP, symmetry breaking 
occurred normally but the reformation of a symmetric IS appeared defective40.  
WASP seems to be required for the production and/or secretion of cytokines in mice 
and humans. Indeed, IL-2 production appeared compromised in murine T cells upon 
in vitro stimulation with anti-CD3 and anti-CD28159, or anti-CD3 alone, as result of 
defective NFAT translocation239. IL-2 production in WASP-deficient mice is also 
defective upon in vivo antigenic stimulation238. For IFN-γ production by murine Th1-
primed CD4+ T cells however, production seems to occur normally, but WASP seems 
to have a selective effect on its secretion. In addition, despite defective cytokine 
production and/or secretion, WASP does not affect chemokine secretion239. Trifari et 
al demonstrated that along with defective TCR/CD28-mediated T cell proliferation, 
the production of IL-2, IFN-γ and TNF-α is severely affected in CD4+ and CD8+ T 
cells from patients with WAS, while the production of IL-4, IL-5 and IL-10 is only 
minimally affected in CD4+ T cells, even when cultured in Th1 polarizing conditions. 
This selective Th1 cytokine defect is regulated on transcriptional level and associated 
with defective induction of T-bet and delayed recruitment NFAT-1 in CD4+ T cells, 
and reduced early recruitment of NFAT-1 and 2 in CD8+ T cells upon CD3/CD28 
stimulation156. Surprisingly however, it has recently been demonstrated that murine 
Th2-primed WASP-deficient CD4+ T cells show a profound defect in IL-4 production 
when restimulated with Ag-loaded APC, whereas Th1-primed CD4+ T cells normally 
produced and secreted IFN-γ, despite their normal differentiation into Th1 or Th2 
cells. mRNA levels of IL-4 seemed normal in WASP-deficient Th2 cells as compared 
to normal CD4+ Th2 cells, despite the reduced IL-4 production. In addition, they 
demonstrated a decrease in ERK phosphorylation upon TCR triggering in WASP-
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deficient CD4+ T cells and this effect seemed more pronounced in Th2 than in Th1 
cells. Since ERK plays a role in translational regulation and protein stability, they 
suggest a role for WASP, possibly via ERK, in the post-transcriptional regulation of 
IL-4 production, but not IFN-γ. Also in contrast with previous data, they show a 
normal in vivo Th1 response in mice against Leishmania major, despite decreased 
numbers of IFN-γ-producing WAS-/- CD4+ T cells in the infected tissues as compared 
to normal mice240.  
Several groups demonstrated severe defects in the function of regulatory T cells. 
Indeed, in vivo and in vitro studies on mice and in vitro human studies have revealed 
reduced suppressor function against normal and WASP-deficient effector T cells. 
Observed suppression defects were associated with, but not entirely explained by 
impaired in vivo homing to target organs162 and inadequate activation160,163. In 
addition, Treg showed defective IL-10 secretion, associated with loss of protection 
against development of colitis in mice162, as well as production of TGF-β upon 
activation163. Only recently, WASP deficiency in iNKT cells has been investigated. A 
profound reduction of circulating iNKT cells has been observed in WAS patients and 
seemed to correlate with severity of disease66. Furthermore, WASP seemed to be 
indispensable for the maturation of murine WAS-/- iNKT cells. In addition, WASP-
deficient iNKT cells displayed defective homeostasis, homing, retention within 
peripheral lymphoid tissues and activation66,67.  
Besides some old studies reporting contradictory results on cytolytic function in total 
lymphocytes, we failed to identify papers that specifically address the role of WASP 
in human CD8+ CTL. Trifari et al demonstrated defective CD8+ T cell proliferation 
upon antibody-mediated TCR-ligation and suggested preserved lytic activity against 
allogeneic EBV-transformed B cells and PHA blasts156. 
 
f) B lymphocytes 
B cell functions are believed to be as affected as those of T cells, although, less 
established due to the difficulty in separating the effects of intrinsic B cell dysfunction 
from those of reduced T cell help and cyto-architectural changes in secondary 
lymphoid organs124. WAS patients usually have reduced numbers of circulating B 
cells and poor lymph node follicle formation121,158,232. Antibody responses are 
adequate to some antigens (eg live virus vaccines) and insufficient to others, such as 
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polysaccharide antigens for which T cell help for the induction of an immune 
response is not required125,241. Activation of primary B cells isolated from WAS 
patients or WASP-/- mice seems to occur normally upon BCR triggering159,236,242. 
Several studies demonstrated the importance of WASP in cytoskeletal rearrangement. 
Decreased F-actin content was shown in EBV-transformed B cell lines generated 
from WAS patients243. Murine WASP-deficient B cells displayed impaired 
polarization, spreading, homotypic aggregation and microvilli formation in response 
to CD40 and IL-4-dependent stimuli241. Suboptimal Ag-uptake and presentation, due 
to decreased numbers of B cells expressing complement receptor 1 (CD35) and 2 
(CD21), has been suggested. In addition, defects in B cell germinal centre maturation 
and differentiation into CD27+ post-germinal center B cells have been demonstrated, 
despite normal isotype switching158. Recently, it has been shown that WASP plays a 
role in peripheral homeostasis of mature B cell subsets in mice210,211. WASP 
deficiency results in a marked reduction of especially splenic marginal zone (MZ) B 
cells and peritoneal B1a B cells, due to defective homeostasis/retention rather than a 
developmental defect or increased apoptosis. In addition, MZ B cells from WASP-
deficient mice displayed reduced immune responses to TNP-ficoll, in part due to 
reduced Ag-uptake. 
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II. The study of CTL in WAS: aim, rationale and working 
hypothesis 
1. Aim and rationale 
The Wiskott-Aldrich syndrome is a severe and lethal disease when left untreated as 
result of serious immune deficiency and bleeding disorders. Besides recurrent 
infections that are present already at very young age, patients with WAS are highly 
susceptible to develop multiple autoimmune pathologies and hematologic 
malignancies. Since CTL are exquisite killers and important actors in cellular 
immunity, our main aim has been to investigate whether intrinsic CTL defects 
contribute to the immune deficiency in WAS.  
In WAS patients however, all cells from hematopoietic origin lack WASP expression, 
including APC. Therefore, a side project aimed to investigate the role of WASP in 
APC, their subsequent role in CD8+ T cell activation and their susceptibility to 
CTL-mediated lysis. 
 
Du fait d’un déficit immunitaire grave et de troubles de la coagulation, le syndrome 
de Wiskott-Aldrich est une maladie mortelle quand elle n’est pas traitée. Outre des 
infections récurrentes qui apparaissent à un très jeune âge, les patients atteints du 
WAS tendent à développer au cours des années de multiples pathologies auto-
immunes et des tumeurs malignes hématologiques. Comme les lymphocytes T CD8+ 
cytotoxiques sont des “tueurs professionnels” et des acteurs importants de l’immunité 
cellulaire, notre principal objectif a été de rechercher si les défauts intrinsèques des 
CTL contribuent à la déficience immunitaire dans WAS. 
Il est important de noter que dans les patients atteints de WAS, toutes les cellules 
d’origine hématopoïétiques sont déficientes pour l’expression de WASP, y compris les 
APC. Par conséquence, un projet parallèle a visé l’étude du rôle de WASP dans les 
APC, leur rôle ultérieur dans l’activation des cellules T CD8+ ainsi que leur 
sensibilité à la lyse par les CTL. 
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2. Working hypothesis: 
Since the actin cytoskeleton plays a pivotal role in T cell biology, we assumed that 
WASP could be involved in the regulation of a multitude of steps in CD8+ T 
lymphocytes, starting with their activation, expansion, differentiation and finally their 
effector function: exterminate sick cells and micro-organisms that do not belong in 
the human body.  
Regarding the defects already described in human and/or mouse T lymphocytes and 
NK cells in the context of WAS, we expected to discover profound dysfunctions in 
the production of IL-2 and subsequent IL-2-driven proliferation, the production of 
Th1 cytokines, and/or killing activity.  
Since cytotoxicity by CTL is mainly mediated by the release of cytotoxic molecules, 
we focused in this study on the granzyme/perforin-mediated pathway. The transport 
of lytic granules to the membrane, their polarization and exocytosis depend on 
dynamic processes involving the cytoskeleton. Therefore, we estimated it was of 
interest to investigate in detail the potential role of WASP in these processes. In 
addition, we investigated the production of the cytokines IFN-γ and TNF-α, since 
these cytokines have antimicrobial activities and contribute to the cytotoxic character 
of CTL. 
 
WAS phenotype most certainly results from a combination of defects in 
hematopoietic cells that might be exacerbated during the different encounters that 
these cells undergo during immune responses. Therefore, we envisaged in this project 
to investigate how WASP deficiency in APC or the target cell might impact on WAS 
CTL activation and killing activity. As 2 papers described reduced priming capacity 
of WASP-deficient DC, we expect to see reduced CD8+ T cell activation and altered 
susceptibility of target cells to CTL-mediated cytotoxicity227,228. Indeed, since the 
actin cytoskeleton is important in the formation of conjugates, we suspect to see 
reduced killing of susceptible target cells. 
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III. Design and organization of the results presented in the thesis 
1. Role of WASP at the T cell side 
As previously described, CD8+ T lymphocytes need to undergo Ag-specific 
activation, clonal expansion and differentiation before they can exert their function as 
exterminators of compromised cells. Therefore, we have investigated the different 
steps of T cell activation and their subsequent differentiation into highly specific 
CTL. 
 
Since at the start of my PhD in 2006, we were not in the possession of patient cells, 
we had to search other approaches in order to investigate WASP function in primary 
CD8+ T cells. At that time, a recently discovered chemical drug, wiskostatin, seemed 
a good candidate, since it was shown to specifically interfere with (N-) WASP-
mediated actin polymerization. The first part of this manuscript (result section IV) is 
therefore devoted to this approach. However, due to toxic effects observed during 
experiments, we abandoned this strategy and moved to a second model. CD8+ T cell 
lines were generated from WAS and XLT patients, and will be described in the 
second (and major) part (result section V) of this work. 
1.1 Experimental design PART I 
Specific aim 1: Generation of antigen-specific CD8+ T cells from healthy individuals. 
To address this aim, we developed a model using DC, which were loaded with a 
mixture of 3 superantigens (SAg) to expand autologous CD8+ T cells with 
corresponding Vβ chains from healthy donors. First, the emphasis was on the 
generation of DC, since only mature DC are capable of activating naïve T cells. The 
maturation status of DC was evaluated by flow cytometric analysis of maturation 
markers and HLA molecules. Next, up-regulation of activation markers and T cell 
proliferation was assessed to demonstrate T cell activation and their responsiveness to 
SAg. Effector function was analyzed by measuring SAg-specific target cell lysis by 
flow cytometry. 
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Specific aim 2: Role of WASP in CD8+ T cell activation and effector function.  
To respond to this aim, we used the previously described model, in combination with 
the inhibitor of WASP-mediated actin polymerization, wiskostatin. To evaluate the 
involvement of WASP in CD8+ T cell activation and effector function, functional 
assays were performed in the presence or absence of different doses of wiskostatin. T 
cell proliferation upon restimulation with anti-CD3/anti-CD28 coated microbeads was 
measured to evaluate T cell activation and SAg-specific target cell lysis against SAg-
loaded target cells was assessed by flow cytometry to evaluate CTL effector function. 
1.2 Experimental design PART II 
Specific aim 1: Generation of SAg-specific CD8+ T cell lines from healthy donors and 
WAS and XLT patients. 
CD8+ T cells from healthy and patient PBMC were isolated through negative 
selection. To address intrinsic CD8+ T cell defects, we used WASP-positive APC for 
their activation, since it is well established that WASP-deficient APC, such as DC 
display impaired immunostimulatory capacity. Highly-enriched CD8+ T cells were 
therefore stimulated at a 3 week interval using feeder cells, consisting of irradiated 
allogeneic PBMC from 2 different healthy donors and irradiated WASP+ SAg-loaded 
EBV-transformed B cells. To enhance proliferation of SAg-specific T cells, IL-2 was 
added only on day 3. WASP expression level was assessed by flow cytometry and 
western blot analysis. SAg-responsiveness of healthy donor and patient CD8+ T cells 
was analyzed by measuring TCR down-regulation upon restimulation with SAg-
loaded APC. 
 
Specific aim 2: Role of WASP in the activation, differentiation, and effector function 
in healthy donor versus patient CD8+ T cells. 
T cell activation was quantified by the measurement of the percentage of cells going 
into division upon restimulation with SAg-loaded APC. To evaluate effector function, 
cytokine production and lytic activity were investigated. Since CTL are involved in 
the killing of viral-infected cells and tumor cells, cytotoxicity against different types 
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of target cells was investigated. In addition, the different progressive steps resulting in 
the delivery of the lethal hit to target cells (differentiation into effector CTL, 
polarization of the lytic machinery and degranulation) were investigated. 
2. Role of WASP at the APC side 
Finally, we also started a side project to investigate whether WASP deficiency at the 
APC side would exacerbate CD8+ T cell defects. T cell activation and lytic function 
of patient and healthy donor CD8+ T cells were evaluated using B-EBV cells 
knocked-down for WASP expression by means of lentiviral transduction or using 
naturally WASP-deficient B-EBV cells from an allogeneic WAS patient. 
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IV. CD8+ T cells stimulated with autologous superantigen-loaded 
mature dendritic cells display reduced antibody-driven T cell 
proliferation but unaffected target cell lysis upon wiskostatin 
treatment 
1. Abstract 
The Wiskott-Aldrich syndrome protein (WASP) is expressed in the cytoplasm of cells 
from hematopoietic origin and is a key regulator of actin cytoskeletal reorganization. 
Activated WASP interacts with the actin nucleator Arp2/3, a pre-existing F-actin 
filament and G-actin monomers and results in the generation of a branched network of 
F-actin. Lack of WASP expression is the cause of the Wiskott-Aldrich syndrome 
(WAS), a severe primary immune deficiency accompanied with bleeding disorders 
and eczema. Human SAg-responding CD8+ T cells were generated and expanded 
through stimulation with autologous SAg-loaded DC in order to clarify the role of 
WASP in CD8+ T cell proliferation and cytotoxicity. WASP function in CD8+ T cells 
was blocked by treatment with wiskostatin, a reversible inhibitor of (N-) WASP. 
Since Wiskostatin was found to exert toxic effects on primary human T cells, careful 
dose titration experiments were necessary. Altogether, our data indicate that intact 
WASP function is indispensable for T cell proliferation in response to anti-CD3/anti-
CD28-coated microbeads, whereas it is dispensable for CTL-mediated lytic activity 
against SAg-loaded EBV-transformed B cell targets.  
 
La protéine du syndrome de Wiskott-Aldrich (WASP) est exprimée dans les cellules 
d’origine hématopoïétique et est un régulateur clé de la réorganisation du 
cytosquelette d’actine. Après activation, WASP interagit avec le complexe Arp2/3, un 
filament pré-existant de F-actine et des monomers de G-actine pour générer un 
réseau ramifié de F-actine. L’abscence d’expression de WASP est la cause du 
syndrome Wiskott-Aldrich (WAS), une grave déficicience immunitaire primaire 
accompagnée de troubles de la coagulation et de l’eczéma. Afin de clarifier le rôle de 
WASP dans la prolifération et la cytotoxicité des cellules T cytotoxiques, des lignées 
de cellules T CD8+ répondant à un mélange de SAg ont été générées et expandues par 
stimulation avec des DC autologues chargées de SAg. La fonction de WASP dans les 
cellules T CD8+ a été bloquée par traitement avec la wiskostatin, un inhibiteur 
Results: experimental part I 
 66 
réversible de (N-) WASP. Par cause des effets toxiques exercés par la Wiskostatin sur 
les cellules T primaires humaines, des expériences de titration de dose ont été 
nécessaires. Nos données indiquent que la fonction intacte de WASP est indispensable 
pour la prolifération des cellules T en réponse à des microbilles revêtues avec des 
anticorps anti-CD3/anti-CD28, alors qu’elle n’est pas indispensable pour l’activité 
lytique des CTL contre des cellules B transformées par EBV et chargées avec des 
SAg. 
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2. Introduction 
Dynamic actin cytoskeleton function is indispensable for normal cell biology,  and 
regulates many cellular functions, such as migration, integrin-mediated adhesion, IS 
formation, cellular polarization, cell signaling, endo- and exocytosis etc … A key 
regulator of Arp2/3-mediated actin polymerization is WASP. This multi-domain 
protein is capable to integrate signals from many different inputs, tightly regulating its 
subcellular localization and activity. In its inactive form, WASP is folded in an auto-
inhibited conformation through hydrophobic interactions between the VCA domain 
and the CRIB domain. Upon activation through amongst other the binding of GTP-
bound Cdc42 to the CRIB domain, WASP unfolds. The VCA domain recruits both G-
actin monomers and the actin nucleator Arp2/3, resulting in the activation of the latter 
and the nucleation of actin G-monomers on a pre-existing F-actin filament, generating 
a branched filamentous meshwork of F-actin124,125,244,245. 
The importance of WASP expression in hematopoietic cells is evidenced by the 
existence of the Wiskott-Aldrich syndrome. This X-linked disorder is fatal when not 
treated, and is characterized by the triad of immune deficiency, severe bleeding 
episodes and eczema. Indeed, multiple defects have been described in a variety of 
immune cells and is associated with the severe clinical phenotype observed in patients 
with WAS123-125,199,227. 
A theoretically easy and rapid approach to investigate the role of WASP in cellular 
function is the use of a chemical drug that interferes with the conformational 
activation of WASP. Wiskostatin is a small molecule that specifically binds a pocket 
in the CRIB domain of WASP. Wiskostatin-CRIB interaction results in the 
stabilization of the protein in its inactive auto-inhibited conformation, thereby 
inhibiting Arp2/3-mediated generation of new actin filaments246. 
With the objective to characterize the role of WASP in CD8+ T cell activation and 
lytic function, we set up a cellular model consisting of primary CD8+ T cells 
responding to a mixture of 3 SAg presented by autologous DC. Following treatment 
with wiskostatin, T cell proliferation and lytic activity were measured by flow 
cytometry. We show that wiskostatin-induced WASP inhibition results in defective T 
cell proliferation in response to anti-CD3/anti-CD28-coated microbeads whereas the 
cytolytic potential appears to be preserved against SAg-loaded EBV-B target cells. 
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Our study also highlights the limitation of wiskostatin since it displayed toxic effects 
on primary T cells. 
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3. Cells, Material and Methods 
3.1 Cells and media 
EBV-transformed B cells (JY) were cultured in RPMI1640 (Gibco) supplemented 
with 100µg/ml Penicillin/Streptomycin, 2mM L-glutamine, 10mM Hepes, 0.1mM 
MEM non-essential amino acids and 1mM sodium pyruvate (supplements invitrogen) 
and 10% heat-inactivated FCS (PAA). Dendritic cells were cultured in RPMI1640 
supplemented with 1% heat-inactivated human AB-serum (HS; PAA) and 
supplements. CD8+ T lymphocytes were cultured in RMPI1640 supplemented with 
8% HS (PAA) and supplements (as referred to as complete medium, CM). Blood 
samples from healthy donors were obtained following standard ethical procedures 
(Helsinki protocol) and with the approval of the concerned Internal Review Boards. 
3.2 Buffy Coats 
Peripheral blood mononuclear cells (PBMC) were isolated by density gradient 
centrifugation over a ficoll hypaque gradient (PAA) from blood samples of healthy 
donors. Contaminating granulocytes were eliminated through extensive washing and 
centrifugation at low speed. PBMC were counted by means of trypan-blue exclusion. 
3.3 Generation of allogeneic PBMC 
PBMC from 1 healthy donor (responder) were seeded at 250*103 cells/ml RPMI 10% 
FCS and stimulated with 106 irradiated PBMC/ml from a second healthy donor 
(stimulator) in the presence of 150IU/ml recombinant human (rHu) IL-2. Cells were 
kept for 2 weeks in IL-2 enriched medium. Next, responder-PBMC were restimulated 
with the same stimulator-PBMC in the presence of 1µg/ml PHA and 150IU/ml rHu 
IL-2.  
3.4 Generation of Dendritic cells 
PBMC were seeded at 220*106 per T175 flasks (Falcon) in 44ml RPMI 1% HS. After 
2 hours of incubation at 37°C/ 5%CO2, to allow adherence of CD14+ monocytes to 
plastic, the non-adherent fraction (NAF), enriched in B- and T-lymphocytes, was 
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removed by washing with PBS (Sigma). Adherent cells were cultured in RPMI 1% 
HS supplemented with 750IU/ml rHuGM-CSF and 100IU/ml rHu IL-4 (both from 
R&D systems). On day 3 of culture, new cytokines were added and day 6 immature 
DC were harvested. Dendritic cells were matured at a cell density of 5*105 DC/ml 
RPMI 1% HS supplemented with 750IU/ml rHu GM-CSF, 100IU/ml rHu IL-4 and 
5µg/ml LPS for 24 hours. Immature and mature DC were counted with trypan-blue in 
order to determine DC yields and DC purity by exclusion of dead cells. 
3.5 Loading of DC or JY 
Day 7-mature DC or JY were resuspended in either RPMI 1% HS supplemented with 
rHu GM-CSF, rHu IL-4 and LPS or RPMI 10% FCS at 2,5*106/ml and loaded with 
100ng/ml of SEB, SEE and TSST-1 (SAg)(Toxin Technology) for 1 hour at 
37°C/5%CO2. 
3.6 Generation of effector CD8+ T cells 
CD8+ T cells were purified through negative selection (Miltenyi Biotec) according to 
manufacturer’s instructions from the NAF as described above. CD8+ T cells were 
frozen until fully mature DC were obtained. After thawing, CD8+ T cells were co-
cultured with autologous SAg-loaded mDC (R:S ratio 10:1) in CM in 6 well plates 
(Falcon). At the start of stimulation 10ng/ml rHu IL-7 and 2µM methyl-Tryptophan 
was added. In addition, on day 3, 50IU/ml rHu IL-2 was added to enhance 
proliferation of SAg-responding CD8+ T cells.  
3.7 Freezing and thawing of DC, JY, CD8+ T cells and 
PBMCs 
Cells were centrifugated at 4°C and the pellet was resuspended in cold freezing 
medium. Mature DC were frozen in 90% HS and 10% DMSO (Sigma) at 5-10*106 
cells/ml. Human CD8+ T cells, JY and PBMC were frozen in 50% RPMI1640, 40% 
HS and 10% DMSO at 5-10*106 cells/ml for T cells and JY and at 50-100*106/ml for 
PBMC. One ml of cell suspension was transferred to pre-cooled cryovials (NUNC) 
and slowly frozen in isopropanol containers (Nalgene). After minimum 2 hours at -
80°C, cells were transferred into liquid nitrogen.  
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To thaw, cryotubes were held in a warm-water bath until a small ice crystal was left. 
One ml cell suspension was diluted in 10 ml non-supplemented cold RPMI1640 and 
pelleted for 5’ at 1500 rpm, 4°C. Cell pellets were resuspended in either RPMI1640 
1% HS for DC, CM for CD8+ T cells and RPMI1640 10% FCS for JY and PBMC. 
3.8 Flow cytometry 
All samples were acquired with FACScalibur or FACSscan (Becton Dickinson) and 
data were analyzed with flowjo software. 
a) Phenotype DC, JY and CD8+ T cells 
Expression of surface markers was analyzed by means of flow cytometry. A 
minimum of 2*105 cells was used per sample. Cells were washed in cold PBS/0,5% 
BSA/ 10-4% NaN3 (FACS-buffer) and monoclonal antibodies (directly coupled PE, 
FITC or PEC5 mouse anti-human CD3, CD4, CD8, CD11c, CD25, CD40, CD45RA, 
CD45RO, CD54, CD58, CD80, CD83, CD86, HLA-ABC, HLA-DR)(BD 
Pharmingen), diluted in FACS-buffer, were added to the cell pellets. Samples were 
incubated for 20 minutes at 4°C and analyzed. 
b) Annexin V and propidium iodide staining 
CD8+ T cells were stimulated for 4 or 72 hours with anti-CD3/anti-CD28-coated 
microbeads (Invitrogen) in round- (4h) or flat-bottom (72h) 96 well plates. After 
indicated incubation at 37°C/5%CO2 cells were harvested, centrifuged and 
resuspended in cold FACS-buffer. Annexin V and propidium iodide (PI) staining (BD 
Pharmingen) were performed according manufacturer’s instructions and analyzed as 
described above. 
c) Measurement of TCR down-regulation  
DC or JY were loaded with SAg. After extensive washing they were resuspended at 
105 cells/100µl CM and transferred into corresponding wells of round-bottom 96-well 
plates. CD8+ T cells were resuspended at 105 cells/100µl CM and pre-treated with 
different concentrations of wiskostatin for 15 minutes. Next, 100µl of cell suspension 
was added to plated DC or JY. After 3 hours of incubation at 37°C/5% CO2, cells 
were resuspended in PBS/10mM EDTA on ice, to disrupt conjugates and washed in 
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FACS buffer. Cells were stained simultaneously for PE-coupled CD8 (BD 
Pharmingen) and OKT3 (eBioscience) that was detected by a FITC-coupled 
secondary antibody. The percentage of CD8+ T cells downregulating their TCR was 
measured to determine the responsiveness of CD8+ T cells to SAg presented on APC. 
d) Measurement of T cell proliferation 
To analyze proliferative capacity, CD8+ T cells or allogeneic PBMC were stained for 
10 minutes with 2,5µM CFSE at 37°C/ 5% CO2, 2% FCS was added to block the 
reaction and cells were washed in PBS/2% FCS. Subsequently, CD8+ T cells or allo-
PBMC were resuspended at 105 cells/100µl CM, pre-treated with different 
concentrations of wiskostatin and seeded in flat-bottom 96-well plates. Anti-
CD3/anti-CD28 coated microbeads (Invitrogen) were added at a ratio of 1 bead for 1 
T cell or PBMC. After 4 hours, equal doses of wiskostatin were added. Cells were 
incubated for 72 hours at 37°C/5% CO2. 5ng/ml PI was added just before analyzing 
CFSE dilution to exclude dead CD8+ T cells. 
e) Cytolytic assay 
Target JY cells were left unpulsed or pulsed with SAg. After washing they were re-
suspended at 105 cells/75µl CM and transferred into sterile FACS-tubes (Falcon). 
CD8+ T cells were pre-stained with 1µM CMFDA for 20 minutes at 37°C/ 5% CO2. 
Next, cells were washed, resuspended at 2*105 cells/75µl CM and pre-treated with 
Wiskostatin for 15 minutes. Finally, pre-treated CD8+ T cells were added to the JY. 
Tubes were centrifugated for 1 minute at 1500rpm and incubated at 37°C/5% CO2. 
After 4 hours tubes were vortexed and transferred to ice. Prior to analysis 5ng/ml PI 
(BD Pharmingen) was added to cells to measure the percentage PI-uptake by killed 
target cells. 
3.9 Confocal microscopy 
Mature DC were pulsed in the presence or absence of 100ng/ml of SAg and stained 
with 1µM CMTMR. They were forced to form conjugates with CD8+ T cells by 
centrifugation (2min at 1500rpm) at a ratio of 4:3. Cells were incubated for 8min at 
37°C/5%CO2. After gently resuspension, cells were laid on poly-L-lysine-coated 
slides and allowed to sediment for 10min at 37°C. After fixation in 1%PFA and 
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permeabilization in 3%BSA/0.1%saponin cells were stained in 3%BSA/0.1% saponin 
with mAbs against α-tubulin (Sigma), perforin (BD Pharmingen), phospho-tyrosin 
(Santa Cruz Biotechnology), and F-actin (Molecular Probes) in combination with 
mAbs against WASP (BD Pharmingen) followed by isotype-specific secondary goat 
anti-mouse or rat anti-mouse mAb labelled with Alexa-488 or Alexa-633 (Southern 
Biotech). Samples were mounted and examined on a Carl Zeiss LSM 510 confocal 
microscope (x63-1.4 oil immersion Plan-Apochromat objective) and images 
processed with the MetaMorph software (Universal Imaging Corporation). 
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4. Results 
4.1 Optimization of a human autologous superantigen-
specific system 
Since the aim of this study was to investigate the role of WASP in human CD8+ T 
lymphocytes, we set up a human model in which CD8+ T lymphocytes were 
stimulated with autologous dendritic cells. As antigen we decided to use a mixture of 
3 superantigens (SAg), to cover a large group of T cells expressing TCRs with diverse 
Vβ-chains. 
The most critical step in this model was to obtain DC in sufficient quantity and of 
good quality. First, a sufficient quantity of mature DC was required to perform 
activation experiments and functional assays in order to answer our questions. 
Second, it was of great importance to generate DC that displayed a mature phenotype, 
implying the up-regulation of co-stimulatory molecules, indispensable for T cell 
activation.  
a) Generation of monocyte-derived dendritic cells 
Dendritic cells were generated by plastic adherence of CD14+ monocytes. Adhering 
cells were differentiated and matured in the presence of rHu GM-CSF in combination 
with IL-4 and LPS, respectively. In initial experiments, DC were prepared in the 
presence of 750 IU/ml rHu GM-CSF and 1000 IU/ml of rHu IL-4. Upon LPS-induced 
maturation DC displayed a mature phenotype (data not shown) but only low yields 
were obtained (Fig 7A). To increase DC yield, different doses of IL-4 were tested, in 
combination with 750 IU/ml rHu GM-CSF. As depicted in figure 7A, lowering the 
dose of IL-4 from 1000 to 100 IU/ml enhanced the amount of mature DC obtained 
from fresh PBMC (normal yield from PBMC: 3,4 ± 1,2%247). In parallel, DC purity 
was evaluated by flow cytometry based on FSC/SSC characteristics. No difference 
was seen between immature and mature DC, however, by lowering the IL-4 
concentration in DC cultures, DC purity increased (Fig 7B). Contaminating cells were 
T cells, B cells and monocytes (data not shown). 
No difference was observed in the immuno-stimulatory capacity of DC generated in 
the presence of 1000 IU/ml or 100 IU/ml rHu IL-4. Both induced similar extensive T 
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cell proliferation upon restimulation with SAg-pulsed mDC (Fig 7C) and expected 
modest cytotoxicity against SAg-loaded DC. An internal control CD8+ T cell line 
(NLV), specifically recognizing the CMV-derived pp65 peptide was tested in parallel. 
NLV T cells efficiently kill target cells pulsed with the pp65 peptide, and similar 
killing against SAg-loaded JY cells was observed by NLV or DC-stimulated CD8+ T 
cells (Fig 7D). 
Upon maturation, DC up-regulate co-stimulatory molecules, which are indispensable 
for T cell activation. To determine whether LPS-treatment resulted in the maturation 
of immature DC, surface stainings for CD11c, CD54, CD58, CD80, CD83, CD86, 
HLA class I and II were performed. Indeed, LPS treatment induced DC maturation 
with a marked up-regulation of the co-stimulatory molecules CD80 and CD83. 
Dendritic cells expressed high levels of CD11c, CD86, HLA class I and II molecules, 
independently of their maturation status (Fig 7E). High levels of CD54 and CD58, 2 
molecules important for interaction with T cells, are expressed both on immature and 
mature DC (data not shown). Since the major part of mature DC was frozen for later 
use, phenotype after freezing and thawing was evaluated. Freezing and thawing had 
no effect on DC phenotype (Fig 7F).  
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Figure 7: Effect of IL-4 concentration on (A) DC yield from PBMC (B) DC viability. 
Comparison of immunostimulatory capacity of DC generated in the presence of 100 or 500 
U/ml rHuIL-4 in terms of the induction of T cell proliferation (C) and cytolytic activity (D). 
Phenotypic characterization by flow cytometry of immature and mature DC, before and after 
thawing (E-F). 
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b) Naïve CD8+ T lymphocytes are efficiently activated by 
autologous SAg-loaded mDC and become potent cytotoxic T 
cells 
Mature DC were loaded with a mixture of SAg and used to stimulate autologous 
CD8+ T cells. To evaluate whether DC stimulation resulted in T cell activation, the 
phenotype and functional response of CD8+ T cells was evaluated before and after 
stimulation.  
T cells were more than 90% CD8 positive at the time of stimulation. CD8+ T cells 
were essentially CD45RA positive, a marker for naïve T cells and negative for the 
markers CD25 and CD45RO. Upon stimulation with SAg-loaded mDC, CD8+ T cells 
up-regulated the markers CD25 and CD45RO and down-regulated CD45RA, 
demonstrating an activated effector phenotype. Both naïve and effector T cells 
expressed high levels of LFA-1, the ligand for CD54 expressed on DC (Fig 8A). In 
addition, 60% of the CD8+ T lymphocytes expressed the lytic molecules granzyme B 
and perforin upon activation with mDC (Fig 8B).  
Besides the phenotypic shift upon differentiation of naïve T cells towards effector T 
cells, it was important to know whether the generated CD8+ T cells had been 
“primed” to respond in a specific manner to the SAg. TCR down-regulation was 
performed to measure SAg responsiveness and proliferative capacity and lytic activity 
were evaluated to test functional responses.  
Freshly purified CD8+ T cells do not down-regulate their TCR upon stimulation with 
SAg-loaded mDC. However, 12 days after priming with SAg-loaded mDC, the 
majority of T cells respond to SAg-restimulation by down-regulating their TCR (Fig 
8C).  
Upon recognition of danger signals, an important feature of T cells is their clonal 
expansion in order to fight infection. Therefore, the T cell proliferative capacity 
towards SAg was measured by means of CFSE dilution. Only few naïve CD8+ T cells 
responded to stimulation with SAg-loaded DC in a 72-hour proliferation assay before 
priming. However, over 60% of DC-primed CD8+ T cells divided up to 3 times upon 
restimulation with SAg-loaded DC (Fig 8D). 
Since mature DC have intrinsic mechanisms to protect themselves from CTL-
mediated killing68, we used B-EBV JY cells as target cells in lytic assays. Naïve CD8+ 
T cells did not kill SAg-loaded JY. As an internal control, an oligoclonal CD8+ T cell 
line (NLV), recognizing the pp65 peptide was tested in parallel. Clearly, the NLV T 
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cells killed very efficiently pp65-pulsed JY cells. However, day 7 after stimulation 
with SAg-loaded DC, primed CD8+ T cells killed the majority of SAg-loaded JY cells 
almost as efficiently as the control NLV T cell line killed pp65-pulsed JY, indicating 
that they differentiated into effector cytolytic T lymphocytes (CTL) (Fig 8E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: Flow cytometric analysis of T cell phenotype (A) and expression levels of lytic 
molecules (B) before and after stimulation of CD8+ T lymphocytes by mature SAg-loaded DC. 
Mature SAg-loaded DC stimulate CD8+ T cells to down-regulate their TCR (C), proliferate 
(D) and lyse SAg-loaded target JY cells (E). 
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c) SAg-specific stimulation of CD8+ T cells induces 
polarization of MTOC and perforin towards the APC contact 
site 
Complementary microscopy analysis was performed to analyze SAg-induced 
activation of CD8+ T cells. It is well described that upon Ag-recognition, CD8+ T 
cells polarize their MTOC and lytic molecules towards target cells. This is 
accompanied by a marked enrichment in phosphorylated (P) Tyrosine and 
polymerized F-actin at the contact site between the two cells. As shown in figure 9, in 
the absence of SAg on DC, CD8+ T cells do not polarize their MTOC (α-tubulin) and 
perforin and there is no accumulation of phalloidin or P-Tyrosine at the IS. However, 
in the presence of SAg, both the MTOC and perforin polarize towards the target cell 
and there is a marked enrichment of P-Tyrosine and phalloidin. In addition, WASP 
also seems to accumulate at the IS. 
 
Altogether, these data provide evidence that the generated DC differentiated into fully 
mature APC and efficiently activated CD8+ T cells, highly responsive in terms of 
proliferation and lytic activity. 
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Figure 9: Analysis by confocal microscopy of DC-induced polarization/enrichment of α-
tubulin (MTOC), P-Tyrosine, perforin and WASP at the IS. In the presence of SAg on the DC 
membrane (stained with the red dye, CMTMR), CD8+ T cells polarize their MTOC and lytic 
molecules toward the stimulating DC and accumulate P-Tyr and WASP at the contact site. 
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4.2 Wiskostatin treatment inhibits proliferation of allo-
PBMC and CD8+ T cells in response to anti-CD3/anti-CD28 
stimulation 
Since it has been shown that T cell proliferation upon antibody-mediated TCR-
triggering is affected in WAS patients, we thought to check first whether wiskostatin 
treatment affects proliferation of allogeneic PBMC. Allo-PBMC were treated with 
different doses of wiskostatin at the onset of the stimulation and seeded in the 
presence or absence of anti-CD3/anti-CD28-coated microbeads. After 4 hours, a 
second dose was administered to wiskostatin-treated cells. The percentage of 
proliferating allo-PBMC was analyzed after an incubation of 72 hours at 37°C/5% 
CO2 (Fig 10A). Over 50% of the allo-PBMC responded to anti-CD3/anti-CD28 
stimulation in the non-treated condition. Wiskostatin treatment resulted in a dose-
dependent decrease of proliferating PBMC (Fig 10B: mean +/- SEM (n=3) except for 
7,5µM and 10µM). Treatment with 7,5µM induced a 50% reduction of proliferating 
PBMC. However, treatment with 50µM wiskostatin appeared to induce massive cell 
death, since no more live cells were detected in the T cell gate during analysis.  
These preliminary experiments suggested that interference with WASP-regulated 
actin polymerization affects T cell proliferation. Additionally, wiskostatin treatment at 
high dose appeared to be toxic and to affect the viability of human PBMC. 
Next, the effect of wiskostatin treatment on DC-primed CD8+ T cells was 
investigated. Therefore, CD8+ T cells were treated with different doses of wiskostatin 
and restimulated in the presence or absence of anti-CD3/anti-CD28-coated 
microbeads for 72 hours. Before analysis of CFSE dilution by flow cytometry, 
propidium iodide (PI) was added to the samples to take into account only live T cells. 
Similar to allo-PBMC, a dose-dependent inhibition of T cell proliferation was 
observed. As depicted in fig 10C, almost all CD8+ T cells that did not receive any 
treatment proliferated vigorously upon TCR triggering. Administration of increasing 
doses of wiskostatin gradually impaired anti-CD3/anti-CD28-induced proliferative 
responses, with an almost complete abrogation at 10µM. Higher doses were not tested 
since they appeared to be toxic in the preliminary experiments using PBMC. Addition 
of 10µM DMSO, the solvent for wiskostatin, had no effect on T cell proliferation. In 
figure 10D the mean of 3 independent experiments is represented and shows the same 
tendency as the representative experiment showed above. 
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These data indicate that chemical inhibition of WASP in CD8+ T cells by treatment 
with wiskostatin inhibits TCR-driven T cell proliferation, and this effect is dose-
dependent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: (A) Allo-geneic PBMC (or CD8+ T cells) are stimulated with anti-CD3/anti-
CD28-coated microbeads in the presence of different doses of wiskostatin at t=0h and t=4h. 
T cell proliferation is measured after 72h of incubation by flow cytometric analysis. (B) Effect 
of wiskostatin on the proliferation of allo-PBMC. (C-D) Flow cytometric analysis of the 
proliferative capacity of CD8+ T cells upon anti-CD3/anti-CD28-mediated stimulation in the 
presence of different doses of wiskostatin. 
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4.3 Wiskostatin has no effect on CTL-mediated 
cytotoxicity 
In order to address the role of WASP in CTL-mediated killing, we first confirmed that 
an intact cytoskeleton is required for cytotoxicity. Therefore, DC-primed CD8+ T 
cells were left non-treated or pretreated with 5µM wiskostatin, latrunculin B, 
cytochalasin D or DMSO (the solvent for the 3 products). Next CD8+ T cells were co-
cultured with EBV-B target cells (JY) either non-pulsed or pulsed with 100ng/ml SAg 
and PI-uptake by lysed target cells was measured to evaluate lytic activity. Non-
treated CD8+ T cells killed target JY in a SAg-dependent manner and treatment with 
wiskostatin or DMSO had no effect on killing activity. Treatment with latrunculin B 
or cytochalasin D, however, induced a complete abrogation of CTL-mediated 
cytotoxicity against SAg-loaded JY, confirming the requirement of a functional actin 
cytoskeleton for cytolytic activity (Fig 11A). 
Next, CD8+ T cells were exposed to different doses of wiskostatin and killing activity 
was measured against SAg-loaded JY. Target JY cells were efficiently killed by CD8+ 
T cells and Wiskostatin treatment had no effect on SAg-specific killing. Even at high 
dose, that resulted in an almost abrogation of T cell proliferation, CD8+ T cells 
displayed normal cytotoxic activity as compared to non-treated cells (Fig 11B-C). 
These data confirm that an intact cytoskeleton is required for CTL-mediated 
cytotoxicity, but that WASP seems to be dispensable for this activity. 
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Figure 11: flow cytometric 
analysis of target cell lysis by PI-
uptake. (A) Treatment of CD8+ T 
cells with Latrunculin B or 
cytochalasin D abrogates cytotoxic 
activity against SAg-loaded target 
cells, as compared to non-treated 
(NT) or DMSO-treated (solvent) 
CD8+ T cells. (B-C) Addition of 
increasing doses of wiskostatin 
does not affect CTL-mediated lysis 
of target JY cells loaded with 100 
ng/ml SAg. 
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4.4 Wiskostatin is toxic when used in long-term assays 
A possible toxic effect of wiskostatin was suspected, since the percentage of CD8+ T 
cells in the “T cell gate” during analysis of T cell proliferation, based on FSC/SSC 
characteristics, decreased with increasing doses of wiskostatin. Additionally, the 
addition of PI during analysis, provided a tool to address this possible toxicity more 
carefully. Re-analyzing those data by focusing on PI-staining of dead cells, confirmed 
that wiskostatin treatment induced cell death in a dose-dependent manner. Indeed, the 
percentage of PI-positive cells increased with increasing doses of wiskostatin. At a 
dose of 5µM, 50% of the cells present in the T cell gate, were PI+, and almost all cells 
were PI+ at 10µM (Fig 12A). To confirm this toxic effect, experiments were repeated 
in the same stimulation conditions, but instead of measuring T cell proliferation, 
CD8+ T cells were stained for annexinV (to measure phosphatidylserine exposure) 
and PI to measure the anti-CD3/anti-CD28-mediated apoptosis and/or necrosis after 
72 hours of incubation. As depicted in figure 12B, upon TCR-triggering, the 
percentage of live, annexinV- and PI-, CD8+ T cells decreased with increasing doses 
of wiskostatin in T cell cultures. Inversely, the percentage of late-apoptotic, 
annexinV+ and PI+ CD8+ T cells, increased with increasing doses of wiskostatin, 
indicating that wiskostatin treatment induced apoptosis in CD8+ T cells upon 
activation of the TCR. Wiskostatin treatment did not seem to be involved in the 
induction of necrosis (annexin- and PI+ cells). In the absence of TCR triggering, no 
difference was observed in cell death between non-treated and wiskostatin-treated 
CD8+ T cells (data not shown). 
Because of this observed toxicity of wiskostatin treatment in long-term assays, 
toxicity was also measured in short-term assays with an incubation of 4 hours, as in 
the cytolytic assay. Therefore, CD8+ T cells were pretreated with different doses of 
wiskostatin and subsequently cultured in the presence or absence of anti-CD3/anti-
CD28-coated microbeads. In the absence of TCR activation signals, most CD8+ T 
cells were annexinV- and PI- and no difference was observed between treated and 
non-treated cells (Fig 12C-D). Upon TCR triggering, however, independently of the 
treatment, almost all cells became annexinV+. Around 40% of the cells appeared to be 
late-apoptotic (annexinV+ and PI+) and around 50% of the cells appeared to be early 
apoptotic (annexinV+ and PI-). However, phosphatidylserine exposure on the cell 
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surface has been described on CD8+ T cells upon Ag-recognition and anti-CD3/anti-
CD28-mediated TCR stimulation, without induction of apoptosis (Fig 12C-D)248. 
These data therefore indicate that wiskostatin needs to be used with caution in cellular 
cultures, since it induces apoptosis in long-term assays, even at low dose. 
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Figure 12: (A) Analysis by flow cytometry of non-viable (PI+) cells in CD8+ T cell 
proliferation assay. (B) anti-CD3/anti-CD28-mediated stimulation of CD8+ T cells induces 
apoptosis (AnnexinV+/PI+ cells) in a dose-dependent manner in a 72h assay. (C-D) Up-
regulation of phosphatidylserine (AnnexinV+ cells) on CD8+ T cells upon stimulation with 
anti-CD3/anti-CD28 in a 4h assay.  
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4.5 Discussion 
The generation of an autologous human model enabled us to investigate the role of 
the actin regulator WASP in CD8+ T cell activation and effector function. The 
availability of a chemical component, wiskostatin, selectively inhibiting (N-) WASP, 
provided an easy and rapid tool to achieve our objectives. In addition, this strategy 
enabled us to use healthy donor cells in which the only variable was the interference 
with WASP, excluding potential additional effects related to disease progression in 
patients. We demonstrate in this study the pivotal role of WASP in T cell proliferation 
upon anti-CD3/anti-CD28-mediated TCR triggering, whereas WASP seems to be 
dispensable for the cytolytic activity of CTL towards SAg-loaded EBV-B cells. In 
addition we show that wiskostatin exerts dose-dependent toxic effects on primary 
CD8+ T cells, suggesting that wiskostatin needs to be used with caution. 
In this study we thought to use autologous dendritic cells to provide both antigenic 
stimulation and simultaneous co-stimulation to CD8+ T cells. T cell activation in the 
absence of co-stimulation has been shown to result in unresponsiveness to subsequent 
antigen stimulation249. Evidence for efficient SAg presentation and co-stimulation is 
provided by robust TCR down-regulation upon restimulation of CD8+ T cells with 
SAg-loaded mature DC, expressing high levels of the co-stimulatory molecules 
CD80, CD83 and CD86. In addition, DC expressed high levels of HLA class II 
molecules, the binding partner for SAg, mediating Ag-recognition by T cells. 
However, the mechanism by which CD8+ T cells interact with SAg-bound HLA class 
II molecules is unclear, even if this strategy is now commonly used in many 
laboratories68,250. We also demonstrate that SAg-loaded DC efficiently activate CD8+ 
T cells to promote proliferation and differentiation into highly cytotoxic cells. 
Interference with WASP activation in allogeneic PBMC or CD8+ T cells, through the 
use of wiskostatin, resulted in defective proliferation upon stimulation with anti-
CD3/anti-CD28 microbeads, clearly indicating that WASP-mediated actin 
polymerization is indispensable for T cell proliferation. Many papers have described 
severely affected T cell proliferative responses in human and mice models upon 
antibody-mediated TCR triggering156,159,234-236. This reduced proliferation might be 
explained by defective spreading of WASP-deficient T cells over surfaces coated with 
immobilized antibodies or by defective IL-2 production235, since IL-2 is produced by 
the activated T cells themselves and works mainly in an autocrine fashion251. Indeed, 
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studies on CD4+ and/or CD8+ T cells isolated from WAS patients as well as in vivo 
and in vitro studies in mice have demonstrated defective IL-2 production upon T cell 
activation. Another possible role for WASP in T cell proliferation could be explained 
by its role in cytokinesis156,159,238,239. Cytokinesis is the final step of cell division 
during which cytoplasmic content and genetic material are equally divided from the 
parental cell to two daughter cells. This dynamic process requires the regulated 
assembly of a contractile ring of actin and myosin to cleave the cell in two and 
involves the recruitment of pre-existing actin filaments and de novo actin 
polymerization142,252. It has been demonstrated that gain-of-function mutations in 
WASP resulted in the inhibition of myelopoiesis through defective mitosis and 
cytokinesis due to hyperactivation and mislocalization of actin polymerization142. 
Another study using wiskostatin confirmed defective cytokinesis, however, 
demonstrated that this defect did not depend on the inhibition of the (N-) WASP 
mediated pathway, suggesting that wiskostatin interacts with other compounds than 
(N-) WASP involved in cytokinesis252. The non-selective character of wiskostatin has 
been confirmed recently. Guerrioro et al described that wiskostatin does not function 
as a specific (N-) WASP inhibitor in intact cells, but instead causes a global change in 
the energy status of cells. Indeed, wiskostatin poisons cells by affecting multiple steps 
in protein synthesis, endocytosis and membrane traffic as result of irreversible loss of 
cellular ATP levels253. 
Careful analysis of wiskostatin treatment in long-term assays revealed that even small 
doses induced apoptosis in CD8+ T cells upon TCR activation, suggesting that the 
severe proliferative defect is most probably a combination of WASP dysfunction as 
well as cytotoxicity caused by the drug itself.  
Surprisingly in short-term assays, we observed that independently of wiskostatin 
treatment, over 80% of the CD8+ T cells expressed Annexin V, a marker for 
apoptosis, upon stimulation with anti-CD3/anti-CD28-coated microbeads. However, 
the cells that are AnnV+ and PI-, normally designated as “early apoptotic”, seem to be 
just “activated” T cells transiently up-regulating Annexin V248. The percentage of late 
apoptotic cells (AnnV+ and PI+) is the same for wiskostatin-treated and control cells, 
indicating that wiskostatin has no toxic effect in short term assay.  
We confirmed that actin cytoskeleton integrity is required for CTL lytic activity. 
Indeed, CTL lytic activity towards SAg-loaded JY cells was abrogated following 
treatment with either latrunculin B or cytochalasin D. However, we found no 
Results: experimental part I 
 90 
reduction in CTL lytic activity following treatment with wiskostatin, even at high 
dose, where T cell proliferation was almost completely abrogated. These observations 
suggest that WASP is not required for lytic activity and match with the recent finding 
that silencing Arp2/3 in T cells does not affect cytotoxicity. It seems that MTOC 
polarization and cytotoxic activity of human CD8+ T cells is dependent on another 
family of actin regulators, namely the formins. Silencing DIA1 and FMNL1, two 
members of the formin family, resulted in defective MTOC polarization and 
cytotoxicity250. Our data are also in agreement with the observation that WAS patient 
CD8+ T cells displayed preserved cytotoxicity against allogeneic B-EBV cells and 
PHA-blasts156. 
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V. The Wiskott-Aldrich syndrome protein regulates CTL 
cytotoxicity and is required for efficient killing of B cell lymphoma 
targets 
1. 
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1. Abstract 
The Wiskott-Aldrich syndrome (WAS) is a primary immunodeficiency due to 
mutations in the gene encoding the WAS protein (WASP), a key actin regulator in 
hematopoietic cells. Whether killing defects in CD8+ cytotoxic T lymphocytes (CTL) 
contribute to WAS-associated immunodeficiency and susceptibility to tumor 
development remains to be explored. CTL lines from WAS patients, generated by 
repeated stimulation with super-antigen (SAg)-loaded EBV-transformed B cells 
displayed reduced production of cytokines (IL-2, IFN-γ and TNF-α) but almost 
normal proliferation upon restimulation. Although WAS CTL killed target B cells in a 
SAg dose-dependent manner, their efficiency was reduced, especially at low SAg 
dose. The cytotoxic efficiency of WAS CTL was particularly reduced against tumoral 
B cell lines. WAS CTL expressed normal levels of lytic molecules and demonstrated 
efficient exocytosis upon target cell encounter. However, the lytic granules appeared 
not to fully polarize toward the centre of the CTL/tumor target cell contact area. 
Importantly, the use of a gene therapy lentiviral vector was sufficient to restore 
efficient cytotoxic activity. Our study suggests that CTL dysfunction contributes to 
the development of hematological malignancies in WAS patients. 
 
Le syndrome de Wiskott-Aldrich (WAS) est une immunodéficience primaire due à des 
mutations dans le gène codant pour la protéine WAS (WASP), un régulateur clé de 
l’actine dans les cellules hématopoïétiques. Il reste à explorer si l’immunodéficience 
associée à WAS et la susceptibilité au développement de tumeurs peut être causée par 
une cytotoxicité défectueuse des lymphocytes T CD8+ cytotoxiques (CTL). Des lignées 
de CTL de patients atteints de WAS, générées par stimulation répétée avec des 
cellules B transformées par EBV chargées avec un des super-antigène (SAg), 
présentent une production de cytokines (IL-2, IFN-γ et TNF-α) réduite, mais une 
prolifération près de la normale lors de la restimulation. Bien que les CTL WAS tuent 
les cellules cibles B d’une manière dose-dépendante, leur efficacité s’avère réduite, 
en particulier à faible dose de SAg. L’efficacité cytotoxique des CTL WAS se révèle 
particulièrement réduite contre des lignées de cellules B tumorales. Les CTL WAS 
expriment des niveaux normaux de molécules lytiques et démontrent une efficacité 
d’exocytose normale lors d’une rencontre d’une cellule cible. Cependant, les 
granules lytiques ne semblent pas totalement polarisés vers le centre de la zone de 
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contact entre CTL et cellules cibles. Fait important, l’utilisation d’un vecteur 
lentiviral de thérapie génique est capable de rétablir l’efficacité cytotoxique. Notre 
étude suggère que le dysfonctionnement des CTL contribue au développement de 
tumeurs malignes hématologiques chez les patients atteints de WAS. 
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2. Introduction  
The Wiskott-Aldrich syndrome (WAS) is a severe X-linked primary 
immunodeficiency, resulting from defective expression of the WAS protein (WASP) 
in hematopoietic cells127. This syndrome is characterized by micro-thrombocytopenia, 
eczema, recurrent viral, bacterial and fungal infections, increased incidence of 
autoimmune diseases and hematological malignancies125,208. Patients carrying WAS 
gene point mutations and expressing residual WASP, display a milder phenotype 
referred to as X-linked thrombocytopenia (XLT) 254. XLT is characterized by micro-
thrombocytopenia, whereas the occurrence of recurrent infections and malignancies is 
much less frequent than in the full-blown syndrome123. 
WASP is expressed in the cytoplasm of hematopoietic cells, where it participates to 
actin cytoskeletal remodelling following cell stimulation. Upon activation via Cdc42 
and numerous interactors, WASP associates with the Arp2/3 complex to nucleate 
actin and generate a branched actin network200,255. WASP activity appears to 
predominantly control peripheral homeostatis of hematopoietic cells and a wide array 
of functions known to depend on actin cytoskeleton integrity. These functions include 
chemotaxis of myeloid and lymphoid cell lineages219,256, antigen uptake by 
macrophages130, podosome formation by macrophages and DC214,220, immunological 
synapse assembly by T cells and NK cells165,189,238, DC stimulatory capacity227-229, 
effector functions of T cells156,239 and iNKT cells66,67, suppressive activity of T 
regulatory cells161-163, B cell maturation and immunoglobulin production158,210,211. 
Therefore, the severe clinical manifestations of WAS are thought to result from a 
complex combination of cellular defects affecting both innate and adaptive immunity. 
However, it is still unclear whether WASP controls the cytotoxic activity of CD8+ 
cytolytic T lymphocytes (CTL). This activity is a key component of the immune 
system in the control of viral infections and tumors257. Since WAS patients suffer 
from recurrent viral infections (mainly HSV) and are prone to develop tumors (mainly 
EBV-positive B cell malignancies)123, one would expect their CTL-mediated 
cytotoxicity to be impaired. Attempts to study the cytotoxic activity of T lymphocytes 
from WAS patients against allogeneic targets have yielded controversial results, 
ranging from defective to preserved activity156,258,259. 
In order to clarify the role of WASP in CTL effector functions, we exploited the 
ability of CD8+ T cells to respond to bacterial super-antigens (SAg)260 to generate 
Results: experimental part II 
 95 
SAg-specific CD8+ T cell lines from WAS patients. They differentiated into effector 
cells expressing high levels of perforin and granzyme B. However, their lytic 
potential was reduced, particularly when tumoral B cells were used as targets. 
Although WAS CTL oriented their lytic machinery toward the target cells and 
degranulated efficiently, perforin-containing lytic granules were not fully polarized 
toward the centre of the immunological synapse. Our study shows that reduced CTL 
lytic activity can contribute to reduced immune surveillance in WAS patients. 
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3. Patients, material and methods 
3.1 Patients 
Patient WAS1 is an 8-month old male newborn presenting severe thrombocytopenia 
and eczema. He carries a WAS gene non-stop mutation (c.1509A>C), resulting in 
undetectable WASP expression in PBMC. Patients WAS2, WAS4 and XLT6 have 
been previously described156,163. WAS4 was recently identified as carrying a 
secondary mutation leading to revertant WASP expression in a fraction of peripheral 
blood T cells. However, the CD8+ T cell lines generated from this patient failed to 
express detectable revertant WASP. A WASP-deficient EBV-transformed B-cell line 
(B-EBV) was generated from an additional WAS patient previously referred as 
W1156. Age-matched healthy donors (HD) were used as controls. Blood samples from 
patients and healthy donors were obtained following standard ethical procedures 
(Helsinki protocol) and with the approval of the concerned Internal Review Boards.  
3.2 Transformed cell lines and untransformed CD8+ T cell 
lines 
WAS patient B-EBV and normal B-EBV (JY) cells as well as Burkitt lymphoma 
Daudi cells were cultured in RPMI1640 (Gibco) supplemented with 100µg/ml 
Penicillin/Streptomycin, 2mM L-glutamine, 10mM Hepes, 0.1mM MEM non-
essential amino acids, 1mM sodium pyruvate (all from Invitrogen) and 10%FCS 
(PAA). Burkitt lymphoma Raji cells were cultured in IMDM (Gibco) supplemented 
as above. T cell lines were generated from blood samples of HD and WAS/XLT 
patients. PBMC were isolated by density gradient centrifugation over a ficoll hypaque 
gradient (PAA). CD8+ T cells were purified by negative selection (Miltenyi Biotec) 
according to manufacturer’s instructions and seeded at 7.5x105 cells/ml in complete 
medium consisting of RPMI1640 supplemented with 8% human AB serum (PAA) 
and supplements (as above). Cells were stimulated in the presence of 1x106/ml 
irradiated allogeneic PBMC and 1x105/ml irradiated EBV-transformed JY cells 
loaded with a SAg cocktail (100ng/ml SEB, SEE and TSST-1 from Toxin 
Technology). To stimulate proliferation of SAg-specific CD8+ T cells, 50IU/ml rhIL-
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2 was added only on day 3. CD8+ T cell lines were maintained in complete medium 
supplemented with 50IU/ml rhIL-2 and restimulated every 3 weeks. 
3.3 Characterization of CD8+ T cell lines 
CD8+ T cells were stained with FITC- or PECy5-labelled anti-CD8 mAb (clone 
HIT8a, BD Pharmingen) in FACS buffer (PBS, 0,5%BSA, 10-4% NaN3) for 20min 
at 4°C. Cells were then fixed and permeabilized using the BD Pharmingen fixation 
and permeabilization kit. Intracellular staining of WASP and perforin was performed 
using non-labeled mAb against WASP (clone 5A5, BD Pharmingen) and perforin 
(clone dG9, R&D systems), followed by PE-labeled secondary Abs (BD 
Pharmingen). Granzyme B staining was performed with a specific FITC-labeled mAb 
(clone GB11, BD Pharmingen). Data were acquired on the FACSCalibur (Beckton 
Dickinson) and analyzed with Flowjo software. 
3.4 Measurement of TCR down-regulation and 
proliferation  
JY, Daudi, Raji or WAS patient B-EBV were loaded with different doses SAg (0.1 to 
100ng/ml) or left unpulsed during 1hr at 37°C/5%CO2 and stained with 1µM 
CMTMR during the last 20min. Subsequently, APC were washed, resuspended at 
1x105 cells/100µl complete medium without IL-2 and added to the CD8+ T cells 
previously seeded at 1x105 cells/100µl complete medium without IL-2 in U-bottom 
96-well plates. After 3hr at 37°C/5%CO2, cells were resuspended in PBS/10mM 
EDTA on ice, washed in FACS buffer and stained with a PE-labeled CD8 mAb (clone 
RPA-T8, BD Pharmingen) and OKT3 (eBioscience), detected by a FITC-labeled 
secondary Ab. To analyze T cell proliferation, healthy donor and patient CD8+ T cells 
were stained for 10min with 2.5µM CFSE at 37°C/5%CO2. Subsequently, CFSE-
labeled T cells were seeded at 1x105 cells/100µl complete medium without IL-2 in 
flat-bottom 96-well plates. JY were left unpulsed or pulsed as described above. After 
fixation in 1%PFA for 15min at room temperature and washing, they were 
resuspended at 1x105 cells/100µl complete medium without IL-2 and co-cultured with 
CD8+ T cells for 72hr at 37°C/5%CO2. TCR down-regulation and CFSE dilution were 
analyzed by flow cytometry (FACSCalibur cytometer and Flowjo software). 
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3.5 Detection of intracellular cytokines 
B-EBV JY cells were pulsed as described above. Cells were washed, resuspended at 
1x105/100µl complete medium and seeded in flat-bottom 96-well plates. CD8+ T cells 
at 1x105 T cells/100µl complete medium without IL-2 were added to the SAg-loaded 
JY, stimulated with 0.25µM PMA and 2.5µM ionomycin, or seeded in flat-bottom 96-
well plates, precoated with 0.1µg/ml OKT3 and 1µg/ml anti-CD28 (eBioscience). 
Brefeldin A (BD Pharmingen) was added after 2hr, and after an additional 4hr 
incubation, cells were first stained for CD8, then fixed and permeabilized, as 
described above and stained with FITC-labeled anti-IL-2, PE-labeled anti-IFN-γ and 
PECy7-labeled anti-TNF-α (clones MQ1-17H12, B27 and Mab11, respectively, all 
from BD Pharmingen) for 30min at 4°C. The percentage of cytokine producing cells 
was measured by flow cytometry (FACSCalibur cytometer and Flowjo software). 
3.6 Cytolytic assay 
Target cells were left unpulsed or pulsed with SAg (doses ranging from 100ng/ml to 
1pg/ml) during 1hr at 37°C/5%CO2, and subsequently transferred to sterile FACS 
tubes at 1x105 cells/75µl complete medium without IL-2. CD8+ T cells prestained 
with 0.1µM CMFDA for 20min at 37°C/5%CO2 were added to the target cells at 
2x105 cells/75µl complete medium without IL-2 (effector/target ratio: 2/1). When 
indicated, 150 IU/ml rHuIL-2 or 20ng/ml rHuTNFα were added to the co-cultures. 
Cells were pelleted for 1min, 1500rpm and incubated at 37°C/5%CO2 for 4hr. Tubes 
were vortexed and transferred on ice. 7AAD (BD Pharmingen) was added (1/100) 
10min before flow cytometry analysis to measure the percentage of lysed target cells. 
In parallel, Lamp1 surface exposure was measured on CD8+ T cells upon 1hr 
stimulation with pulsed or non-pulsed target cells. Cells were washed in FACS buffer 
and stained with PE-labeled Lamp1(clone H4A3, BD Pharmingen) and FITC-labeled 
anti-CD8 (clone HIT8a, BD Pharmingen) for 20min at 4°C. The percentage of target 
cells staining positive for 7AAD and of CTL staining positive for surface Lamp1 was 
measured by flow cytometry (FACSCalibur cytometer and Flowjo software). 
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3.7 Western Blot  
Cells were lysed for 30min on ice in a modified RIPA buffer containing 50mM Tris-
HCl, pH8, 150mM NaCl, 1% IGEPAL, 1% sodium deoxycholate, 1mM EDTA, 
0.2mM AEBSF, 1mM Na3VO4, 1mM sodium orthovanadate and protease inhibitor 
cocktail (Sigma Aldrich). After clearing the supernatants by centrifugation, lysates 
were boiled in reducing sample buffer, separated through 7.5% SDS-polyacrylamide 
and transferred to nitrocellulose membranes. Membranes were blocked with Odyssey 
blocking buffer (LI-COR Biosciences, Nebraska) and incubated overnight at 4°C with 
anti-WASP (polyclonal Ab H250, Santa Cruz) and anti-β-actin (clone AC15, Sigma) 
Abs. After washing, goat anti-rabbit IgG-IR Dye 800CW (LI-COR Biosciences) and 
goat anti-mouse-AlexaFluor-680 mAbs (Molecular Probes) were added. WASP and 
β-actin expression was visualized and recorded on an Odyssey Infrared Imaging 
System (LI-COR Biosciences). 
3.8 Confocal microscopy 
Daudi cells were pulsed in the presence or absence of 100ng/ml of SAg and stained 
with 1µM CMTMR. They were then conjugated with CD8+ T cells at a ratio of 4:3 by 
centrifugation (2min at 1500rpm) and incubated for 8min at 37°C/5%CO2. Following 
resuspension, cells were transferred to poly-L-lysine-coated slides and allowed to 
sediment for 10min at 37°C. After fixation in 1%PFA and permeabilization in 
3%BSA/0.1%saponin cells were stained in 3%BSA/0.1%saponin with mAbs against 
α-tubulin (clone DM1A, Sigma) and perforin (clone dG9, BD Pharmingen), followed 
by isotype-specific secondary goat anti-mouse mAb labelled with Alexa-488 or 
Alexa-633 (Southern Biotech), respectively. Samples were mounted and examined on 
a Carl Zeiss LSM 510 confocal microscope (x63-1.4 oil immersion Plan-Apochromat 
objective) and images processed with the MetaMorph software (Universal Imaging 
Corporation). Images of randomly selected conjugates were obtained without further 
processing with the Zeiss LSM image browser. A non-subjective analysis of lytic 
granule polarization was performed on the basis of a previously reported approach261. 
In brief, distances of single perforin positive granules to the centre of the CTL/target 
contact area were measured using the single line function of the MetaMorph software 
(Universal Imaging Corporation). For each CTL, the mean distance of the lytic 
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granules to the centre of the CTL/target contact area was calculated. Only CTL 
containing at least 4 distinct lytic granules were considered for the analysis. 
3.9 Lentiviral vector transduction of CD8+ T cells 
Resting CD8+ T cells were stimulated with irradiated JY cells pulsed with 100ng/ml 
SAg at a ratio of 10:1 in complete medium supplemented with 100IU/ml rhIL-2. 
Three days after stimulation, CD8+ T cells were transferred to 48-well plates at 
2.5x105/well in 200µl complete medium supplemented with 100IU/ml rhIL-2, and 
incubated in the presence of 4µg/ml polybrene (Fluka) with 2.5x107 (MOI:100) or 
3.75x107 (MOI:150) transducing units of the w1.6W lentiviral vector (VSVg-
pseudotyped self-inactivating lentiviral vector containing human WAS 
promoter/cDNA in its clinical configuration: pCCL backbone and mutated WPRE 
sequence198). After 8hr, the medium was replaced with fresh complete medium 
supplemented with 100IU/mL rhIL-2.  
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4. Results 
4.1 CD8+ T cells from WAS patients differentiate into 
armed effector CTL upon stimulation with SAg-loaded APC 
To investigate the activation and function of CD8+ T lymphocytes from WAS and 
XLT patients in the context of APC stimulation, purified CD8+ T cell lines were 
generated by repeated stimulation with SAg-loaded B-EBV JY cells. WASP was 
expressed homogeneously in all HD CD8+ T cells, as shown by flow cytometry 
analysis (Fig 13A). The CD8+ T cells from the 3 WAS patients appeared negative for 
WASP expression, whereas the CD8+ T cells from the XLT patient showed a modest 
level of WASP expression. Western blot analysis confirmed that full-length WASP 
was absent in WAS CD8+ T cells and expressed at low level in XLT CD8+ T cells 
(Fig 13B). Analysis of perforin and granzyme B expression by flow cytometry 
demonstrated that both HD and WAS/XLT CD8+ T cell lines coexpressed the 2 lytic 
molecules homogeneously (Fig 13C). This suggests that the WAS CD8+ T cell lines 
developed normally into armed effector CTLs. Both HD and WAS CD8+ T cell lines 
displayed a homogeneous SAg-induced TCR down-regulation, indicating that most 
cells of each line responded to the SAg stimulation (Fig 13D). In addition, all cell 
lines displayed a dose-dependent TCR down-regulation (Fig 13E). WAS1 and XLT6 
cells responded similarly to HD cells, whereas WAS2 and WAS4 cells showed 
slightly reduced levels of TCR down-regulation. These data therefore indicate that 
CD8+ T cells from WAS and XLT patients can be differentiated into SAg-responsive 
CTL. 
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Figure 13: Generation of SAg-responsive CD8+ T cell lines from WAS and XLT patients. 
(A) Analysis by flow cytometry of CD8 and WASP expression in untransformed CD8+ T cell 
lines generated from healthy donors (HD) and WAS or XLT patients. (B) Parallel Western 
blot analysis of WASP expression in the HD, WAS and XLT CD8+ T cells. (C) Analysis by 
flow cytometry of the expression of the lytic molecules, granzyme B and perforin, in the HD, 
WAS and XLT CD8+ T cells. (D-E) Quantification of SAg-responding CD8+ T cells by 
measurement of the percentage of CD8+ T cells down-regulating their TCR upon stimulation 
with JY cells pulsed with the indicated doses of SAg. The mean ± SD of 3 experiments is 
shown in E. 
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4.2 Reduced cytokine production by WAS CD8+ T cells 
upon APC stimulation 
The capacity of CD8+ T cells from WAS patients to produce cytokines and to 
proliferate was analyzed in order to investigate whether these cells undergo a 
productive engagement of their TCR in the context of APC stimulation. As a 
confirmation of previous data156, PMA/ionomycin treatment resulted in normal 
production of IL-2 and IFN-γ in WAS CD8+ T cells, whereas a complete block of 
cytokine production was observed upon antibody-mediated TCR stimulation (Fig 
14A). This defect appeared however not as profound after stimulation with SAg-
loaded APC since a few WAS CD8+ T cells were able to produce IL-2 and IFN-γ, 
although at reduced levels as compared to HD CD8+ T cells. Cytokine production in 
CD8+ T cell lines from different WAS and XLT patients was further assessed at 
different doses of SAg. It was compared to cytokine production in 2 control HD CD8+ 
T cell lines representative of the normal range distribution (Fig 14B). At high SAg 
dose (100ng/ml), all 3 tested cytokines (IL-2, IFN-γ and TNF-α) were detected in the 
WAS and XLT CD8+ T cell lines. WAS1 and XLT6 cells produced cytokines at 
levels very close to the low range of normal values, while WAS2 and WAS4 cells 
showed reduced cytokine production. At lower SAg dose (1ng/ml), cytokines could 
not be detected in WAS and XLT cell lines, whereas they were still produced by HD 
cell lines. Despite reduced IL-2 production, all WAS and XLT CD8+ T cell lines 
proliferated similarly to HD CD8+ T cell lines at high SAg dose (Fig 14C). At lower 
SAg dose, only 2 WAS CD8+ T cell lines (WAS2 and WAS4) showed defective 
proliferation that was partially restored by adding exogenous IL-2 (Fig 14C-D). These 
data show that instead of a complete activation blockade, CD8+ T cells from WAS 
patients have only a moderate activation defect in the context of APC stimulation. 
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Figure 14: Cytokine production and proliferation of WAS CD8+ T cells upon APC 
stimulation. (A) Analysis by flow cytometry of cytokine production in CD8+ T cells from a 
representative healthy donor (HD1) and WAS patient (WAS1), in response to 
PMA/ionomycin, sub-optimal dose of plate-bound anti-CD3 and anti-CD28 mAbs, and SAg-
loaded JY cells. (B) Production of IL-2, IFN-γ and TNF-α in CD8+ T cells from healthy 
donors and WAS/XLT patients stimulated with JY cells loaded with the indicated doses of 
SAg. The mean ± SD of 3 experiments is shown. (C-D) Percentage of proliferating cells 
measured by CFSE dilution in CD8+ T cells from healthy donors and WAS/XLT patients 
stimulated with JY cells loaded with the indicated doses of SAg, in the absence (C) or 
presence (D) of exogenous IL-2. One experiment, representative of 3 experiments is shown. 
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4.3 Exocytic activity and lytic potential of WAS CTLs 
The cytotoxic activity of WAS CD8+ T cells was first tested against B-EBV (JY) cells 
pulsed with SAg. Analysis of JY cell lysis by measurement of 7AAD uptake showed 
a similarly high SAg-dependent killing efficiency by WAS and HD CD8+ CTL (Fig 
15A). However, lowering the SAg dose to 0.1ng/ml resulted in a reduction of the 
killing efficiency of WAS CTL as compared to HD CD8+ T cells. Further analysis 
clearly indicated that all tested WAS, XLT and HD CD8+ T cell lines killed JY target 
cells in a SAg dose-dependent manner (Fig 15B). At SAg doses ranging from 100 to 
1ng/ml, the killing efficiency of WAS1 and XLT6 CTL was comparable to that of HD 
CTL, whereas it was reduced in WAS2 and WAS4 CTL. Interestingly, at very low 
SAg dose (0.02ng/ml), detectable killing activity was observed only in HD and XLT6 
CTL, whereas WAS CTL failed to kill. We next investigated the capacity of WAS 
CTL to exocytose their lytic granules, as measured by Lamp1 surface exposure. 
Figure 15C shows that WAS and HD CTL similarly exposed Lamp1 at their surface 
in a SAg-dependent manner. Parallel analysis of the different WAS and XLT CD8+ T 
cells lines confirmed normal to slightly elevated SAg dose-dependent Lamp1 surface 
exposure (Fig 15D). Therefore, these data suggest that WAS CTL exocytose their 
lytic granules efficiently and have the potential to kill SAg-presenting B-EBV cells. 
The reduced killing efficiency observed at low SAg concentration is in agreement 
with the moderately diminished activation (measured as cytokine production and 
proliferation) observed above. 
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Figure 15: Cytotoxic activity of WAS CD8+ T cells. (A) Measurement by flow cytometry of 
7AAD uptake by target JY cells pulsed with the indicated doses of SAg, as a result of killing 
by CD8+ T cells from a representative healthy donor (HD1) and WAS patient (WAS1). 7AAD 
uptake in pulsed condition is represented by the lined histograms, while background 7AAD 
uptake is shown as plain grey histograms. (B) Parallel comparison of the efficiency of CD8+ 
T cells from healthy donors and WAS/XLT patients to kill target JY cells loaded with the 
indicated doses of SAg (represented as %7AAD+ JY cells in pulsed condition - %7AAD+ JY 
cells in unpulsed condition). The mean ± SD of 4 experiments is shown. (C) Analysis of 
Lamp1 surface exposure in CD8+ T cells from a representative healthy donor (HD1) and 
WAS patient (WAS1) upon stimulation with JY cells loaded with the indicated doses of SAg. 
(D) Parallel comparison of Lamp1 surface exposure in the CD8+ T cells from healthy donors 
and WAS/XLT patients upon stimulation with JY cells loaded with the indicated doses of SAg. 
The mean ± SD of 3 experiments is shown. 
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4.4 WASP expression is required for efficient killing of B 
cell lymphoma cells by CTL 
Given the high incidence of B cell malignancies in WAS, we next investigated the 
lytic activity of WAS CTL against two Burkitt lymphoma cell lines. As compared to 
control HD CTL, WAS CTL showed a strongly reduced lytic activity against both 
Daudi and Raji target cells loaded with high dose of SAg (Fig 16A). Further analysis 
confirmed that CTL generated from full-blown WAS patients (WAS1 and WAS4) 
displayed a strongly reduced lytic activity against Daudi and Raji target cells (Fig 
16B). However, the CTL generated from the XLT patient (XLT6) appeared to have a 
preserved killing activity against those targets. Lamp1 exposure was measured in 
parallel to the killing assays, in order to investigate whether reduced lytic granule 
exocytosis could explain the decreased killing activity of WAS CTL against Daudi 
and Raji target cells (Fig 16C). However, as previously shown upon stimulation with 
JY cells, WAS CTL exposed Lamp1 at their surface very efficiently upon stimulation 
with Daudi and Raji cells. Detailed analysis clearly failed to reveal reduced Lamp1 
exposure in the different WAS/XLT CTL lines tested (Fig 16D). Importantly, these 
data suggest that in WAS patients with no residual WASP expression, CD8+ CTL are 
particularly impaired in their lytic activity against tumoral B cell targets, even at high 
dose of stimulation.  
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Figure 16: WAS CTL inefficiently kill B cell lymphoma target cells. (A) Cytotoxic efficiency 
of CD8+ T cells from a representative healthy donor (HD1) and a WAS patient (WAS1) 
against JY cells and the tumoral B cell lines Daudi and Raji loaded with 100ng/ml SAg 
(measured by 7AAD uptake). (B) Parallel comparison of the cytotoxic efficiency of CD8+ T 
cells from healthy donors and WAS/XLT patients against SAg-loaded JY and tumoral B cells. 
Percentage of SAg-specific killing is calculated as %7AAD+ target cells in pulsed condition - 
%7AAD+ target cells in unpulsed condition. The mean ± SD of 4 experiments is shown. 
Conditions in which WAS CTL were found to kill less efficiently that HD CTL are indicated 
by the asterisks (* p≤0.05, ** p≤0.01, Student’s t test). (C) Analysis of Lamp1 surface 
exposure on CD8+ T cells from a representative healthy donor (HD1) and a WAS patient 
(WAS1) upon stimulation with JY and tumoral B cells loaded with 100ng/ml SAg. (D) Parallel 
comparison of Lamp1 surface exposure on CD8+ T cells from healthy donors and WAS/XLT 
patients upon stimulation with SAg-loaded JY and tumoral B cells. Percentage of Lamp1+ 
cells in the unpulsed condition was subtracted. The mean ± SD of 4 experiments is shown. 
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4.5 Incomplete polarization of WAS CTL lytic granules 
toward tumoral targets 
Since immunological synapse assembly has been reported to be impaired in WAS 
CD4+ T cells and NK cells165,238, we reasoned that the reduced killing activity of 
WAS CTL might result from an abnormal polarization of the lytic machinery toward 
target cells. WAS CTL were compared to control CTL in their ability to polarize their 
microtubule organization centre (MTOC) and perforin-containing lytic granules upon 
contact with SAg-pulsed Daudi cells. Representative confocal microscopy images 
show that in the absence of SAg, WAS and HD CTL did not polarize their MTOC and 
lytic granules toward Daudi cells (Fig 17A). Formation of conjugates with SAg-
pulsed Daudi cells however clearly induced a polarization of MTOC and lytic 
granules toward the target cell in both control and WAS CTL. Quantification of 3 
independent experiments indicates that the proportion of WAS CTL polarizing their 
lytic machinery toward SAg-pulsed Daudi target cells was comparable to that of 
control CTL (Fig 17B). These data however do not exclude subtle defects in lytic 
molecule delivery parameters such as precise localization and timing that might be 
sufficient to result in reduced killing efficiency. To address this point, we measured 
the distance between individual perforin positive lytic granules and the centre of the 
immunological synapse at the CTL/target cell contact area. This analysis revealed that 
the lytic granules from WAS CTL were not localized as close to the immunological 
synapse as the lytic granules from HD CTL (Fig 17C). These data therefore indicate 
that although WAS CTL oriented their lytic machinery toward the target cells, their 
lytic granules were not fully mobilized to the site of the immunological synapse.  
Results: experimental part II 
 110 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results: experimental part II 
 111 
Figure 17: WAS CTL orientate their lytic machinery toward B cell lymphoma target cells, 
yet lytic granule polarization is incomplete. (A) Representative confocal microscopy images 
of CD8+ T cells from a healthy donor (HD1) and a WAS patient (WAS1) conjugated with 
Daudi cells (prestained with CMTMR, in red) either non-pulsed or pulsed with 100ng/ml SAg. 
Polarization of the MTOC (green) and perforin (blue) at the CTL/SAg-pulsed target contact 
is indicated by the white arrows. (B) Quantification of the percentage of CTL polarizing 
simultaneously the MTOC and perforin toward the target cells. CTL were considered positive 
for polarized MTOC and perforin if both stainings were oriented toward the site of contact 
with the target cells and occupied less than one third of the CTL surface. Scoring was 
performed by eye in a double-blind fashion. The mean ± SD of 3 experiments, representing at 
least 60 conjugates per condition is shown. The proportion of HD1 and WAS1 CTL able to 
polarize their lytic machinery toward the target cell contact site in response to SAg 
stimulation was compared with a Student’s t test (n.s.: not significative, p=0.10). (C) 
Quantification of the distance between perforin positive lytic granules and the centre of the 
immunological synapse. In unpulsed conditions, 272 individual granules from 30 HD CTL 
and 416 individual granules from 40 WAS CTL were evaluated. In SAg-pulsed conditions, 
450 individual granules from 50 HD CTL and 458 individual granules from 50 WAS CTL 
were evaluated. Each dot of the graph represents one CTL, for which the mean distance of the 
perforin granules to the centre of the CTL/target cell contact area is plotted. Mean perforin 
granule distances to the immunological synapse were compared with a Student’s t test (n.s. : 
not significative, ** p≤0.01). 
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4.6 Correction of anti-tumoral CTL cytotoxity with a gene 
therapy lentiviral vector  
To confirm that the observed reduction in WAS CTL killing of tumor cells is a result 
of WASP deficiency, WAS cDNA was introduced in CD8+ T cells of a WAS patient 
by means of a lentiviral vector recently developed and approved for gene therapy 
trials198. Two independent transduction experiments with the w1.6W lentiviral vector, 
used at MOI 100 and 150, led to expression of WASP in 33 and 43% WAS CD8+ T 
cells, respectively (Fig 18A). Gene transfer-mediated expression of WASP with 
correct molecular weight was confirmed by Western blot analysis (Fig 18B). The 
cytotoxic efficiency of the transduced WAS CD8+ T cells was assessed against Daudi 
target cells presenting high SAg dose. As shown above, untransduced WAS CTL 
killed SAg-pulsed Daudi cells with reduced efficiency (Fig 18C-D). Importantly, the 
transduced WAS CTL displayed increased killing of SAg-pulsed Daudi cells, 
reaching similar efficiency to that of control CTL. Altogether, our study provides 
evidence that WASP is required for efficient killing of B cell lymphoma cells and that 
WAS gene transfer can correct the cytotoxic defect of WAS patient CTL. 
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Figure 18: Lentiviral vector-mediated WASP expression restores the cytotoxic activity of 
WAS CTL. (A) WASP expression in CD8+ T cells from a healthy donor (HD1) and a WAS 
patient (WAS1) analyzed before or after transduction with a WASP-encoding lentiviral vector 
used either at MOI 100 (LV100) or MOI 150 (LV150). (B) Western blot analysis of WASP 
expression in the same CD8+ T cells as in A. (C) Measurement of 7AAD uptake by Daudi 
cells loaded with 100ng/ml SAg following incubation with the same CD8+ T cells as in A and 
B. (D) Quantification of SAg-specific killing of SAg-loaded Daudi cells by the same CD8+ T 
cells as in A, B and C (represented as %7AAD+ target cells in pulsed condition - %7AAD+ 
target cells in unpulsed condition). The mean ± SD of 4 experiments is shown. Untransduced 
WAS1 CTL killed SAg-pulsed Daudi less efficiently that HD CTL (p=0.02, Student’s t test), 
while transduced WAS1 CTL killed at levels comparable to that of HD CTL (p>0.05, 
Student’s t test). 
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5. Discussion  
Using untransformed CD8+ T cell lines generated from WAS patients, we identified 
WASP as a molecule required for efficient CTL-driven cytotoxicity, in particular 
against B cell lymphoma targets. Our data suggest that the CTL dysfunction identified 
here might participate to the high susceptibility of WAS patients to develop viral 
infections and B cell malignancies. 
What is the mechanistic role of the actin regulator WASP during CTL cytotoxic 
activity? We confirmed in our cellular model that actin cytoskeleton integrity is 
required for CTL lytic activity. Indeed, CTL lytic activity toward SAg-loaded JY cells 
was abrogated following treatment with either latrunculin B or cytochalasin D (Fig 
S1). Conversely, our data indicate that WASP deficiency does not fully abrogate CTL 
lytic activity. WASP appears to be rather a fine tuner of CTL lytic activity. In contrast 
to the reduced cytokine production, WAS CD8+ T cells express normal levels of lytic 
effector molecules. Indeed, in addition to the data presented in Figure 1C, normal up-
regulation of perforin and granzyme B was observed following SAg-stimulation in the 
presence or absence of exogenous cytokines (Fig S2). In accordance with the fact that 
Arp2/3 is dispensable for MTOC polarization250, we show here that WAS CTL do 
orientate their MTOC and perforin-containing lytic granules toward target cells, even 
in conditions in which lytic activity is reduced (SAg-loaded Daudi target cells). This 
is however in contrast to data in NK cells showing that WASP promotes both 
adhesion to target cells and polarization of the lytic granules at the lytic synapse165,213. 
It is possible that in comparison with CTL, NK cells regulate lytic granule 
polarization and exocytosis with an additional layer of molecular control involving 
WASP. Interestingly, exogenous IL-2 can restore lytic granule polarization and lytic 
activity in WAS NK cells213. However, in our hands IL-2 did not restore the lytic 
activity of WAS CTL (data not shown), reinforcing the notion that WASP plays a 
distinct role in NK and CTL. High-level surface expression of Lamp1 following SAg-
loaded target encounter indicates that WAS CTL secrete their granules efficiently. 
However, given the recently described role of WASP in the immunological synapse40, 
it is possible that WAS CTL form relatively unstable lytic synapses, such as the ones 
formed by CD4+ CTL262. In particular, WAS CTL may not correctly assemble the 
actin ring at the periphery of the lytic synapse required to drive polarized secretion of 
the lytic granules32,84. As a result, lytic granule secretion may not be precisely directed 
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within the synapse cleft32, favouring leakage of lytic molecules and reduced efficiency 
in delivering the lethal hit. This hypothesis is in line with our observation that, in 
WAS CTL, perforin positive lytic granules appeared to not fully polarize toward the 
centre of the immunological synapse. A defect in the stability of the lytic synapse of 
WAS CTL might also explain why the killing appeared less efficient against tumoral 
B cell targets (although these targets expressed high MHC-II levels (Fig S3) and 
efficiently induced Lamp1 exposure on CTL). Indeed, tumoral B cell targets have 
been shown to impede formation of stable CTL lytic synapses263, a mechanism that 
might be amplified in the context of WASP-deficient CTL. 
What could be the contribution of CTL defects to the physio-pathology of WAS? The 
reduced killing efficiency of B cell lymphoma lines identified in this study is the first 
identification in WAS of a direct defect in eliminating tumoral cells. This data is of 
importance since WAS patients develop with a high incidence hematological 
malignancies comprising mainly EBV-positive B cell lymphomas123. Interestingly, we 
found normal CTL activity in CTL from a patient belonging to the milder XLT 
subgroup in which incidence of tumors does not appear to be abnormally elevated. 
This finding points to a link between CTL cytotoxic defect and B cell lymphoma 
susceptibility. However, we favour the hypothesis that the intrinsic CTL cytotoxic 
defect identified here, together with the previously described NK cell cytotoxic 
defect165,213, do not account alone for the development of B cell lymphoma in WAS 
patients. Indeed, additional defects such as reduced homing and stimulatory capacities 
of dendritic cells227,228, and reduced Th1 cytokine production by CD4+ T cells156 are 
likely to contribute to reduced CTL activation and to a state of reduced immune 
surveillance. Furthermore, in the absence of WASP, hematopoietic target cells may be 
more prone to resist CTL-mediated killing. Therefore, the selective susceptibility of 
WAS patients toward the development of hematological malignancies may result 
from a combination of reduced immune surveillance and resistance of emerging 
hematopoietic tumors to cytotoxicity. 
Our findings are also relevant to the understanding of the contribution of WASP to T 
cell activation. We found here that proliferation and cytokine production by WAS 
CD8+ T cells was less severely reduced in the context of APC stimulation, as 
compared to stimulation with anti-CD3/anti-CD28 Abs156. This finding extends 
previous data from the WASP knock-out murine model showing that WASP may not 
be strictly required for antigen-driven T cell proliferation and cytokine production 
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under physiological situation238,264,265. Accordingly, the killing efficiency of WAS 
CTL against the non-tumoral B-EBV JY cells was only moderately affected and 
revealed at low dose of stimulation. Interestingly, the physio-pathological 
consequences of the lytic defect observed in WAS appear to be distinct from those 
occurring in genetic defects affecting specifically CTL and NK cell cytotoxicity, such 
as the different forms of hemophagocytic lymphohistiocytosis (HLH)266. Indeed, in 
HLH patients, viral infection triggers uncontrolled CD8+ T cell expansion as well as 
abnormal macrophage activation leading to deleterious infiltration of visceral organs. 
Those manifestations are not present in WAS patients, probably because the lytic 
defect is only partial and because additional WAS-related defects such as the reduced 
IFN-γ production may prevent abnormal activation of macrophages. 
Finally, it may be proposed that CTL undergo functional exhaustion or replicative 
senescence in WAS patients as a result of chronic viral infection and persistent 
antigenic stimulation. However, our data show that WASP re-expression restored 
cytotoxic function, therefore demonstrating that the WAS associated defect is an 
intrinsic mechanistic defect. The WAS gene transfer experiment done with a vector 
designed for clinical application also argues that gene therapy will be able to restore 
the cytotoxic efficiency of CTL from treated patients.  
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Figure S1: Intact actin cytoskeleton is required for the killing of SAg-loaded target B cells. 
Cytotoxic activity measured as 7AAD uptake by SAg-loaded JY target cells, following 15-min 
pre-treatment of the CTL with latrunculin B, cytochalasin D (all reconstituted in DMSO and 
used at 5µM) or DMSO. SAg-specific lytic activity was calculated by subtracting the 
background lysis in absence of SAg. 
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Figure S2: Normal expression of granzyme B and perforin in CD8+ T cells from WAS and 
XLT patients. Analysis by flow cytometry of perforin and granzyme B expression in CD8+ T 
cell lines from 2 healthy donors (HD) and 2 WAS patients (WAS), either unstimulated or 
stimulated for 3 days with JY cells loaded with 100ng/ml SAg in the absence or presence of a 
cytokine cocktail (100IU/ml IL-2, 10ng/ml IL-7 and 10ng/ml IL-15). These data indicate that 
WAS CTL lines express perforin and Granzyme B levels within the normal range, both at the 
resting stage and following antigenic stimulation. In addition, WAS CTL lines normally 
further increase their perforin and Granzyme B content following exogenous cytokine 
treatment. 
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Figure S3: Analysis of HLA-DR and Fas expression in JY, Daudi and Raji cells. Flow 
cytometry analysis of HLA-DR and Fas expression levels in Daudi, Raji and JY cells. These 
data show that all 3 cell lines used as targets in this work express similar levels of MHC 
class-II molecules, suggesting that their ability to present SAg is similar. Daudi cells do not 
express Fas on their surface. Therefore, the lysis of those cells by CTL is through the 
exocytosis of lytic granules rather than through the Fas-FasL pathways. 
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VI. Increased resistance of WASP-deficient EBV-transformed B 
cells to CTL-mediated killing 
1. Introduction 
The Wiskott-Aldrich syndrome protein is expressed in all hematopoietic cells and 
patients who lack WASP expression, as in the Wiskott-Aldrich syndrome, suffer from 
serious immune deficiency, severe hemorraghes and eczema. Immune deficiency 
results in the occurrence of recurrent infections and increased risk to develop 
autoimmune disorders and hematologic malignancies with age123-125,208. As previously 
described, WASP is activated in response to a variety of signals that eventually leads 
to the reorganization of the actin cytoskeleton, regulating a multitude of cellular 
functions200,255. 
It is well established since several years now that WASP deficiency in DC, but also in 
less professional APC, such as B cells and macrophages, leads to defective 
chemotaxis, Ag-uptake, migration to lymphoid tissues, cell interactions, 
etc.124,125,208… There is no doubt that without good-functioning APC, the mounting of 
an efficient immune response becomes very difficult, if even possible. The 
importance of WASP at the DC side has recently been documented by papers 
describing impaired in vivo priming of murine CD4+ and CD8+ T cells, even when the 
migratory defect is bypassed, suggesting that intrinsic defects in WASP-deficient DC 
are at the origin of defective T cell activation227,228. In both studies however, the 
functional outcome was evaluated in normal WASP-expressing T cells. The activation 
of WASP-deficient T cells by WASP-deficient APC, reflecting the real situation in 
patients with WAS, and subsequent induction of effector functions remains to be 
explored. 
Patients with full-blown WAS have an extremely high susceptibility to develop 
tumors, and in particular hematopoietic malignancies123. Since WASP is exclusively 
expressed in hematopoietic cells, a role for WASP in tumorigenesis has been 
suggested. In this context both CTL and target cells are WASP-deficient. In WAS 
patients, most of the tumors appear to be EBV-positive. EBV-infected B cells can 
occasionally undergo in vivo transformation into malignant cells, causing B cell 
“Burkitt’s” lymphoma1. Abnormal chromosome distribution due to defective 
cytokinesis could also contribute to cell transformation into malignant cells, leading 
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to uncontrolled cell growth142. Immune deficiency and defective immune surveillance 
is likely to contribute to the high frequency of malignancies in WAS patients. 
Given the increased resistance of tumoral B cell lines to CTL-mediated killing, we 
wondered whether WASP-deficiency at the target cell side would exacerbate this 
finding. Therefore, we started evaluating CTL-mediated cytotoxicity by HD or WAS 
patient CD8+ T cells against B-EBV cells either knock-down for WASP, by means of 
lentiviral transduction with sh-RNA against WASP, or against naturally WASP-
deficient B-EBV cells generated from a complementary allogeneic WAS patient. 
Preliminary experiments demonstrate that B-EBV target cells completely lacking 
WASP expression exacerbate CTL-mediated lysis, independently from WASP 
expression in CTL, suggesting a prominent role for WASP at the target cell side. 
 
Compte tenu de l’augmentation de la résistance des lignées de cellules tumorales B à 
la cytotoxicité médiée par des CTL, nous nous sommes demandés si l’absence de 
WASP du côté de la cellule cible pourrait aggraver ce défaut fonctionnel. Par 
conséquent, nous avons commencé à évaluer la cytotoxicité médiée par des CTL de 
donneurs sains ou de patients atteints de WAS contre les cellules B-EBV, soit knock-
down pour WASP par transduction lentivirale avec sh-ARN contre WASP, soit contre 
des cellules B-EBV allogéniques, naturellement déficientes en WASP et générées à 
partir d’un patient complémentaire. Des expériences préliminaires démontrent que la 
lyse médiée par les CTL contre des cellules cibles B-EBV qui n’expriment pas WASP 
est aggravée, indépendamment de l’expression de WASP dans les CTL, suggérant un 
rôle de premier plan pour WASP du côté de la cellule cible. 
 
Results: experimental part II 
 122 
2. Materials and Methods 
2.1 Patients 
Patient WAS1 is an 8-month old male newborn presenting severe thrombocytopenia 
and eczema. He carries a WAS gene nonstop mutation (c.1509A>C), resulting in 
undetectable WASP expression in PBMC. A WASP-deficient EBV-transformed B-
cell line (B-EBV) was generated from an additional WAS patient previously referred 
as W1156. Age-matched healthy donors (HD) were used as controls. Blood samples 
from patients and healthy donors were obtained following standard ethical procedures 
(Helsinki protocol) and with the approval of the concerned Internal Review Boards. 
2.2 Transformed cell lines and untransformed DC and 
CD8+ T cell lines 
WAS patient B-EBV and normal B-EBV (JY) were cultured in RPMI1640 (Gibco) 
supplemented with 100µg/ml Penicillin/Streptomycin, 2mM L-glutamine, 10mM 
Hepes, 0.1mM MEM non-essential amino acids, 1mM sodium pyruvate (all from 
Invitrogen) and 10%FCS (PAA). T cell lines and DC were generated and kept in 
culture as described above. 
2.3 Lentiviral transduction of EBV-transformed B cells 
JY cells were transferred to 48-well plates at 2.5x105/well in 200µl RPMI/10% FCS, 
and incubated in the presence of 4µg/ml polybrene (Fluka) with 3.75x106 (MOI:15) 
transducing units of the w1.6W lentiviral vector encoding sh-RNA against WASP or 
sh-scramble (VSVg-pseudotyped self-inactivating lentiviral vector containing human 
WAS promoter/cDNA in its clinical configuration: pCCL backbone and mutated 
WPRE sequence198) or with a control LVV encoding scramble sh-RNA. After 8hr, the 
medium was replaced with fresh medium.  
2.4 Analysis of transduction efficiency 
Transduction efficiency was analyzed by flow cytometry. Minimum 10 days after 
transduction, transduced cells, that are GFP+, were washed, fixed and permeabilized 
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using the fixation and permeabilization kit (BD Pharmingen) according to 
manufacturer’s instructions. Intra-cellular staining of WASP was performed using a 
non-coupled primary anti-WASP mAb followed by a PE-coupled secondary antibody 
(BD Pharmingen). Stained cells were analysed on the FACSCalibur (Beckton 
Dickinson) and data were analyzed with Flowjo software. 
2.5 Cytolytic assay 
See description above. 
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3. Results 
3.1 Down-modulation of WASP in target EBV-B cells does 
not seem to alter their susceptibility to CTL-mediated killing 
Transduction of EBV-transformed B cells (JY) with the lentiviral vector encoding sh-
RNA against WASP, led to efficient down-modulation in 67% of the cells. As 
confirmed by flow cytometry, cells transduced with the control vector (sh-scramble) 
co-express homogeneously GFP and WASP, whereas GFP+ cells, transduced with the 
sh-WASP vector, displayed down-modulated levels of WASP (Fig 19A). These 
WASP knock-down JY cells were then used as target cells in a lytic assay. Previously 
we described that WAS CTL killed control JY target cells less efficiently, especially 
at low SAg doses, and all CTL lines killed in a dose-dependent manner. Here we 
confirm these observations and demonstrate that down-modulation of WASP in JY 
cells did not alter their susceptibility to CTL-mediated killing as compared to control 
target cells (Fig 19B). These preliminary data suggest that reducing WASP expression 
in EBV-transformed B cells may not affect their susceptibility to CTL-mediated 
killing. 
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Figure 19: target cells knock-down for WASP are similarly susceptible to CTL-mediated 
lysis. (A) Flow cytometry analysis of target JY cells transduced with lentiviral control 
(scramble) vectors or vectors to down-modulate WASP expression (sh-WASP). (B) Knocked-
down target cells are killed with similar efficiency as control target cells. 
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3.2 WAS patient target B cells activate normally CD8+ T 
cells but are resistant to CTL lysis 
However, since we did not obtain 100% transduction efficiency and since the Sh-
RNA-mediated knock-down most probably results in residual WASP expression, we 
thought to use a WASP negative B-EBV cell line, generated from a WAS patient, as 
target cells. WASP deficiency in B-EBV cells from patient W1 was confirmed by 
western blot analysis (Fig 20A). Obviously, this setting better mimics the situation 
encountered in WAS patients. As compared to control WASP positive JY cells, WAS 
B-EBV cells were very efficient at presenting SAg to different CD8+ T cells (HD1, 
WAS1 and XLT6) as revealed by robust TCR down-regulation (Fig 20B). However, 
when the WAS B-EBV cells were used as target cells in a lytic assay, they appeared 
more resistant to CTL-mediated killing than the control B-EBV cells (Fig 20C). This 
resistance was particularly pronounced when CTL were from the WAS/XLT patients. 
These data strongly suggest that WASP not only tunes the lytic activity at the CD8+ T 
cell side, but also modulates the resistance to lytic attack at the APC side. 
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Figure 20: WASP deficient target B cells are partially resistant to CTL-mediated lysis. (A) 
WASP expression analysis by western blot in an EBV-transformed B cell line generated from 
a WAS patient as compared to normal EBV-B JY cells. (B) Measurement of TCR down-
regulation by CD8+ T cells from a healthy donor (HD1), a WAS patient (WAS1) and a XLT 
patient (XLT6) upon stimulation with either WASP-positive B-EBV (JY) cells or WASP-
deficient B-EBV cells pulsed with 100ng/ml SAg. (C) Analysis of SAg-specific killing of JY 
(black bars) and WASP-deficient B-EBV cells (white bars) (by measurement of 7AAD uptake) 
induced by CD8+ T cells from a healthy donor (HD1), a WAS patient (WAS1) and a XLT 
patient (XLT6). WASP-deficient B-EBV cells were found to be partially resistant to CTL-
mediated lysis, as compared to WASP-positive B-EBV cells (see p values, Student’s t test). 
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4. Discussion  
Using WASP-deficient EBV-transformed cell line from a complementary WAS 
patient, we showed evidence that WASP might play a role in target cell susceptibility 
to CTL-mediated lysis. However, WASP down-modulation by means of a sh-RNA 
encoding lentiviral vector did not result in significantly reduced susceptibility to CTL 
killing. This may suggest that only full ablation of WASP in target hematopoietic 
cells may render them more susceptible to CTL killing. Very interestingly, we found 
that WASP-deficient B-EBV cells from a WAS patient displayed resistance against 
the cytotoxic action of both control and WAS CTL. This indicates that in EBV-
infected target B cells, WASP deficiency may impede delivery of the lethal hit and in 
particular the active uptake of lytic molecules. This might be an additional 
explanation to the particularly strong defect in controlling EBV infection in WAS 
patients.  
These results show that WASP deficiency at the APC side combined with WASP 
deficiency at the T cell side will complicate even more the functional outcome of 
efficient immune responses, both in the context of infection and tumor development. 
As described in the previous chapter, WAS CTL showed a severe defect in the 
cytolysis of tumoral EBV+ B cell lines, even if they were fully equipped with lytic 
molecules and showed normal degranulation upon activation. When one considers our 
data together, there is reason to believe that tumoral EBV+ WASP-deficient B cells, 
are likely to show the same resistance to CTL killing, or even increased resistance, if 
both defects can be summed. Therefore it would be interesting to investigate the 
cytolytic potential of WAS CTL against B cells isolated from tumors of WAS 
patients.  
It is worth to note that even small expression levels of WASP in target cells appears 
to be sufficient for normal lysis by WAS or HD CTL, as demonstrated in the WASP-
KD target cells, transduced with lentiviral vectors to silence WASP expression. This 
might explain the milder phenotype of XLT patients as compared to WAS patients 
both in the decreased occurrence of infections as well as in the absence of the 
development of tumors. In addition, it enforces the importance to further optimize 
gene therapy strategies, since gene corrected cells appear to display normal 
functionality, as demonstrated for HSC, T cells, DC and macrophages. 
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The reason why EBV would render infected WASP-deficient B cells more prone to 
transformation is unclear. It has been suggested that immune deficiency and defective 
immune surveillance would play a role in this process. 
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VII. General discussion:  
1. Technical aspects and relevance of this work 
1.1 Working environment 
Our young team was set up in 2006 thanks to a Marie Curie Excellence grant from the 
European Community. During the first year, many efforts went to the development of 
new experimental models and strategies to investigate WASP function in T 
lymphocytes in attendance to receive patient samples from clinical collaborators.  
Our team was twined with the laboratory of Salvatore Valitutti, an expert in T 
lymphocyte- and immunological synapse dynamics, therefore, this project aimed to 
“bridge” the expertise on WAS of my supervisor with T cell activation at the 
immunological synapse. 
1.2 Set-up of cellular models 
Since I had a lot of experience in DC generation and DC interactions with T cells, 
from former lab-experiences, the set-up of the autologous DC-T cell model seemed 
feasible to accomplish in a limited time frame.  
The development of the second cellular model was commonly used in the former lab 
of my supervisor and had proven its efficacy in expanding low numbers of cells. This 
was of great importance for us, since blood samples (in our case from patient WAS1) 
from little children are much smaller than samples from adults. Second, since WAS is 
a rare disease, finding a local donor is a rare event. Third, once treatment with bone 
marrow transplantation had been performed, we could not use new blood samples.  
Since we wanted to generate CD8+ T cell lines responding to a mixture of SAg from 
patient PBMC, we “refined” the classical feeder protocol, in several ways. We did not 
add PHA, a stimulator of non-specific T cell proliferation, IL-2 was administered only 
on day 3 and we loaded our EBV-transformed B cells with SAg. The latter raised 
several questions… Superantigen is known to bind to HLA class II molecules, and not 
HLA class I molecules, which are involved in Ag-recognition and activation of CD8+ 
T cells. In addition, at that time, we did not find other publications using SAg for the 
stimulation of purified CD8+ T cells. And finally, since we also made use of 
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allogeneic EBV-transformed B cells both in feeders and functional assays, we 
wondered whether the response would be allo-specific, SAg-specific or a combination 
of both. Throughout the years, we got reassured both by our own data and the fact that 
other groups were using SAg for CD8+ T cell stimulation. Indeed, the fact that we see 
a dose-response in terms of TCR down-regulation, T cell proliferation and lytic 
activity, and in particular the low background killing in cytolytic assays against non-
pulsed target cells, demonstrates that our CD8+ T cells respond specifically to the SAg 
and not to the allo-antigen presented by the APC. We hypothesized that SAg, which 
are big and sticky molecules, mask the allogeneic HLA molecules on APC. This 
would imply that during feeder stimulation, cells encounter only SAg-loaded APC, 
and not empty APC. When restimulated in functional assays, they will recognize the 
SAg, but not allogeneic antigens, since they have not been primed to allo-antigens. 
The delayed administration of rHuIL-2 resulted in a marked enrichment of SAg-
specific T cells, as observed by staining of specific Vβ chains in CD8+ T cell cultures 
(data not shown). 
We made several attempts in setting-up another SAg-based model: the generation of 
TSST-1-responding Vβ2 CD8+ T cell lines. This consisted of the purification of Vβ2 
CD8+ T cells, which we stimulated with anti-CD3/anti-CD28-coated microbeads. 
However, this approach induced massive cell death in CD8+ T cell cultures and a state 
of non-responsiveness to restimulation with TSST-1-loaded APC of the few cells we 
obtained after expansion. Moreover, repeated stimulation of Vβ2 CD4+ T cells with 
anti-CD3/anti-CD28-coated microbeads also resulted in the generation of non-
responsive cells, displaying abrogated proliferation and cytokine production upon 
consequent re-stimulation with TSST-1-loaded B-EBV cells (unpublished data of 
Ronan Calvez). 
1.3 Advantages and drawbacks of the cellular models 
The advantages of the second model to the first autologous model (and general 
advantages), is the facility of the system, the less time-consuming experimental 
procedure, the lower cost of reagents and the fact that we obtain high numbers of 
oligo-clonal SAg-specific CD8+ T cells after only 1 round of stimulation. The major 
drawback of both systems is the use of SAg as antigenic stimulus for T cell activation. 
It would be more useful/ physiological to use pathogens or pathogen-derived proteins 
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(in case of the DC model) or antigenic peptides (that can be loaded on JY cells), 
relevant for patients with WAS. For example, it would be of interest to generate 
CMV-, EBV-, or HSV-specific lines. This would be a very time-consuming 
challenge, but definitely worth-doing! Another limitation of our model is the 
extrapolation of our results to the pathology seen in WAS. Indeed, it is difficult to say 
that the in vivo situation will resemble to what we observed. We are convinced that 
CTL function in WAS is compromised, however, since many cell types display 
intrinsic defects, CTL dysfunction might be only a minor contribution to the severe 
phenotype. In addition, we suspect that T cell activation might be much more affected 
than estimated in this work, because of the intrinsic defects described in dendritic 
cells and CD4+ T helper cells, which could in turn exacerbate the defects described in 
CTL effector functions. 
1.4 Relevance of investing efforts on the study of WAS 
WAS is a very rare disease, affecting 1 to 10 boys on ten million newborns. One 
might think, why all these efforts for the only few affected by this disease? 
Unfortunately, newborns with WAS die before the age of 15, in the absence of 
treatment. I hope not to be the only one to see the importance of continuing research 
on very rare diseases, including WAS, besides research on cancer, HIV, Alzheimer 
etc… I consider (based on my own ethical and educational convictions) that every 
individual, whether he or she is affected by a very common, or in contrast a very rare 
disease, has the right to receive the best treatment available, and for that research is 
indispensable.  
This work and the cellular models we developed do not only contribute to the 
understanding of CTL biology in WAS, but may also contribute to the study of other 
primary immune deficiencies, or to the implementation of gene therapy strategies.  
Disease progression is unpredictable and can occur very fast for some patients with 
WAS. As described in the introduction, patients who develop autoimmune disorders 
or tumors, automatically receive clinical score 5, independently from their previous 
score. However, prognosis drops, once a WAS patient presents with autoimmune or 
malignant manifestations. We showed here a lytic defect in WAS patients both 
against normal and tumoral B-EBV cells. However, we observed some donor 
variability between the different WAS patients, and the XLT patient behaved 
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normally against tumoral B cell lines. We wonder whether investigating CTL lytic 
function against tumoral target cells could have a predictive value during the 
screening of patients with WAS, to pick out patients who may have increased risks to 
develop tumors in the future. It could therefore be interesting to set up a retrospective 
trial to look whether decreased CTL and NK cell cytotoxicity is associated with 
increased risk to develop hematopoietic malignancies. 
2. Different approaches to look at WASP function 
In this study we tried to use different approaches to address the role of WASP in 
CD8+ T cell activation and function. As described before, while attending the arrival 
of patient cell samples, other approaches were explored. The first one was the use of 
wiskostatin, a reversible inhibitor of (N-) WASP-mediated actin polymerization. Even 
though this approach was very attractive because of its simplicity in use, wiskostatin 
exerted toxic effects in functional assays, such as T cell proliferation. Even though 
toxicity appeared absent in short-term assays, we preferred to abandon this approach 
and we invested a lot of efforts in the lentiviral transduction of CD8+ T cells with 
vectors encoding sh-RNA to knock-down WASP expression. Therefore, autologous 
SAg-loaded DC were used to stimulate primary CD8+ T cells and the transduction 
was performed on day 3 at different MOIs. Unfortunately, even at high MOI, we did 
not obtain our pre-fixed 50% transduction efficiency after several attempts (Fig S1). 
In addition, the small numbers of transduced cells we obtained after stimulation were 
not sufficient to perform the experiments necessary to answer our questions. 
Finally we obtained several patient cell lines. Theoretically, this is the ideal model for 
the study of WASP, since all cells derived from hematopoietic stem cells, including T 
and B lymphocytes, from patients with WAS are naturally knock-out for WASP. 
However, the use of patient cells has several drawbacks as well. It has been suggested 
that lymphocytes from WAS patients display a degree of “exhaustion”, due to the 
recurrent encounter of pathogens and cycles of activation and expansion, and they 
would have a decreased TCR repertoire. Additionally, they display signs of 
“senescence” and therefore could transform more frequently into malignant cells. We 
also have to take into account that WAS patients are frequently under treatment 
(immuno-suppression, antibiotics, antiviral drugs, etc…) also affecting normal T cell 
physiology.  
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A final approach used in this work was the reconstitution of WASP in patient CD8+ T 
cells by means of lentiviral transduction. Again, transduction experiments did not 
result in predetermined conditions; it is 50% transduction efficiency. However, 
beneficial effects were demonstrated in terms of cytolytic potential against tumoral B 
cell lines. 
3. Meaning of the scientific findings 
3.1 Molecular level 
a) TCR-mediated T cell activation 
WASP plays an important role in T cell activation and links TCR stimulatory signals 
to signal transduction pathways mediating Arp2/3-regulated actin 
polymerization159,235,236. It has been suggested that WASP would play a role down-
stream the TCR and the co-stimulatory molecule CD28. Indeed, data from WASP-/- 
mice revealed a role for WASP in TCR internalization upon triggering of this 
receptor159. TCR internalization depends on an intact cytoskeleton, as it is abrogated 
by cytoskeleton-disrupting agens, such as dihydrocytochalasin B and latrunculin B. 
Intersectin-2 has been shown to co-localize with WASP and Cdc42 in endocytic 
vesicles upon TCR triggering and these interactions would be required for Arp2/3-
mediated actin polymerization and TCR internalization267. In addition, it has been 
demonstrated that WASP is required for the endocytosis of CD28 upon TCR 
triggering in combination with co-stimulation, a process that is required for efficient 
co-stimulation during T cell activation268. We were unable to demonstrate a role for 
WASP down-stream TCR triggering in the regulation of TCR internalization. Indeed, 
TCR down-regulation upon SAg recognition on APC was normal in CD8+ T cells 
from WAS patients, as compared to healthy donor cells and was dose-dependent. In 
addition, TCR down-regulation was also preserved, to slightly increased, in CD8+ T 
cells treated with wiskostatin during stimulation with SAg-loaded autologous DC 
(data not shown). 
General discussion 
 135 
b) Proliferative- and cytokine response to T cell activation 
However, whereas TCR down-regulation appeared unaffected, cytokine production 
and T cell proliferation were defective in CD8+ T cells from WAS patients upon 
stimulation with SAg-loaded APC. This is in accordance with in vivo studies 
performed in mice238 or in vitro studies using mouse239 or human156 WASP-deficient 
CD4+ and/or CD8+ T cells and suggests that WASP is implicated either on the 
transcriptional or post-transcriptional regulation of genes encoding cytokines. For 
WAS CD8+ T cells it has been demonstrated that mRNA levels for IL-2 and IFN-γ are 
reduced as compared to healthy donor cells, following anti-CD3/ anti-CD28 
stimulation, suggesting a role for WASP at transcriptional level for IL-2 and IFN-γ156. 
Indeed, the recruitment of the nuclear factors NFAT-1 and NFAT-2 was reduced upon 
TCR stimulation in CD8+ T cells from patients with WAS. In mice however, although 
IFN-γ is normally produced, intracellularly it does not polarize normally towards APC 
and is not secreted, suggesting a secretory defect239. More recently WASP has been 
shown to be involved in the post-transcriptional regulation of IL-4. Indeed, mRNA 
levels for IL-4 are normal to increased in WAS CD4+ T cells, as compared to control 
cells, whereas at protein level, IL-4 production is reduced in effector Th2 cells in 
response to infection with Nippostronglyus brasilensis or Leishmania major240.  
Defective IL-2 production could explain the reduced proliferative responses to SAg-
stimulation in 2 out of 3 WAS patients. However, addition of high doses of 
exogenous IL-2 does not completely restore T cell proliferation to normal levels, 
suggesting that WAS CD8+ T cells might be less responsive to IL-2 or show intrinsic 
defects in cytokinesis. Decreased responsiveness to IL-2 has been described only 
recently. The IL-2 receptor seems to be normally up-regulated, but the signal 
transduction pathway upon binding of IL-2 to its receptor, inducing STAT5 
phosphorylation, appeared slightly reduced in WASP-KO mice and completely absent 
in mice lacking both WASP and WIP265. Defective cytokinesis has been described in 
myeloid cells displaying constitutively activated WASP, as in XLN, and appears 
associated with the generation of cells with altered chromosome numbers142, 
commonly found in tumor cells and potentially at the origin in cancer development269. 
Although not yet investigated, WASP-deficiency might also be accompanied by 
polyploidy and defective cytokinesis, since patients with WAS are particularly 
susceptible for lymphoreticular malignancies142. 
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c) Cytolytic effector function upon target cell recognition 
The present study also highlights the contribution of the actin regulator WASP to 
CTL lytic activity. We confirmed that an intact actin cytoskeleton is required for CTL 
lytic activity and that specific inhibition of WASP by means of Wiskostatin did not 
affect CTL-mediated killing towards B-EBV cells. In agreement, WAS CTL maintain 
a strong lytic potential against JY target cells, at least at high SAg dose. However, a 
severe lytic defect was observed against 2 tumoral B-EBV cell lines. Direct evidence 
for WASP involvement in the CTL lytic defect against target Daudi cells, came from 
experiments in which we reconstituted WASP expression in CD8+ T cells from one 
WAS patient (WAS1) and compared the lytic activity with non-transduced CTL from 
the same patient and a healthy donor. Despite the low transduction efficiency, we 
observed a significant improvement of the lytic potential of CTL who re-expressed 
WASP as compared to its non-transduced counterpart.  
Since NK cell perforin/granzyme-mediated cytotoxicity is also severely 
impaired165,213, we then reasoned that WASP deficiency might be involved in the up-
regulation of the lytic molecules granzyme B and perforin. Indeed, mutations in the 
gene encoding the lytic granule compound, perforin, leads to the abrogation of CTL- 
and NK-mediated cytotoxicity, both in mice and human97,266. However, flow 
cytometric analysis did not show any difference in the expression levels between 
WAS and healthy donor CD8+ T cells. In addition, we could rule out a possible role of 
Fas-FasL-mediated killing in the defective cytotoxicity against tumoral B-EBV cells, 
since Daudi cells lack the expression of FasL. 
An essential function of the immunological synapse is directed secretion. CTL direct 
lytic granules to the synapse upon activation, which enables cytotoxicity, and 
facilitates host defense. This process requires rearrangement of the actin cytoskeleton, 
trafficking of the lytic granules to the IS and directed secretion. Genetic defects that 
block one of those steps, such as mutations in the genes encoding Rab27a and 
Munc13-4, result in impaired cytotoxicity and susceptibility to viral infection85,98. In 
NK cells WASP deficiency or down-modulation of endogenous CIP4 expression 
leads to impaired MTOC polarization and cytotoxicity270. Since polarization of lytic 
granules to the IS requires polarization of the MTOC84, we wondered whether WAS 
CTL were capable to polarize their lytic machinery towards SAg-pulsed tumoral 
target cells. We clearly demonstrate that WAS CTL were able to polarize their MTOC 
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and lytic molecules toward target cells, even if they displayed reduced cytotoxic 
potential against those target cells. These observations are in agreement with the 
findings of the group of Billadeau, who demonstrated that MTOC polarization does 
not require Arp2/3-mediated actin polymerization, but requires a different family of 
actin regulators, the formins250. However, careful examination of the distance between 
individual lytic granules to the center of the lytic IS in WAS CTL/target cell 
conjugates revealed that although WAS CTL globally orientate their lytic machinery 
toward the target cell, numerous individual lytic granules appeared not to be delivered 
properly at the lytic synapse. The observed lytic granule dispersion may account for 
the reduced lytic activity of WAS CTL, especially against resistant targets such as 
tumor cells. This reduced polarization is reminiscent of parallel observations made in 
the laboratory by Ronan Calvez on WAS CD4+ T cells. Indeed, he observed that the 
WAS CD4+ T cell IS is unfocused as revealed by abnormal cell morphology, reduced 
MTOC polarization and dispersed TCR activation (phosphotyrosine staining). These 
fine observations and measurements were done by 3-D reconstruction of confocal 
planes and by time-lapse video-microscopy. It would therefore be interesting to 
reconsider the mechanisms responsible for the reduced cytotoxicity of WAS CTL 
with similar approaches. 
3.2 Cellular level 
a) Cytokine production and proliferation:  
We have demonstrated that WASP is required for the production of IL-2, IFN-γ and 
TNF-α in CD8+ T cells upon stimulation, especially at low SAg dose. These 
cytokines are extremely important for the initiation and normal evolution of immune 
responses. Indeed, as described previously, IL-2 is important to drive clonal 
expansion of Ag-specific T cells, and in our case, CD8+ T cells, in response to Ag-
recognition. This expansion will generate an army of Ag-specific CTL, that will chase 
infected cells and eradicate them.  
Because of the many physiological effects of TNF-α, defective production might 
result in a multitude of dysfunctions. In addition, TNF-α is produced not only by 
CD8+ T cells, but also by activated macrophages and NK cells. Whether in these cells 
TNF-α production is affected in the absence of WASP is not known, but likely. 
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Defective production of TNF-α might result in impaired TNF-α-mediated maturation 
of DC in vivo with consequent defective IL-12 production271. Inappropriate 
maturation of DC implies defective up-regulation of maturation-associated co-
stimulatory molecules, such as the B7-molecules, indispensable for T cell 
activation4,271. Additionally, defective IL-12 production would inhibit the stimulation 
of CD4+ Th1 cells and CTL and thereby dempen the development of a cellular IR. In 
DC knock-down for WASP expression, defective IL-12 polarization has been 
reported with subsequent defective NK cell activation and cytotoxicity229, reflecting 
the importance of cytokine-driven co-activation of effector cells from the immune 
response by DC. Defective TNF-α might also interfere with the up-regulation of PI-9 
in DC, normally protecting them from CTL-mediated killing. By this mechanism, 
memory CD8+ T cells promote cellular immunity through the prolonging Ag-
presentation by DC to effector CTL. In the absence of TNF-α, DC could become 
highly susceptible to GrB/PRF-mediated CTL killing, resulting in more rapid 
termination of immune responses without complete clearance68. This could be at the 
origin of chronic infection, leading to the development of chronically activated T cells 
and the onset of autoimmune disease.  
T cells are the main source of IFN-γ and its production is triggered in particular 
during immune responses against virusses and tumors. Defective IFN-γ in WAS CTL 
may therefore explain the increased susceptibility of patients with WAS for infections 
and tumor development. Indeed, IFN-γ promotes antigen processing and class I and II 
presentation to CTL and Th1 cells, respectively. It also appears to stimulate the up-
regulation of co-stimulatory molecules on APC for full T cell activation. IFN-γ would 
also regulate the up-regulation of adhesion molecules, both on leucocytes as on 
endothelial cells, promoting extravasation and infiltration into infected or tumoral 
tissues.  
The defect in cytokine production is milder when real APC are used instead of 
antibodies to provide activation signals, suggesting that other molecules than CD3 
and CD28, present on APC, might promote cytokine production. Indeed, co-
stimulatory signaling via LFA-1272,273, CD2273,274, CD45273, and VLA-4275 have been 
described to enhance cytokine production by T cells. In addition, the defect in 
cytokine production is not an intrinsic failure of T cells, since PMA/Ionomycin 
induces robust production in both WAS and control CD8+ T cells. 
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b) Cytotoxicity 
Since we failed to demonstrate a defect in granzyme B and perforin production, in the 
polarization of the lytic machinery towards SAg-loaded target cells, we investigated 
whether WAS CTL normally disposed of their lytic granules. Measuring Lamp-1 
exposure on WAS CTL demonstrates that CTL from WAS patients de-granulate 
normally, or even in higher extent, as compared to normal CTL in response to SAg 
recognition presented by normal or tumoral B-EBV target cells. We observed similar 
preserved Lamp-1 exposure in CD8+ T cells, in which we down-modulated WASP by 
means of lentiviral vectors encoding sh-RNA against WASP (Fig 21). Strikingly 
however, Lamp-1 exposure does not completely correlate with the kinetics of target 
cell killing. Indeed, at a dose of 1 ng/ml, target cell killing still reaches maximal 
levels in CTL from HD and WAS1, whereas Lamp-1 exposure dropped substantially. 
This is in line with recent observations by Beal et al, and suggests that CTL need to 
release only few lytic granules to lyse target cells262. Since addition of exogenous IL-
2 corrected NK cell mediated lysis agaist succeptible target cells213, exogenous 
cytokines were added during lytic assays to see whether correction of defective 
cytokine production would restore lytic capacity against Daudi cells. However, 
addition of exogenous IL-2 or TNF-α did not affect the impaired lytic activity of 
WAS CTL against target Daudi cells. 
As presented in the introduction, effector CTL are not only very efficace in 
exterminating compromised cells (sniper function), but they also play an important 
role in the extinction of immune responses by killing Ag-presenting DC (suppressor 
function). Memory CD8+ T cells, on the contrary, have been shown to exert a helper 
function, by promoting immune responses. This function would be mediated through 
the production of TNF-α, a cytokine which production is severely affected in WAS 
patients68. First, TNF-α would stimulate IL-12 production by DC, indispensable for 
the differentiation of Th1 cells and the activation of naive CTL. Second, TNF-α acts 
on DC by promoting the up-regulation of PI-9, a granzyme B inhibitor, protecting 
them from killing by CTL, and prolonging the timespan of Ag-presentation (Fig 22).  
We tested in a preliminary experiment, using the autologous DC-CD8+ T cell model, 
the contradictary cytolytic function of effector versus memory CTL. As expected 
from the study of Watchmaker, we confirmed that effector CTL kill SAg-pulsed DC 
in a SAg-dose-dependent manner, whereas memory CTL lost the ability to kill, even 
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at high SAg dose. As confirmed by flow cytometry, effector CTL were 
CD45RA+/CD25+, whereas memory T cells were CD45RO+/CD25- (Fig 23).  
Based on these observations and the defective TNF-α production by WAS CD8+ T 
cells, we hypothesized that besides the impaired sniper function, their helper function 
could be impaired as well (Fig 24). Indeed, CD8+ T cells that do not optimally 
produce TNF-α, could be impaired in their capacity to induce the up-regulation of IL-
12 and PI-9 in DC, leading to sub-optimal cellular immune response due to impaired 
stimulation of CTL and killing of DC. This hypothesis could be tested using our 
autologous model and by silencing WASP expression in CD8+ T cells (and possibly 
also in DC). 
Besides the intrinsic defects at the CTL side, we observed increased resistance of 
WASP-deficient B-EBV cells to CTL-mediated lysis, independently of WASP 
expression at the T cell side. This might suggest a role for WASP in the active uptake 
of lytic molecules. It is also plausible to believe that the so called “micro-
environment” and escape mechanisms, created by tumor cells to protect themselves 
against lysis might as well be altered as a consequence of WASP deficiency. It would 
therefore be interesting to look at the cytokine production of tumoral WASP-deficient 
cells, and more specifically at the production of IL-10 and TGF-β, both cytokines that 
interfere with the mounting of an adaptive immune response. Interestingly, IL-10 and 
TGF-β are also produced by CD4+ regulatory T cells, and their production seems to 
be defective in WAS, as demonstrated in mice162,163. It might also be worth to look at 
the expression levels of FasL on tumoral WASP-deficient B-EBV cells, since 
mutations in Fas are at the origin of severe lymphoproliferative disease and 
autoimmunity, 2 symptoms in WAS. Fas is expressed by activated CD4+ Th1 cells 
and CD8+ CTL and can directly initiate apoptosis by ligation of FasL, expressed on 
target cells. 
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Figure 21: CD8+ T cells transduced with either sh-RNA for WASP at MOI=12 and MOI=50 
or sh-scramble were co-cultured with SAg-loaded JY for 1 hour. Then cells were stained for 
Lamp-1 in order to evaluate their degranulation activity to measure their lytic potential. 
Degranulation occurred in a SAg-specific manner in transduced, GFP+ CD8+ T cells and 
independently from WASP expression, since no difference was observed between sh-WASP or 
sh-scramble transduced cells, indicating that indeed, WASP does not seem to play a role in 
the regulation of degranulation of CD8+ CTL. 
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Figure 22: different functions exerted by CTL: effector CTL efficiently kill compromised 
cells (sniper function) and also play a role in the extinction of immune responses by killing 
antigen-presenting DCs (suppressor function). Memory CD8+ T cells promote cellular 
immunity by the production of TNF-α. TNF-α stimulates the up-regulation of PI-9 and IL-12 
production in DC, prolonging Ag-presentation and stimulating effector CD8+ T cells, 
respectively. 
 
General discussion 
 143 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23: SAg-loaded DC are efficiently killed by primed CD8+ T cells. (A) CD8+ T cells up-
regulate granzyme B and perforin upon DC-stimulation. (B) Flow cytometric analysis of 
target cell lysis by CD8+ T cells on different time points after activation. Effector CD8+ T 
cells efficiently kill SAg-loaded DC, whereas memory CD8+ T cells loose this capacity. 
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Figure 24: hypothetical model of CD8+ T cell dysfunction in WAS: impaired TNF-α 
production by memory CD8+ T cells (helper function) could result in premature extinction of 
immune responses (suppressor function) and compromised target cell killing (sniper function) 
by effector CTL through its negative effect on the up-regulation of PI-9 and IL-12 in DC.  
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3.3 Extrapolation to the situation in the WAS patients 
How could WASP deficiency in CTL explain the clinical symptoms characteristic of 
WAS patients? Defective production of IFN-γ and TNF-α  might result in decreased 
recruitment of supplementary immune cells to infected tissues, as well as to sub-
optimal maturation/activation/differentiation of DC, macrophages, CD4+ T cells etc. 
Indeed, Ag-presentation by mature DC needs to be maintained until complete 
eradication of the infectious agens, activated macrophages will help to destroy and 
clear infected cells and CD4+ T cells are important in helping other immune cells to 
exert their effector functions by the secretion of cytokines. In addition, IFN-γ and 
TNF-α have anti-viral properties and are involved in the fight against tumor cells, 2 
features that characterize WAS.  
The defective IL-2 production is likely to contribute to the impaired T cell 
proliferation, besides described defects in decreased IL-2 responsiveness and 
defective cytokinesis. Reduced proliferation, in particular at low Ag dose, might 
contribute to the decreased T cell numbers observed in WAS patients. In adults T cell 
counts are maintained constant through the division of pre-existing terminally 
differentiated T cells, whereas in young subjects, there is still de novo generation of T 
cells from bone marrow-derived hematopoietic stem cells that migrate to the thymus 
where they undergo maturation. In addition, decreased T cell proliferation in response 
to antigenic stimulation might contribute to the increased susceptibility of WAS 
patients to infection and tumor development. Insufficient numbers of effector T cells 
could also be at the cause of incomplete eradication of infected or tumoral cells. This 
might result in persistence of infection and the outgrowth of tumors. Moreover, 
chronically activated T cells can damage surrounding healthy tissues, contributing to 
the development of autoimmune disease. 
Cytotoxicity of CTL from WAS patients was decreased against B-EBV target cells, 
especially at low SAg-doses.   In addition, we observed some patient intervariability 
in lytic potential (WAS2 and WAS4 clearly having inferior killing potential as 
compared to WAS1), however, all donor CTL displayed similar load of lytic 
molecules and de-granulated in the same extent (or even more for WAS1 and XLT6). 
Decreased killing capacity of WAS2 and WAS4 might be due to lower SAg 
specificity, since we observed slightly decreased TCR down-regulation in response to 
SAg-loaded APC. Another possibility could be secondary defects due to advanced 
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stage of disease. The XLT6 patient killed JY target cells as efficiently as compared to 
HD cells at very low SAg dose, where patient cells are below the normal range, 
suggesting that the XLT patient has preserved Ag-sensitivity. This is in agreement 
with the milder phenotype in XLT patient as compared to patient with full-blown 
WAS. Indeed, patients with residual WASP expression present less frequently with 
infections than patients deficient for WASP. Interestingly, a more pronounced lytic 
defect was observed in CTL from WAS patients against tumoral B-EBV cells. In 
contrast, CTL from the XLT6 patient were as efficient as HD cells in the killing of 
tumoral B cells. This is also in agreement with the fact that XLT patients generally do 
not develop tumors as patients with full-blown WAS. WAS gene correction in a 
fraction of CTL led to partial restauration of cytotoxicity against tumoral B cells, 
encouraging the development of gene therapy strategies to restore the myriad of 
cellular defects in immune cells, including the cytolytic defect of CTL against tumoral 
cells.  
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